








I declare that this thesis has been composed by myself and has not been submitted for
any other degree. The work described herein is my own except where otherwise
indicated and all work of other authors is duly acknowledged.
Madeleine N. Wakeling
Laboratory for Clinical and Molecular Virology,







I would like to thank my supervisors, Dr James Stewart and Professor Tony Nash for
all their help and guidance during this project. I am grateful to James for being
generous with his time and knowledge and Tony for providing a stimulating research
environment. Also, a big thank you is due to everyone in the MHV-68 group and the
whole department for all their support and useful advice. It goes without saying that
the unstinting support of Peter, my family and friends has been invaluable in
completing this degree. I thank the Wellcome Trust for funding this research.
111
Abstract
Gammaherpesviruses are lymphotropic viruses that establish lifelong latent
infections in their host. The most intensively studied gammaherpesviruses are the
clinically important Epstein Barr virus (EBV) and Kaposi's sarcoma associated
herpesvirus (KSHV). EBV is associated with infectious mononucleosis, Burkitt's
lymphoma, nasopharyngeal carcinoma and Elodgkin's lymphoma. KSHV is almost
certainly the causative agent of Kaposi's sarcoma, body cavity based lymphoma and
multicentric Castleman's disease. Analysis of EBV and KSHV is limited by the
inherent species specificity of these viruses and their restricted growth in vitro.
Murine gammaherpesvirus 68 (MHV-68) is a naturally occurring virus found in wild
rodents. It productively infects a range of cells and can be grown to high titres.
MHV-68 also infects laboratory mice, thus making it an excellent small animal
model for studying gammaherpesvirus infection. Herpesvirus genomes contain a
variety of homologues of cellular genes involved in immune regulation and/or cell
growth and proliferation. Cellular homologues encoded by MHV-68 include Bcl-2,
cyclin D and a G protein-coupled receptor (GPCR) that shares greatest amino acid
identity with the mammalian chemokine receptor, CXCR2. GPCRs are a
superfamily of seven-transmembrane signalling molecules, and homologues occur in
several herpesviruses. The KSHV GPCR is a functional, constitutively active
oncoprotein that induces vascular endothelial growth factor.
The aim of this project was to characterise the MHV-68 GPCR (ORF74) and
investigate its role in viral pathogenesis. This was approached in several ways.
Firstly, the transcription pattern of the gene was determined using Northern analysis:
GPCR expression was detected at early and late time-points during lytic infection on
multiple rare transcripts. The size of the transcripts suggested they might be
polycistronic and subsequent RT-PCR analysis demonstrated that the GPCR was co-
expressed with v-Bcl-2, both in vitro and possibly in vivo. The subcellular
localisation of the GPCR protein was investigated using an "epitope-tagging"
strategy and immunofluorescence experiments revealed an expression pattern
consistent with localisation to the cell surface. The transforming activity of the
GPCR was examined using conventional tissue culture-based assays. NIH3T3 cells
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expressing the GPCR exhibited focus formation and anchorage independent growth
in soft agar. Lastly, a recombinant virus lacking the GPCR was generated by
homologous recombination. However, this recombinant virus could not be purified
from the parental wild type virus. In conclusion, the MHV-68 GPCR is a viral
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1.1. The Herpesviridae
The herpesviridae comprise a large family of viruses, numbering at least one hundred
members that are widespread in both animals and humans. All herpesviruses share
the ability to establish latent infection, which allows them to persist for the lifetime
of the host. Eight human herpesviruses have been identified, several of which are
endemic in the population. For instance, 95% of people carry the herpes simplex
virus (HSV-1) and about 90% are seropositive for the Epstein Barr virus (EBV). In
the majority of cases, reactivation or recrudescence does not occur in
immunocompetent hosts. The genetic and environmental cues that elicit reactivation
in some individuals but not others have not been clearly defined. However,
herpesvirus reactivation is strongly associated with immunosuppression and, in this
context, may cause serious and potentially fatal disease.
HSV-1 (HHV-1) and HSV-2 (HHV-2) recurrently infect epidermal tissue resulting in
the development of cold sores and genital lesions, while varicella zoster virus (VZV,
HHV-3) is the causative agent of chicken pox and shingles. These infections are
usually resolved by the host's immune system but life-threatening complications
such as meningitis and encephalitis can occur (Arvin, 1996; Whitley, 1996). EBV
(HHV-4) is the aetiologic agent associated with infectious mononucleosis and a
number of malignancies including Burkitt's lymphoma, nasopharyngeal carcinoma
and post-transplant lymphoproliferative disease (Kieff, 1996). Cytomegalovirus
(HCMV, HHV-5) infection is largely asymptomatic but vertical transmission can
cause blindness, deafness or mental retardation in the developing foetus. A lethal
disseminated CMV infection has also been reported in AIDS patients and transplant
recipients receiving immunosuppressive drugs (Britt, 1996). CMV has also been
associated with certain types of vascular disease such as atherosclerosis (Melnick et
al., 1996). Human herpesvirus 6 (HHV-6) is associated with the childhood disease,
Roseola infantum and a link with multiple sclerosis has also been postulated. Little
is known of any pathology associated with human herpesvirus 7 (HHV-7). Kaposi's
sarcoma herpesvirus (KSHV, HHV-8) is a more recent addition to the family (Chang
et al., 1994). It is associated with Kaposi's sarcoma, body cavity based lymphoma
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and multicentric Castleman's disease, a previously rare group of conditions now
observed more commonly in AIDS patients.
1.1.1. Herpesvirus Composition and Classification
Herpesviruses have large linear, double-stranded DNA genomes encased in
icosahedral capsids that are 100-1 lOnm in diameter and comprise 162 capsomeres
(figure 1.1.1). Between the capsid and the envelope lies the tegument, an amorphous
materia] consisting of virus proteins. The capsid is enveloped in host-cell derived
membrane containing numerous virus glycoproteins that protrude from the
membrane surface like spikes. Herpes simplex (HSV-1) possesses at least eleven
different glycoproteins, some ofwhich facilitate virus entry.
The size of the viral genome varies between 120-230kb. A size difference of up to
lOkb has been observed between individual virions of the same virus strain that
arises from the variability of the number of internal and terminal repeats. The
herpesviruses have been classified into six subtypes (A-F) depending on the
arrangement of the repeat structures and unique regions. The GC content of
herpesvirus genomes ranges from 31-75% between family members and there is also
heterogeneity in base sequence distribution across the length of the genome
(Roizman, 1996b). Herpesvirus genomes are economically arranged: open reading
frames tend to be closely spaced and often overlap; genes may be transcribed in
leftward or rightward direction and use alternative initiation, polyadenylation or
splice sites. The unique region of the genome encodes blocks of conserved genes
that are present in the majority of herpesviruses (Chee & Barrell, 1990; Davison &
Taylor, 1987). The conserved gene blocks are interspersed with genes that are
unique to individual herpesviruses, although they may be encoded by more than one
virus. The unique genes include a number of novel genes and also genes that are
likely to have been acquired from the host cell genome (discussed in later sections).
The known herpesviruses appear to share four significant biological properties: they
all synthesise a large number of enzymes involved in nucleic acid metabolism
3
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Figure 1.1.1. Electron Micrograph of Epstein Barr Virions
Electron micrograph of un-enveloped Epstein Barr virions taken from a cell spread of
EBV-infected cells. The image depicts the icosahedral structure of the herpesvirus
nucleocapsid. Note the collapsed nucleocapsid towards the bottom right-hand
corner. Adapted from (Madeley, 1972).
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(e.g. thymidine kinase) and DNA replication (e.g. DNA polymerase); DNA synthesis
and assembly of virus capsids occurs in the nucleus; lytic replication and production
of infectious progeny results in destruction of the infected host cell; all herpesviruses
have the capacity to establish a latent infection in natural host cells, with genomes
adopting a closed circular formation and expressing a limited subset of genes.
However, despite these similarities, members of the family can be differentiated by
their specific biological properties. The herpesviruses have been clustered into three
subfamilies (a, p, y) on the basis of host range, duration of reproductive cycle,
cytopathology, genome structure, characteristics of latent infection and more
recently, genetic conservation (Roizman, 1982). Table 1.1.1 lists examples of each
subfamily.
1.1.2. The Alphaherpesviruses
The alphaherpesvirinae are characterised by their variable host range, short
reproductive cycle and rapid destruction of susceptible cells. Examples include
HSV-1 and HSV-2 and VZV. The alphaherpesviruses establish latency primarily but
not exclusively in the sensory ganglia.
1.1.3. The Betaherpesviruses
The betaherpesviruses have a comparatively long reproductive cycle and are less
cytopathic, giving rise to typically enlarged cells (cytomegalia) exemplified by
cytomegalovirus (CMV). Latency is established in a variety of tissues including
secretory glands, lymphoreticular cells and kidneys. The human herpesviruses,
HHV-6 and HHV-7, have recently been classified as betaherpesviruses (Gompels et
al., 1995; Nicholas, 1996). HHV-6 and HHV-7 are CD4+ T cell tropic whereas
CMV infects monocytes and lymphocytes.
1.1.4. The Gammaherpesviruses
The gammaherpesviruses such as EBV, KSHV and MHV-68 have a narrower host
range than the alphaherpesviruses. All members replicate in lymphoblastoid cell
lines and some can lytically infect fibroblastic and epithelial lines in vitro. Latency
is established primarily in lymphocytes: EBV, KSHV and MHV-68 are B-cell
5
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Table 1.1.1. Examples of the Herpesvirus Family
Name Host Disease
Alphaherpesviruses (a1 Simplexvirus □ and a2 Varicellovirus □ subgroups)
Herpes simplex 1 (HSV-1) Human Cold sores, keratitis, ocular disease
Herpes simplex 2 (HSV-2) Human Genital herpes
Bovine herpesvirus 2 (BHV-2) Cow
Marek's Disease Virus (MDV) Chicken T cell lymphoma
Varicella zoster (VZV) Human Chicken pox, shingles
Pseudorabies virus Pig Aujeszky's disease
Equine herpesvirus 1 (EHV-1) Horse Spontaneous abortion
Betaherpesviruses (pi Cytomegalovirus □ and p2 Roseolovirus □ subgroups)
Cytomegalovirus (HCMV) Human Foetal deformities
Lymphoproliferation in immunocompromised
Murine cytomegalovirus (MCMV) Mouse
Human herpesvirus 6 (HHV-6) Human Roseola infantum
Human herpesvirus 7 (HHV-7) Human
Gammaherpesviruses (y1 Lymphocryptovirus □ and y2 Rhadinovirus □ subgroups)





Herpesvirus saimiri (HVS) Squirrel Fatal lymphoproliferative disease in cotton tail
Monkey rabbits, New World monkeys e.g. marmosets
Kaposi's sarcoma herpesvirus Human Kaposi's sarcoma




Rhesus monkey rhadinovirus (RRV) Old world Experimental lymphadenopathy and
monkey vascular hyperplasia
Equine herpesvirus 2 (EHV-2) Horse
Herpesvirus sylvilagus Cotton tail Lymphomas
rabbit Lymphoproliferations
Woodchuck herpesvirus Woodchuck
Murine gammaherpesvirus 68 Murid rodents Lymphomas
(MHV-68)
Bovine herpesvirus 4 (BHV-4) Cow
Alcelaphine herpesvirus 1 Wildebeest Malignant catarrhal fever in cattle
Ovine herpesvirus 2 (OHV-2) Sheep Malignant catarrhal fever in cattle
Gammaherpesviruses are over-represented among these examples of herpesviruses
as a gammaherpesvirus, MHV-68, is the focus of this thesis
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tropic, whereas HVS is a T-cell tropic virus. Classification of the
gammaherpesviruses into subgroups has proved difficult as members of the
subfamily sharing cell tropism or other biological properties do not necessarily have
similar genomic structure or sequence homology. However, two genera are
recognised, Lymphocryptovirus (gamma-1-herpesvirus) and Rhadinovirus (gamma-
2-herpesvirus), that are exemplified by EBV and HVS respectively.
1.1.5. Replication of Herpesviruses
Herpesvirus infection of a cell can result in two different replicative outcomes: lytic
replication with production of virus progeny and consequent death of the host cell; or
latent infection, during which the virus genome is maintained as a circular episome
and expresses a restricted subset of genes. Replication of the latent genome occurs
during host cell division and utilises host cell machinery but does not generate virus
progeny. The term "lytic replication" implies cytolytic destruction of the cell,
although not all herpesviruses engender cytolysis. A more accurate definition of
herpesvirus replication that results in generation of progeny is "productive
replication". However, herpesvirus terminology has been defined by the prototypical
cytolytic herpesvirus, HSV-1, and the terms are used interchangeably.
Figure 1.1.5 depicts the lytic replication cycle schematically. In order to initiate
infection, the virus must attach to receptors on the cell surface via an interaction with
virion envelope glycoproteins. The cellular receptors utilised by herpesviruses vary
between individual members of the family, as do the viral glycoproteins necessary
for entry. A great deal of information about attachment, and indeed the lytic
replication cycle, has been amassed from the study of HSV-1 and the generation of
HSV-1 mutants. HSV-1 appears to require multiple glycoproteins for entry and uses
more than one attachment pathway. The cell surface receptor is most likely the
ubiquitous heparan sulphate, although HSV-1 is thought to interact with more than
one cellular receptor. Conversely, the in vitro host range restriction of EBV to B
lymphocytes is partly due to the specificity of the EBV glycoprotein, gp340/220, for
the B-lineage-associated C3d complement receptor, CD21 (CR2).
7
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Figure legend on following page.
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Figure 1.1.5. 1. The virus attaches to the cell via an interaction between a virion
membrane glycoprotein and a cell surface receptor, which in the case of EBV is the
complement receptor CR2/CD21. 2. Following attachment, the virion is internalised
into a vesicle derived from the plasma membrane. The virion membrane fuses with
the vesicle membrane in a pH-independent manner, resulting in the release of the viral
capsid into the cytoplasm. 3. The uncoated capsid traffics to the nuclear membrane
and releases the linear double-stranded DNA virus genome into the nucleus. 4. The
linear virus genome immediately circularises. 5. Sequential viral protein expression
ensues; commencing with the immediate early proteins that include the viral
transactivators required for expression of the early proteins such as DNA polymerase
and other enzymes, which mediate DNA replication. Lastly, the late viral proteins are
synthesised; these include the structural capsid proteins and viral glycoproteins. 6.
Virus DNA replication occurs via a rolling circle mechanism: the concatenated
genomes are cleaved and packaged into the newly formed nucleocapsids, which then
enter the endoplasmic reticulum (ER). 7. Newly synthesised virus proteins are
directed from the ribosome to the ER for modifications such as N-linked
glycosylation. 8. The majority of glycoproteins also receive further processing in the
Golgi before trafficking to the plasma membrane. 9. Vesicles release nucleocapsids
into the cytoplasm. 10. It is proposed that the nucleocapsids acquire a definitive
envelope either by 11. budding through the plasma membrane containing mature
Golgi-processed glycoproteins or 12. by budding into post-Golgi derived vesicles
containing viral glycoproteins prior to exocytosis of the enveloped virion. Adapted
from (Roizman, 1996a) and (Gong & Kieff, 1990).
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Following attachment, the HSV-1 envelope fuses directly with the plasma membrane
resulting in endocytosis of the nucleocapsid, a process that is also dependent upon
multiple viral glycoproteins. In the case of EBV, the virion is internalised and the
virus envelope fuses with the vesicular membrane, releasing the nucleocapsid into
the cytoplasm. Transport of nucleocapsids to the nucleus is probably mediated by
the cell cytoskeleton (Kristensson et al., 1986) and results in the release of viral
DNA into the nucleus, where it immediately circularises. Several tegument proteins
are important for the initiation ofDNA replication such as the HSV-1 VP 16 protein,
a transactivator that induces transcription of the immediate early viral genes.
Transcription of viral DNA by host RNA polymerase II occurs in the nucleus in a co-
ordinately regulated cascade. There are three kinetic groups of genes: the immediate
early (a) genes, the early (P) genes and the late (y) genes. In addition to these,
herpesviruses encode a small subset of genes and non-translated RNAs during latent
infection. There are five immediate early viral proteins, which are expressed in the
absence of protein synthesis and all serve to regulate the sequential expression of the
early and late gene subsets. In the main, the early genes encode the viral proteins
necessary for nucleic acid metabolism, DNA replication and virus assembly e.g.
DNA polymerase, helicase-primase, dUTPase and thymidine kinase; the virus
structural proteins are encoded by the late genes.
The virus genome is replicated by a rolling circle mechanism, producing head-to-tail
concatemers (Jacob & Roizman, 1977) that are cleaved at consensus sequences into
single genome units and packaged into newly synthesised capsids (Deiss et al.,
1986). Late gene transactivators are expressed at early time points resulting in
subsequent transcription of the late genes following DNA replication e.g. tegument
proteins, glycoproteins.
Envelopment and egress of the virus from the cell is less well characterised. There is
evidence to suggest that HSV-1 capsids bud through the nuclear membrane,
acquiring immature viral glycoproteins that were transported there previously
(Vlazny et al., 1982). Immature virus particles would then pass through the Golgi
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network, facilitating glycoprotein processing, and traffic to the plasma membrane in
a Golgi-derived vesicle before being released from the cell by a process of reverse
exocytosis (Desai et al., 1988; Johnson & Spear, 1982). Alternatively, the
nucleocapsid may acquire its final envelope at the plasma membrane. There is also
evidence to suggest that the virus is enveloped in the Golgi and undergoes uncoating
and re-envelopment steps during egress (Whiteley et al., 1999). EBV envelopment is
thought to occur at the plasma membrane or following envelopment by post-Golgi
vesicles (Gong & Kieff, 1990).
1.2-1.5. The Gammaherpesviruses
The most intensively investigated gammaherpesvirus is EBV, although much interest
is currently being directed towards KSHV. Of the non-human gammaherpesviruses,
herpesvirus saimiri (HVS) and murine gammaherpesvirus 68 (MHV-68) are studied
in the context of animal models for human disease. Gammaherpesviruses affecting
cattle and other ruminants such as alcelaphine herpesvirus 1 (AHV-1) and ovine
herpesvirus 2 (OHV-2) are also of considerable interest due to their economic impact
on agriculture and devastating effect on conservation programmes.
1.2. The Epstein Barr Virus
EBV, the prototypical Lymphocryptovirus, is widespread in all human populations
with approximately 90% of adults testing positively for EBV-specific antibody
(Rowe et al., 1988). Like all human herpesviruses, it establishes lifelong persistence
in the host. Epstein and colleagues first isolated the virus from lymphoblastoid cell
lines derived from an endemic Burkitt's lymphoma biopsy (Epstein, 1964). EBV is
the aetiological agent associated with a number of human diseases. Primary
infection with EBV, while often asymptomatic, can produce a condition known as
infectious mononucleosis or glandular fever (Schooley, 1985). EBV is also the
aetiologic agent associated with Burkitt's lymphoma (BL), nasopharyngeal
carcinoma (NPC) and post-transplant lymphoproliferative disease (BLPD). It has
also been implicated in the pathogenesis of X-linked lymphoproliferative syndrome,
Hodgkin's disease (Anagnostopoulos et al., 1989), Sjogren's syndrome (Inoue et al.,
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1991), rheumatoid arthritis (Moss et al., 1983) and other epithelial malignancies such
as carcinoma of the parotid gland (Jones et al., 1988; Raab-Traub et al., 1991).
The EBV genome is 172kb in length and comprises a short and a long unique region
interspersed by 3kb internal repeats and flanked by 500bp terminal repeats. The
EBV genome, which has a 60% GC content, encodes over 90 proteins and was the
first herpesvirus to be fully cloned and sequenced (Baer et al., 1984; Dambaugh et
al., 1980; Hatfull et al., 1988). There are two subtypes, EBV-1 and EBV-2, which
share extensive homology but exhibit variation in the small polyadenylated RNAs
(EBERs) and the nuclear antigen genes (Sample et al., 1990). EBV-1 is more
prevalent in developed societies whereas African isolates show a more even
distribution between EBV-1 and EBV-2 (Zimber et al., 1986).
EBV, like other gammaherpesviruses, has a restricted host range with humans as its
natural host. This presents difficulties when attempting to study the course of
infection in vivo (see section 1.5.1 entitled MHV-68 as an animal model). EBV
lyrically infects squamous epithelial cells but the infection is far from efficient and
no other fully permissive tissue culture system is available for studying productive
infection. The virus infects and immortalises B lymphocytes in vitro (Pattengale et
al., 1973), generating lymphoblastoid cell lines which have been used to study EBV
latent infection in depth (Pope et al., 1968). In these cells, the genome immediately
circularises upon infection and is maintained as an episome in the absence of
productive replication. However, within an LCL population, a small number of cells
(0-5%) undergo productive replication. The switch from latency to the lytic cycle is
associated with B cell activation and differentiation (Crawford & Ando, 1986) and
can be triggered using activating agents such as phorbol esters (zur Hausen et al.,
1978), sodium butyrate (Luka et al., 1979) and anti-immunoglobulin (Tovey et al.,
1978).
1.2.1. Infectious Mononucleosis
Infectious mononucleosis (IM) is characterised by the presence of heterophile
antibodies in the serum accompanied by an atypical lymphocytosis. Symptoms
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include pharyngitis, lymphadenopathy, general malaise, fever and splenomegaly
(Henle, 1979). However, the severity of the illness can vary from a mild fever to
prolonged debilitating illness. Symptomatic IM is more likely to occur when the
individual is infected in early adulthood, with 50% of these cases manifesting as IM.
The virus replicates in the oropharyngeal epithelium and is intermittently secreted in
the saliva of most seropositive individuals, thus resulting in oral transmission
(Rickinson et al., 1975; Yao et al., 1989). While the primary site of lytic replication
is the pharyngeal epithelium, the virus establishes latency in B lymphocytes. This is
supported by the finding that B cell-deficient patients with X-linked
agammaglobulinaemia are not infected with EBV (Faulkner et al., 1999). It is
thought that recirculating B cells become infected in the oropharynx and that the
bone marrow, lymphoid tissue and peripheral blood lymphocytes are major
reservoirs for EBV (Decker et al., 1996; Khan et al., 1996). Approximately one in
one million B cells of asymptomatic carriers are latently infected with EBV (Khan et
al., 1996; Lewin et al., 1987; Miyashitaeta/., 1995). However, sporadic reactivation
of the virus and proliferation of EBV-infected cells is held in check by virus-specific
cytotoxic T cells (Moss et al., 1979; Rickinson et al., 1979; Rickinson et al., 1980).
The importance of this immune surveillance is highlighted in the case of
immunosuppressed transplant patients who frequently experience
lymphoproliferation of EBV-infected B cells, resulting in malignant lymphomas
(Hanto et al., 1983).
1.2.2. Burkitt's Lymphoma
Burkitt's lymphoma occurs in three recognised forms: endemic, sporadic and AIDS-
associated BL. Endemic BL was first described by Denis Burkitt, a surgeon working
in Africa, and is most tightly associated with EBV (Burkitt, 1963). BL, a B cell
tumour localised to the jaw, is the most common childhood lymphoma in equatorial
Africa and Papua New Guinea and affects approximately 1 in 10,000 individuals
annually. Without treatment, BL is fatal within a few months.
The EBV genome is detectable in the vast majority of tumours (97%, zur Hausen &
Schulte-Holthausen, 1970) and patients exhibit high levels of virus-specific
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antibodies about five years prior to the onset of clinical symptoms (Geser et al.,
1982). EBV is considered to be a necessary element in the causation ofBL, although
other risk factors such as hyperendemic falciparum malaria, or HIV in the case of
AIDS-associated BL, act together in a complex chain of events leading to malignant
change. BL cells possess a characteristic chromosomal translocation, t(8:14, 2 or
22), resulting in juxtaposition of the c-myc oncogene and the Ig heavy-chain locus
(chromosome 14, 80% of tumours) or one of the light-chain loci. It is thought that
infection with malaria leads to a high level of EBV-driven B cell proliferation that
increases the probability of a translocation (Klein, 1985). Subsequent deregulation
of c-myc results in B cell proliferation and hence BL (Bornkamm et al., 1987; Klein,
1985; Leder et al., 1983).
1.2.3. Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a squamous epithelial tumour localised to the
postnasal space. It is especially prevalent in southern China where it is the most
common cancer affecting men and the second commonest cancer of women. A
genetic predisposition has been demonstrated in this population (Chan, 1983; Simons
et al., 1974) but studies on Chinese migrants have implicated environmental co-
factors such as traditional Chinese herbal remedies and salt fish dishes, which
contain tumour-promoting phorbol esters and nitrosamines respectively (Buell, 1974;
Hirayama & Ito, 1981; Huang, 1978). An association of EBV with NPC was
proposed following the observation that patients exhibit elevated levels of EBV-
specific antibodies (Old, 1966) and that the EBV genome can be detected in all NPC
samples (Desgranges et al., 1982; Nonoyama & Pagano, 1973; Wolf et al., 1973).
1.2.4. EBV and Immunosuppression
The occurrence of EBV-driven lymphomas has been described in immunosuppressed
individuals (Crawford et al., 1980; Kalter et al., 1985). In these cases, loss of
immune surveillance results in increased viral replication in the oropharynx and B-
cell proliferation. Again, detection of EBV-specific antigens in these tumours
suggests a strong association with the virus (Hemdier et al., 1994; Thomas et al.,
1990). Organ graft recipients, who receive lifelong immunosuppressive drugs that
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inhibit T cell activity, are 28-100 times more likely to develop lymphoproliferative
disease (Penn, 1983). Reducing the level of immunosuppressive drugs has been
shown to cause regression but carries the risk of graft rejection (Starzl et al., 1984).
It may be possible to control the condition by adoptive transfer of EBV-specific
cytotoxic T cells (Haque et al., 1998; Rooney et al., 1995). In addition to BL, AIDS
patients frequently develop large-cell lymphomas and oral hairy leukoplakia
(Greenspan et al., 1985). The vital role of the immune system in controlling
proliferation of EBV-infected B cells is also demonstrated in cases of X-linked
immunodeficiency. Following primary infection with EBV, 75% of affected men
succumb to fatal IM. Those who survive are at risk of developing
hypogammaglobuliaemia or lymphoma (Purtilo et al., 1992; Tatsumi & Purtilo,
1986).
1.2.5. Other EBV-Associated Diseases
EBV genomes and viral proteins are present in approximately 60% of cases of
Hodgkin's disease and there is an epidemiological correlation between IM in early
adulthood and the development ofHodgkin's disease in later life (Herbst et al., 1991;
Weiss et al., 1989). EBV has also been detected, in a varying percentage of cases, in
certain types of T cell lymphoma: angioimmunoblastic lymphadenopathy (Ott et al.,
1992); nasal lymphoma (Harabuchi et al., 1990) and peripheral T cell lymphoma
(Jones et al., 1988). In all these instances, the contribution of EBV to pathogenesis
remains unclear.
1.2.6. EBV Latent Gene Expression
Like all herpesviruses, EBV expresses a highly restricted subset of genes during
latent infection. The latency-associated genes encoded by EBV are unique genes and
no homologues have been found in other herpesviruses (Virgin et al., 1997). Several
distinct patterns of gene expression have been observed in different in vitro and in
vivo circumstances and have been assigned to three groups: latency type I, II and III.
The full array of latent genes is expressed in latency type III: six EBV nuclear
antigens (EBNAs), EBNA-1, 2, 3A, 3B, 3C and LP (leader protein); three latent
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membrane proteins (LMP), LMP-1, 2A and 2B; two EBV infected cell RNAs known
as EBERs and a group of un-characterised transcripts designated as the BARTs to
denote the region of the genome they originate from (Brooks et al., 1993). This
pattern of expression is observed in LCLs, infectious mononucleosis and post-
transplant lymphomas.
EBNA-1 is a DNA-binding protein that binds to specific sequences in the latent viral
origin of replication (oriP) and is required for maintenance of the viral episome. It
also transactivates expression of the other latency genes and has a role in tethering
the virus genome to host chromosomes thus ensuring equal partitioning during cell
division. EBNA-1 contains a glycine-alanine repeat sequence, which enables it to
escape degradation by the proteasome and therefore antigen presentation to cytotoxic
T cells (Levitskaya et al., 1995). This may help explain how the virus is able to
escape the immune system and persist so effectively in the host. EBNA-2 is essential
for immortalisation of B cells in vitro (Cohen et al., 1989) and has been shown to
transactivate the LMP genes and the cellular oncogenes c-fgr and bcl-2. EBNA-3A,
B and C originate from a single open reading frame and their functions are less well
characterised, although EBNA 3A and C are also necessary for immortalisation
(Tomkinson et al., 1993). LP is not essential for immortalisation but may have a
potential role in controlling cell proliferation. LMP-1 is an integral membrane
protein and a classical viral oncoprotein (Kaye et al., 1993). As discussed in section
3.4.1, LMP-1 induces activation of the cellular transcription factor, NFkB, and up-
regulates the anti-apoptotic protein, Bcl-2 (Henderson et al., 1993). LMP-2A and 2B
are also transmembrane proteins. LMP-2A interacts with the src family of tyrosine
kinases and may be involved in suppressing reactivation (Miller et al., 1995a). The
EBERs are dispensable for viral replication but may have a role in transformation of
Akata cells (Komano et al., 1999).
Latency type I is the pattern of expression detected in biopsy samples in cases of
endemic BL. In these cells, only EBNA-1, the EBERs and the BARTS are
expressed. Latency type II is observed in NPC and HD lymphomas (Brooks et al.,
1992; Deacon et al., 1993; Hamilton-Dutoit et al., 1993; Young et al., 1988).
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Expression is limited to EBNA-1, LMP-2A, LMP-2B, the BARTs and in some cases,
LMP-1. In the persistently infected resting B cells of seropositive immunocompetent
hosts, only LMP-2A and the EBERs are detectable.
1.3. Kaposi's Sarcoma-Associated Herpesvirus
1.3.1. The KSHV Genome
Kaposi's sarcoma herpesvirus (KSHV, HHV-8) was first identified using a technique
known as representational difference analysis (Chang et al., 1994; Lisitsyn & Wigler,
1993). This involves subtractive hybridisation of two different complex genomes.
In this case, differences between DNA from a KS skin lesion and control tissue from
the same patient led to the isolation of fragments of the KSHV genome. KSHV has
since been fully cloned and sequenced and classified as a gammaherpesvirus of the
genus, Rhadinovirus (Moore et al., 1996b; Russo et al., 1996). The unique region of
the genome is 140.5kb in length and is interspersed with five internal repeat regions
and flanked by multiple GC rich (85%) 801 bp repeats. There are at least 81 ORFs,
of which 66 share homology with herpesvirus saimiri. These include the full
contingent of conserved herpesvirus genes, gammaherpesvirus-specific genes and a
number of unique genes.
1.3.2. Diseases Associated with KSHV
Kaposi's sarcoma was previously a rare tumour affecting mainly middle-aged or
elderly men in Mediterranean countries. The onset of the AIDS epidemic saw a vast
increase in the number of cases and KS is now the most common neoplasm of AIDS
patients, whose risk of developing the disease is 20,000 fold above the general
population (Beral, 1991). There are four known epidemiological forms of KS:
classic KS, AIDS-KS, endemic HIV-negative KS (Central Africa) and post-
transplant associated KS. Classic KS is usually an indolent condition affecting the
skin of the lower limbs, while endemic KS is associated primarily with the lymph
nodes. AIDS-KS is a much more aggressive multi-system disease with a higher
mortality rate.
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KSHV sequences have been detected in all forms of KS, thus making it almost
certainly the aetiological agent of Kaposi's sarcoma (Dupin et al., 1995; Huang et
al., 1995; Moore & Chang, 1995; Schalling et al., 1995). In addition, treatment of
KS patients with the anti-herpetic drug, foscamet, results in tumour regression,
indicating that the disease is virus-driven (Morfeldt & Torssander, 1994). Unlike
EBV, the seroprevalence of KSHV in the general population is low (0-1% of HTV-
negative US blood donors). However, this figure rises to 35% in HTV7 KS"
homosexual men, suggesting that the disease is sexually transmitted (Blackbourn et
al., 1999; Kedes et al., 1996). Seroconversion to KSHV is usually a prognostic
indicator of KS development. Epidemiological studies have revealed high levels of
KSHV seropositivity in Italian and Ugandan populations where the incidence of
childhood KS provides evidence for vertical transmission (Gao et al., 1996). Other
researchers have also demonstrated the presence of KSHV in saliva, which may
provide another route of transmission (Blackboum et al., 1998; Boldogh et al., 1996;
Koelleetal., 1997; Vieira et al., 1997).
KSHV is associated with a number of other malignancies including body cavity-
based lymphoma (BCBL), also known as primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD). As the name suggests, BCBL is a
malignant lymphoma that is localised to the pleural or abdominal cavity and is
generally associated with AIDS. KSHV DNA is observed in the majority of BCBL
lymphomas (Cesarman et al., 1995a), although the EBV genome is usually also
present (Gessain, 1997). However, in some cases KSHV has been detected in the
absence of EBV (Carbone et al., 1996; Cesarman et al., 1996b). The presence of the
KSHV genome has also been demonstrated in MCD, another AIDS-related
lymphoma (Soulier etal., 1995).
1.3.3. KSHV Tropism and Gene Expression
Like EBV, KSHV is a B-cell tropic virus and several latently infected B cell lines
have been derived from the peripheral blood mononuclear cells of BCBL patients
(Cesarman et al., 1995b; Cesarman et al., 1996; Gaidano et al., 1996; Renne et al.,
1996). However, KS is a vascular tumour consisting of bundles of spindle cells,
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which belong to the endothelial lineage but often express markers characteristic of
endothelial, macrophage and smooth muscle cells. In situ hybridisation analysis has
detected the presence of KSHV-specific transcripts in the majority of these cells
(Staskus et al., 1997). There is a restricted pattern ofKSHV gene expression in both
spindle cells and in B-cell lymphoma derived cell lines such as BC-1, indicative of a
latent infection. As with EBV' cell lines, lytic replication can be induced by addition
of phorbol esters or sodium butyrate (Miller et al., 1997; Miller et al., 1996).
Transcriptional analysis of KSHV in the BC-1 cell line has lead to the grouping of
KSHV genes into three classes: constitutively transcribed latent transcripts that are
unaffected by phorbol ester (class I); genes that are up-regulated by phorbol ester and
sodium butyrate (class II); transcripts that are only detectable following induction
(class III, Sarid et al., 1998). Class I genes include the latency associated nuclear
antigen (LANA), a DNA-binding protein which is thought to have a function similar
to that of EBV EBNA-1. In addition, KSHV encodes a relatively large number of
cellular homologues (discussed in later section), two of which, v-cyclin and v-FLIP,
are transcribed during latency. The KSHV GPCR (ORF74) is a class III gene, with
transcripts only observable following induction of productive infection in latent cell
lines (Talbot et al., 1999).
1.4. Other Gammaherpesviruses
1.4.1. Herpesvirus Saimiri
Herpesvirus saimiri (HVS) is a T-cell tropic rhadinovirus whose natural host is the
squirrel monkey. In other species ofNew World primate, HVS infection leads to the
development of fatal T cell lymphomas (Desrosiers, 1981; Desrosiers et al., 1985;
Fleckenstein, 1979; Wright et al., 1977). The unique region (112.9kb) of the HVS
genome is flanked by 1.4kb GC rich repeats and contains at least 76 ORFs, of which
60 are encoded by other herpesviruses. Three strains of HVS (A, B, C) have been
distinguished on the basis of sequence variation in the leftmost region of the unique
sequence, which encodes the HVS transforming genes (Medveczky et al., 1984).
Strains A and C are highly oncogenic and both transform common marmoset T
lymphocytes to IL-2-independent growth in vitro (Desrosiers et al., 1985; Duboise et
19
al., 1998a; Jung et al., 1991). In addition, strain C has the capacity to immortalise
human, rabbit and rhesus monkey cells into continuously proliferating T cell lines
(Ablashi et al., 1985; Mittrucker et al., 1993). Strain C is also more oncogenic than
A and B in vivo: it produces lymphomas in rabbits whereas the other strains do not
(Medveczky et al., 1989). The existence of a permissive tissue culture system has
made HVS a popular model for investigating virus-mediated oncogenicity.
1.4.2. Alcelaphine Herpesvirus 1 and Ovine Herpesvirus 2
Alcelaphine herpesvirus 1 (AHV-1) is the causative agent of malignant catarrhal
fever virus (MCF), a lymphoproliferative disease of ruminants. AHV-1 is
asymptomatic in its natural wildebeest host but gives rise to MCF in cattle and deer,
creating a significant economic impact. Cloning and sequencing of the AHV-1
genome revealed it to be most closely related to HVS (Ensser et al., 1997).
Epidemiological evidence implicated sheep as asymptomatic carriers of MCF and
analysis of lymphoblastoid cell lines derived from infected cattle detected the
presence of AHV-1-like DNA sequences, now known to belong to ovine herpesvirus
2 (Bridgen & Reid, 1991)
1.5. Murine Gammaherpesvirus 68
1.5.1 MHV-68 as an Animal Model
Murine gammaherpesvirus 68 is a naturally occurring gammaherpesvirus, closely
related to the clinically important gammaherpesviruses, EBV and KSHV. The
restricted host range of these viruses and their limited ability to grow in vitro has
hampered studies ofEBV and KSHV. Studies of gammaherpesviruses in humans are
constrained by the frequently asymptomatic nature of the acute infection and the
delay between infection and presentation in patients with disease. Likewise, animal
models of EBV-mediated lymphoproliferative disease such as rhesus macaques,
common marmosets and cottontop tamarins do not mirror the human condition
(Finerty et al., 1992; Moghaddam et al., 1997). Primary infection of marmosets
(Callithrix jacchus) with EBV gives rise to symptoms similar to infectious
mononucleosis, however there is no B cell proliferation and no detectable EBV-
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specific proteins in the peripheral blood lymphocytes (Emini et al., 1986). In
cottontop tamarins, high doses of EBV engendered lethal lymphomas within 14-21
days, thus providing little information about chronic infection. Infection of
chimpanzees via contact with humans has been reported but their limited availability
precludes their use as an effective model (Levine et al., 1980). Two small animal
models involving EBV-related herpesviruses have also been proposed. Rabbits
infected with the baboon (Macaca arctoides) herpesvirus (HVMA) or the
cynomolgus (cyno-EBV), exhibit malignant lymphomas (Hayashi & Akagi, 2000;
Wutzler et al., 1995). However, the tumours produced are primarily T-cell
lymphomas whereas EBV generates predominantly B-cell lymphomas. Lastly, a
mouse model has been proposed that involves reconstitution of severely combined
immunodeficient mice (SCID) with human EBV+ lymphocytes (Johannessen &
Crawford, 1999; Mosier et al., 1992; Rowe et al., 1991). SCID/hu-PBL-SCID mice
rapidly develop multiple monoclonal or oligoclonal lymphomas, which bear
similarity to the large-cell lymphomas observed in patients with post-transplant
lymphoproliferative disease. Criticisms of this model have included the unnatural
route of infection and the cross species differences that may influence the pathology
of the virus. There is also a lack of an animal model for KSHV. As with EBV, the
SCID mouse has been proposed as a model: SCID mice were implanted with human
foetal or liver tissue inoculated with KSHV virions; but although the mice displayed
evidence of viral gene transcription, principally in B cells, there were no disease
symptoms (Dittmer et al., 1999).
The pathogenesis of MHV-68 in laboratory mice resembles that of EBV in humans.
It produces an acute infection similar to infectious mononucleosis and is also
associated with lymphoproliferative disease. Unlike EBV and KSHV, MHV-68
initiates a productive infection in a wide range of tissue culture cells and can be
grown to high titres. It is also possible, using molecular techniques, to manipulate
the virus genome in vitro and investigate the effects in vivo. Therefore MHV-68
provides an amenable small animal model for the study of gammaherpesvirus
infection and associated lymphomagenesis in a natural host system.
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1.5.2. The MHV-68 Genome
MHV-68 is one of five viruses that were originally isolated from the bank vole,
(Clethrionomys glareolus) and the yellow-necked mouse (Apodemus flavicollus) in
Slovakia (Blaskovic et al., 1980). Initially considered to possess the growth
characteristics of an alphaherpesvirus (Svobodova et al., 1982), MHV-68 was later
classified as a gammaherpesvirus on the basis of structural and sequence homology.
Limited sequence analysis revealed a number of open reading frames with greatest
similarity to the homologous proteins of HVS and EBV (Efstathiou et al., 1990a;
Mackett et al., 1997). It also showed that the MHV-68 genome exhibited CpG
dinucleotide suppression, a common feature of gammaherpesviruses thought to arise
from the mutagenic effect of methylation during virus latency (Bird, 1980; Honess et
al., 1989). In addition, the organisation of the MHV-68 genome was found to be
collinear with that ofHVS and EBV genomes (Gompels et al., 1988). Cloning of the
double-stranded DNA genome showed that it consists of 118.2kb of unique DNA
sequence flanked by a variable number of copies of a 1.23kb terminal repeat. The
DNA sequence of the genome has now been fully determined, revealing the presence
of two internal repeats of 40bp and lOObp (Virgin et al., 1997; Davison, in press).
The GC content of the MHV-68 unique region (46%), like HVS (35%) and KSHV
(54%), is lower than that of EBV (60%), whereas the MHV-68 terminal repeats are
very GC rich (78%) (Albrecht et al., 1992a; Russo et al., 1996). The MHV-68
unique region consists of large blocks of conserved genes, interspersed with virus-
specific genes. Approximately 80 open reading frames (ORFs) have been
determined, of which 63 are homologues ofHVS or KSHV genes. On the whole, the
identity of MHV-68 ORFs to those of other gammaherpesviruses indicates that
MHV-68 is more closely related to HVS and KSHV than to EBV, indicating that
MHV-68 belongs to the gamma-2 subfamily.
A schematic representation of the MHV-68 genome is given in figure 1.5.2. The
conserved herpesvirus family genes include the capsid proteins and the
glycoproteins, gB, gH, gM and gL; genes involved in nucleic acid metabolism such
as uracil DNA glycosylase, deoxyuracil triphosphatase and large subunit of
ribonucleotide reductase; DNA replication enzymes e.g. DNA polymerase and
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Figure 1.5.2. The MHV-68 genome. A single dark blue line represents the unique
region with the genome co-ordinates marked at 10kb intervals. The position of the
terminal repeats (TR) and internal repeats (IR) is indicated by dark blue boxes. The
open reading frames (ORFs) are drawn as arrows pointing in the direction of
transcription. Yellow arrows signify genes that are unique to the MHV-68 genome,
while blue arrows denote the MHV-68 glycoproteins. The genes are labelled
according to function: crp, complement regulatory protein; gB, glycoprotein B; K3,
homologue of the KSHV immediate early gene; TK, thymidine kinase; gH, glycoprotein
H; gM, glycoprotein M; ung, uracil DNA glycosylase; gL, glycoprotein L; rta, R
(immediate early) transcriptional transactivator; gp150, glycoprotein with homology to
EBV gp340/220; dut, dUTPase; mta, M (immediate early) transcriptional transactivator;
rr2, small subunit ribonucleotide reductase; rr1, large subunit ribonucleotide
reductase; eye D, homologue of mammalian cyclin D; bcl-2, homologue of mammalian
bcl-2; GPCR, homologue of mammalian CXCR2. Where the function of the gene is
unknown, it is represented by the ORF number. The MHV-68 GPCR is situated at the
















































































































helicase-primase. The semi-conserved genes include thymidine kinase and the small
subunit of ribonucleotide reductase. Unique genes are prefaced by the initial, M.
1.5.3. MHV-68 Gene Expression
During the 24-hour productive cycle, MHV-68 genes are expressed in a conventional
cascade beginning with immediate early genes such as ORF50 (rta), early genes (e.g.
thymidine kinase) and late genes (e.g. glycoprotein 150). Gene expression during
latent infection is less clear but MHV-68 does not appear to encode homologues of
the HVS or EBV latency-associated genes (Virgin et al., 1997). However, MHV-68
does express eight tRNA molecules during latency, which are reminiscent of the
EBV EBER sequences. The M2 gene is expressed during latent infection both in
vivo and in the MHV-68 positive lymphoma cell line, SI 1, which has proved to be a
valuable model for investigating virus latency (Husain et al., 1999). The M3 gene,
however, is not expressed in Sll cells but can be detected in the spleens of
chronically infected mice (Simas et al., 1999). Therefore, like EBV, MHV-68 may
have several forms of latency. Additionally, multiple spliced transcripts crossing the
terminal repeats have been detected in SI 1 cells (Husain et al., 1999). Expression of
known lytic genes such as bcl-2, ORF73 and the GPCR has also been observed in the
absence of other lytic transcripts thus indicating a role in latent infection and virus
persistence (Virgin et al., 1999).
1.5.4. Pathogenesis ofMHV-68 Infection
The natural route ofMHV-68 infection is unconfirmed but most likely involves close
contact and respiratory transmission. Intranasal inoculation results in productive
infection of alveolar epithelial cells and mononuclear cells in the lung causing in a
severe exudative pneumonia and haematogenous dissemination of the virus to other
tissues including kidneys, adrenal glands, heart and spleen depending on the age of
the mice and the route of infection (Blaskovic et al., 1984; Rajcani et al., 1985).
Inflammation and lymphocyte infiltration are observed in the lung during the course
of the acute infection, which peaks around 5 days post-infection and is cleared by
day 14. At this point, the virus is undetectable by conventional assays in every tissue
except the spleen, which is a major site of viral persistence (Sunil-Chandra et al.,
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1992a; Usherwood et al., 1996b). Latency is established in splenic B-lymphocytes,
as confirmed by the absence of splenic latency in p.MT B cell-deficient transgenic
mice (Usherwood et al., 1996a). Latently infected B cells begin to appear during the
first week of infection and peak around the second or third week in a dramatic
splenomegaly similar to that observed during EBV-induced infectious
mononucleosis.
There is evidence that the lung is also a major site of viral persistence: viable
episomal MHV-68 DNA is detectable in the lung long after acute infection by PCR
in both normal and B cell-deficient p.MT mice. Latency-associated transcripts, such
as M2, are also detectable months after the acute infection. In addition, adoptive
transfer of B cells into infected p,MT mice facilitates infection of splenic B cells by
persistent virus in the lung, suggesting that the lung is functioning as a non-lymphoid
virus reservoir (Stewart et al., 1998). In situ hybridisation studies demonstrated that
latent virus persists in pulmonary epithelial cells. Macrophages harvested from the
peritoneal exudate of pMT mice infected intra-peritoneally (IP) with MHV-68, have
also been reported to harbour latent virus (Week et al., 1999). Therefore, MHV-68 is
unlike EBV in that it establishes latency in epithelial cells in addition to B cells.
That said, EBV has been associated with a chronic form of lung disease, cryptic
fibrosing alveolitis, suggesting that the lung may act as a reservoir for EBV (Egan,
1995). Since MHV-68 also appears to be the causative agent of arteritis in
chronically infected mice and splenic fibrosis in interferon gamma receptor knockout
mice, it may prove a useful model in investigating this aspect of gammaherpesvirus
pathogenesis (Week et al., 1997; Dutia et al, 1997).
1.5.5. Immune Response to MHV-68 Infection
Acute infection induces a large inflammatory infiltrate in the lung. At 3-4 days post¬
infection, this is comprised primarily of mononuclear phagocytes, as shown by
analysis of the bronchoalveolar lavage of infected mice (Sunil-Chandra et al.,
1992a). However, the monocytes are replaced by large numbers of CD8+ cytotoxic T
cells, which peak around day 8-10. There is a predominance of CD8+ T cells with a
Vp4 phenotype, which suggests that a viral superantigen may stimulate selective
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expansion of this subset (Doherty et al., 1997). Depletion of T-cell subsets has
shown that CD8 T cells appear to be crucial to the resolution of the acute infection,
whereas the absence of CD4 T cells provokes only a slight delay in virus clearance
(Nash et al., 1996). However, while CD4+ T cells do not dramatically influence the
course of infection of the lung, they contribute to lymphoproliferation in the spleen.
Depletion of CD4+ T cells prevents the development of splenomegaly and greatly
reduces the level of latent virus that is normally observed during the peak of
splenomegaly at 2-3 weeks post-infection (Usherwood et al., 1996a). Splenomegaly
also fails to occur in CD4' T-cell and B-cell deficient mice (Ehtisham et al., 1993;
Usherwood et al., 1996b). While CD4+ T cells are essential for the development of
splenomegaly, CD8+ T cells influence the subsequent fall in cell number, as
demonstrated by the inability of p2-microglobulin-deficient mice to clear infectious
virus from the spleen (Week et al., 1996). This suggests that although CD8+ T cells
reduce the number of infected B cells in the spleen, some infected B cells escape
recognition and establish a lifelong latent infection.
There is only a slight delay in resolution of the acute infection in the lung in B-cell
deficient mice, indicating that antiviral antibody does not play an important role in
virus clearance. Even so, neutralising antibody levels remain high throughout the
lifetime of the animal (Stevenson & Doherty, 1998).
Mice infected intranasally with MHV-68 produce high levels of interferon gamma
(IFNy) and interleukin 6 (IL-6) in lymphoid tissues, with levels peaking around day
10 post-infection. Low levels of interleukin 10 (IL-10) and interleukin 2 (IL-2) are
also produced (Sarawar et al., 1996). IFNy and IL-2 stimulate CD8+ T cells that are
critical for virus clearance. Paradoxically, IFNy and IL-6 stimulate B-cell
proliferation, which may serve to increase the number of latently infected cells.
IFNy does not appear to be essential for viral clearance as transgenic IFNy deficient
mice resolve the acute infection almost as efficiently as wild type mice (Sarawar et
al., 1997). However, mice lacking the IFNy receptor exhibit splenic atrophy when
infected with MHV-68 and display a vast decrease in the number of splenic B and T
cells (Dutia et al., 1997). Type I interferons (interferon alpha and interferon beta)
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have been shown to be vital for clearance of the virus as IFNa/p receptor deficient
mice succumb to a fatal MHV-68 infection. Thus, both the adaptive and innate arms
of the immune response are critical in controlling MHV-68 infection.
1.5.6. Lymphoproliferative Disease Associated with MHV-68
Long-term infection of inbred mice with MHV-68 is associated with development of
tumours (Sunil-Chandra et al., 1994). Lymphoproliferative disease occurred in 9%
of chronically infected mice over a period of 9 months to 3 years following intranasal
infection with MHV-68, of which 50% were high-grade lymphomas. Lymphomas
were associated with both lymphoid and non-lymphoid tissue (lung, liver and
kidney). The number of mice developing lymphoproliferative disease rose to 60%
when treated with the immunosuppressive drug, cyclosporin A. The lymphomas
were of mixed B and T cell origin: in all cases the B cells were light chain restricted,
suggesting a clonal origin; T cells were CD3+ and belonged predominantly to the
CD4+ subset. MHV-68 DNA was detected in the absence of lytic antigen in a
variable number of cells in and around the lymphomas, thus indicating that the cells
were latently infected.
The virus infects myeloma cells (NSO, B cell lineage) in vitro and a state of latency is
achieved in which the virus genome exists in an episomal form (Sunil-Chandra et al.,
1993). Alternatively the B cell line, SI 1, was generated from spleen cells of a
chronically infected mouse showing evidence of lymphoma development. Sll cells
contain the MHV-68 genome in both episomal and linear form, although suppressing
lytic replication via acyclovir treatment can increase the ratio of circular to linear
genomes (Usherwood et al., 1996c).
1.6. Viruses and Immune Evasion
It is not uncommon for viral genomes to encode homologues of mammalian genes,
presumably acquired via a recombination event and conserved because they confer a
selective advantage. There are many such examples of "molecular piracy" among
members of the herpesvirus and the poxvirus family. Many of the cellular
homologues present in these viruses tend to be genes involved in immune regulation
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and such genes appear to confer an obvious advantage to the virus in escaping
immune surveillance and establishing a persistent infection.
1.6.1. Chemokine Binding Proteins
Chemokine binding proteins are a feature of several virus genomes and are
particularly prevalent amongst poxviruses. These are generally abundantly secreted
proteins that compete with cellular chemokine receptors for chemokines, thus
"mopping-up" the inflammatory response. For instance, vaccinia and cowpox virus
encode soluble homologues of the IL-1 (3 receptor that appear to enhance host
survival, and hence viral survival, by protecting against the adverse effects of
excessive cytokine production (Alcami & Smith, 1992; McMahan etal., 1991; Smith
& Chan, 1991; Spriggs et al., 1992). Myxoma virus secretes a glycoprotein (CBP-1)
that interacts with the conserved heparin-binding domain of CXC, CC and C
chemokines. Additionally, several poxviruses (variola, cowpox, vaccinia and Shope
fibroma virus) encode a soluble chemokine inhibitor (vCCI) with no significant
homology to cellular proteins that binds virtually all known CC chemokines and
reduces the influx of inflammatory cells into virus-infected tissues (Graham et al.,
1997; Smith et al., 1997). Soluble receptors for type I and type II interferons have
also been reported, which have the ability to modulate the IFN-induced antiviral state
(Alcami & Smith, 1996). There is also a chemokine-like molecule encoded by the
human poxvirus, Molluscum contagiosum, which has no intrinsic chemotactic ability
but antagonises cellular chemokines and has an inhibitory effect on human
haematopoietic progenitor cells (Krathwohl et al., 1997). Examples of broad-
spectrum chemokine-like antagonists have also been discovered in HHV-6, MCMV,
HCMV and KSHV (Nicholas etal., 1997; Penfold etal., 1999; Saederup etal., 1999;
Zou et al., 1999). The MHV-68 soluble protein, M3, has recently been designated a
chemokine-binding protein. M3, which is detectable during latent infection in vivo,
blocked the action of a more specific range of chemokines: RANTES, MlP-la,




HVS encodes several genes involved in immunomodulation: the ORF13 product has
72% identity with human IL-17, which is produced by CD4+ T cells. Like hIL-17,
vIL-17 activates the transcription factor, NFkB, stimulates IL-6 secretion in
fibroblasts, and co-stimulates T cell proliferation, thereby providing a selective
advantage to a T-lymphotropic virus (Yao et al., 1995).
The EBV genome includes a homologue of IL-10, a pleiotropic cytokine that inhibits
the production of IL-2 and IFNy and promotes the growth of B cells. The virus
homologue is 70% identical to its human counterpart and also functionally
analogous. vIL-10 enhances EBV-driven transformation of B cells. This effect is
likely to be mediated by increasing the number of viable B cells and reducing the
levels of IFNy, a cytokine known to inhibit EBV transformation (Stuart et al., 1995).
KSFTV encodes four cytokine homologues: three with homology to mammalian
macrophage inflammatory protein la (MlP-la), and one that is most closely related
to IL-6 (Moore et al., 1996a; Neipel et al., 1997). vMIPII binds a number of cellular
chemokine receptors but fails to activate any signalling pathways, suggesting that it
acts as a competitive antagonist (Kledal et al., 1997). Consistent with this, vMIPII is
a potent inhibitor of CC and CX3C chemokine-induced chemotaxis in vitro (Chen et
al., 1998). Both vMIPI and vMIPII induce angiogenesis in vitro while vIL-6 has a
proliferative effect on myeloma cells, thus strengthening the theory that deregulated
cytokine production is an important feature in the development of KS (Boshoff et al.,
1997; Burger et al., 1998). Furthermore, the discovery of an interferon regulatory
factor (vIRF) that suppresses type I IFN-induced gene expression and has a
transforming activity in vitro, indicates that KSHV escapes the immune response by
antagonising the IFN-mediated antiviral pathway (Li et al., 1998).
1.6.3. Regulators of Complement Activation
HVS possesses a homologue of mammalian CD59, a molecule involved in T cell
activation and restriction of complement-mediated lysis, that may offer protection to
infected cells (Albrecht et al., 1992b). The complement control protein homologue
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(CCPH) reduces complement-mediated lysis by inhibiting C3 convertase and down-
regulating deposition of the activated complement component, C3d, on the cell
surface (Fodor et al., 1995). CCPH is an alternatively spliced gene producing
soluble and membrane-bound isoforms. Positional homologues ofCCPH are present
in MHV-68 and KSHV, both encoded by ORF4 (Russo et al., 1996; Virgin et al.,
1997). The MHV-68 CCPH, like the HVS CCPH, inhibits cell-surface deposition of
C3d (Kapadiaeta/., 1999).
1.6.4. Super-Antigens
HVS ORF14 shares 22% amino acid identity with the mouse mammary tumour virus
(MMTV7) super-antigen. The ORF14 product is a secreted protein that binds MHC
class II and stimulates T cell proliferation (Yao et al., 1996). The selective
expansion of Vp4+/CD8+ T cell subset during MHV-68 infection is indicative of the
action of an as yet uncharacterised viral super-antigen (Tripp et al., 1997).
1.6.5. Mammalian IL-8 and its Receptors
Several herpesviruses encode homologues of the mammalian chemokine receptor,
CXCR2, which belongs to the superfamily of G protein-coupled receptors (GPCRs).
Many of these viral homologues have been found to be functional chemokine-
binding signalling molecules. Viral GPCRs are discussed in detail in the subsequent
sections but there firstly follows a description of their closest cellular homologue,
CXCR2.
The chemokines are a superfamily of small, structurally related cytokines that have
been shown to promote the rapid adhesion, chemotaxis and activation of leukocyte
effector subpopulations. Chemokines are classified as C, CC, CXC or CX3C, based
on the position of well-conserved cysteine residues. The CC chemokines include
RANTES, monocyte chemotactic protein (MCP-1) and MIP-1. The CXC
chemokines include IL-8, platelet factor 4 (PF4), neutrophil-activating peptide
(NAP-2) and growth-related oncogene (GROa). Lymphotactin and fractalkine are
the sole respective members of the C and CX3C groups.
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As the name suggests, CXCR2 binds CXC chemokines such as IL-8. IL-8 is a pro¬
inflammatory chemokine, which is secreted from many cell types in response to
stimulation by IL-ip, TNFa and lipopolysaccharide. It has also been reported that
EBV-immortalised lymphoblastoid cell lines, some neoplastic B cells and KS spindle
cells produce appreciable levels of IL-8 (di Celle, 1996; Merico et al., 1993; Sciacca
etal., 1994).
Binding of IL-8 to neutrophils results in a transient intracellular calcium flux which
signals changes in morphology, increased motility and transvenule migration (Huber
et al., 1991). Neutrophil effector mechanisms are rapid and antigen independent.
Degranulation results in the release of elastase and myeloperoxidase and a
respiratory burst gives rise to hydrogen peroxide and superoxide radicals, all of
which contribute to destroying pathogens. IL-8 is also a regulator of angiogenesis
(Maione et al., 1990). Angiostatic activity has been reported for other CXC
chemokines such as PF-4 and GROa but IL-8 possesses an ELR motif that confers
angiogenic activity (Strieter et al., 1995).
Two human IL-8 receptors have been identified, CXCR1 and CXCR2 that are 77%
identical at the amino acid level. CXCR1 binds only IL-8 with high affinity whereas
CXCR2 is a more promiscuous receptor with affinity for GROa and NAP-2 (Holmes
et al., 1991; Murphy & Tiffany, 1991). Expression of CXCR2 is confined to
neutrophils, neutrophil cell lines and myeloid-precursor cell lines. CXCR1 is
expressed on a much wider range of cells: PHA-activated T cell blasts, CD4+ cells,
monocytes and monocyte-like cell lines, melanoma cells, synovial fibroblasts in
addition to the myeloid cells which express CXCR2. Both human genes map closely
together on chromosome 2q35 along with a pseudogene for CXCR2. All three genes
probably arose as the result of a duplication event.
Mice encode only one gene with a high degree of homology to the two human
receptors for IL-8 (Lee et al., 1995). Although no rodent IL-8 has yet been
identified, human IL-8 induces chemotaxis of murine neutrophils and antibodies to
human IL-8 inhibit lung inflammation in the rat. This suggests that the absence of
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IL-8 is compensated by similar chemokines such as mouse MIP-2 (Tekamp-Olson et
al., 1990) and KC (Oquendo et al., 1989). Transgenic mice in which the receptor has
been deleted are outwardly healthy but exhibit lymphadenopathy and splenomegaly
indicative of increased B cells, melanocytes and neutrophils. The murine chemokine
receptor may therefore have a negative regulatory role in B cell and neutrophil
development. The migrational ability of neutrophils to sites of inflammation was
also severely compromised (Cacalano et al., 1994).
1.7. G Protein-Coupled Receptors
The guanine nucleotide binding (G) protein-coupled receptors (GPCRs) superfamily
of receptors contains almost 200 members, which are involved in a wide range of
processes such as neurotransmission, vision, olfaction and cardiac output. GPCRs
respond to such functionally diverse ligands as small biogenic amines (e.g.
adrenaline), chemokines (e.g. IL-8), neuropeptides (e.g. bradykinin) and large
glycoprotein hormones (e.g. luteinising hormone and parathyroid hormone).
1.7.1. GPCR Structure
Despite their functional diversity, GPCRs share a common structure characterised by
seven transmembrane domains, an extracellular N-terminus and a cytoplasmic C-
terminus (Gether & Kobilka, 1998). The conserved transmembrane domains contain
20-25 hydrophobic residues with an a-helical structure and are connected by
divergent hydrophilic loops. Evidence from X-ray diffraction studies of bacterial
rhodopsin indicates that the transmembrane domains are arranged in a barrel-like
structure with a tightly packed core (Pebay-Peyroula et al., 1997; Peitsch et al.,
1996). Mutational analysis of two chemokine receptors (CXCR4 and CCR5) has
revealed that five transmembrane domains (TM3-7) are sufficient for cellular
expression, signalling, internalisation and desensitisation (Ling et al., 1999).
However, this specificity is likely to be limited to certain GPCR subtypes since other
receptors such as the adenosine Al receptor require TM1 and TM2 for ligand
binding (Casey & Gilman, 1988).
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The majority of GPCRs are N-glycosylated at a consensus site (Asn-X-Ser/Thr) in
the N-terminal region, a modification that appears to affect the level of receptor
expression but not binding of the ligand (Strader et al., 1995). GPCRs invariantly
possess conserved cysteine residues that form a disulphide bridge linking the second
and third intracytoplasmic loops. This is thought to be critical for maintaining the
active conformation of the receptor (Karnik et al., 1988). Conserved serine and
threonine residues in the C-terminus are thought to be involved in receptor
desensitisation.
Deletion analysis of the aib-adrenergic receptor, P2-adrenergic receptor and the
angiotensin II receptor has revealed the importance of residues in the 2nd and 3rd
intracellular loops of GPCRs for coupling of G proteins (Samama et al., 1993;
Scheer et al., 1996; Scheer et al., 1997). In particular, a well-conserved motif, DRY,
occurs at the beginning of the second intracytoplasmic loop. Mutations in this
consensus motif are associated with constitutive signalling and oncogenicity. For
instance, the agonist-independent KSHV GPCR encodes a VRY motif at this
position and mutation of the CXCR2 DRY sequence to VRY results in constitutive
signalling and confers oncogenic properties. It is thought that substitution of the
aspartate residue with the hydrophobic valine alters the receptor structure by drawing
the loop into the plasma membrane, thus constraining the GPCR in an active
conformation (Burger et al., 1999). Further examination of the DRY motif in the
histamine (H2) receptor reinforced the importance of the aspartate and arginine
residues. Substitution of the aspartate residue resulted in high-level constitutive
signalling and increased agonist-affinity. Interestingly, mutations in these amino
acids also resulted in structural instability (Alewijnse et al., 2000).
1.7.2. GPCR Signalling
A common property of GPCRs is that upon activation they transmit signals across
the plasma membrane via an interaction with heterotrimeric G proteins (Stadel et al.,
1997). The signalling pathway shown in figure 1.7.2 is initiated by binding of the
specific ligand which, depending on the GPCR, may bind to the TM core, the TM
core and extracellular loops, extracellular loops and N-terminus, or exclusively to the
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Figure 1.7.2. G Protein-Coupled Receptor Signalling
G protein-coupled receptors transduce signals via their interaction with G proteins.
Ligand binding elicits a conformational change in the second intracellular loop of the
receptor that facilitates coupling of the heterotrimeric G protein. This results in GTP
hydrolysis, which leads to disassociation of the activated alpha (a) subunit from the
beta/gamma (p/y) complex. The alpha subunit binds to a second messenger such as
phospholipase C (PLC) thus triggering a signalling cascade. PLC breaks down into
inositol phosphate (lnsP3) and diaglycerol (DAG) which in turn mobilise intracellular
calcium and protein kinase C (PKC).
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N-terminus. This results in a conformational change in the receptor cytoplasmic
domain, allowing interaction of heterotrimeric G proteins with binding sites in the
second and third intra-cytoplasmic loops. The high-affinity agonist-receptor-G
protein complex catalyses guanine nucleotide exchange on the a subunit leading to
its dissociation from the p and y subunits. The active GTP-bound a subunit then
dissociates from the receptor and stimulates an intracellular effector molecule such as
adenylate cyclase, guanyl cyclase, phospholipases A2, C and D, calcium and
potassium channels (Strader et al., 1995). The GPCR may be desensitised by
GPCR-specific kinases or second messenger-activated protein kinases (e.g. protein
kinase C).
A major question regarding the sheer number and diversity of GPCRs is how the
specificity of the signal is determined. Some specificity is achieved via ligand
binding but since some GPCRs bind multiple ligands, a degree of specificity is also
mediated by G protein-coupling. At least twenty different Ga, five Gp and eleven
Gy subunits have been identified so far (Ray et al., 1995; Simon et al., 1991), The
Ga subunits can be subdivided (Gs, Gi, Gq) according to the pathways they activate
and GPCRs can be grouped according to the particular G protein subtypes they
predominantly interact with. Thus, receptors that couple to G; proteins stimulate
adenylate cyclase while Gq proteins mobilise intracellular calcium via activation of
phospholipase C. Nevertheless, there are some cellular GPCRs that can activate
more than one Ga subtype (Eason & Liggett, 1995; Laugwitz et al., 1996) and in
general, GPCRs display promiscuity for different Ga subunits in reconstitution
experiments. This potential for a large number of interactions between G proteins
and a single GPCR can therefore result in multifunctional signalling (Milligan,
1993). There is some evidence to suggest that the GPy subunits, which show only
limited coupling to other GPCRs in this type of experiment, are the more important
determinants of specificity. Also, targeting of GPCRs to specific membranes allows
the selectivity to be achieved by compartmentalisation of signalling components
(Neubig, 1998). Another dimension of GPCR signalling is their ability to function
synergistically. There are several examples, particularly among neurotransmitters,
where GPCR cross-talk results in amplification of a signal. For instance, the
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contractile effect of noradrenaline on blood vessels can be augmented by binding of
neuropeptide Y or serotonin to their GPCRs. In addition, GPCRs may also interact
with other receptor classes such as receptor tyrosine kinases to enhance signalling
(Selbie & Hill, 1998).
1.7.3. Oncogenicity of GPCRs
Many GPCRs are involved in growth and differentiation and have been shown to be
oncogenic in some contexts. For instance, the human mas oncogene was found to
encode the angiotensin receptor, a member of the GPCR family (Young et al., 1986).
Transfection of the serotonin 5HTlc receptor into NIH3T3 cells results in the
generation of transformed cellular foci, which produce tumours when injected into
nude mice (Julius et al., 1989). Similarly, a constitutively activating mutation in the
ctiB-adrenergic receptor enhances mitogenesis and tumorigenicity in Rat-1 and
NIH3T3 cells (Allen et al., 1991). The muscarinic acetylcholine receptor subtypes
have also been described as proto-oncogenes (Gutkind et al., 1991). The initial
transformation event appears to be agonist-dependent in the case of the serotonin
receptor and muscarinic acetylcholine receptors whereas transformation by the cxib-
adrenergic receptor is merely agonist-enhanced.
1.7.4. GPCRs and Disease
The ubiquitous nature of GPCRs ensures their involvement in a wide range of
diseases. For instance, naturally occurring mutations in cellular GPCRs such as the
thyrotropin receptor and PTH-PTHrP receptor have been linked with thyroid
adenomas and Jansen-type metaphyseal chondrodysplasia respectively (Parma et al.,
1993; Schipani etal., 1995; Van Sandeetal., 1995).
Several GPCRs appear to have an involvement in HTV pathogenesis. Although CD4
is the primary cell surface receptor for HIV, a number of chemokine receptors have
been identified that act as co-receptors for the virus, thus reflecting the extended
tropism of non-syncytium-inducing strains, which infect primary macrophage and T-
cell cultures. CXCR4 has been shown to be the principal co-receptor for primary
syncytium-inducing HTV isolates (Feng et al., 1996; McKnight et al., 1997), while
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CCR5 is the main co-receptor for non-syncytium-inducing isolates (Alkhatib et al.,
1996). Thus, HTV entry is inhibited in the presence of the chemokine ligands for
these receptors: RANTES, MlP-la and MIP-ip for CCR5 and SDF-1 for CXCR4
(Cocchi et al., 1995; Bleul et al., 1996; Oberlin et al., 1996). The finding that CCR5
appears important for transmission while CXCR4-using viruses develop late in
infection, make both these receptors important targets for anti-viral therapies (Huang
et al., 1996; Connor et al., 1997). However, there is evidence to suggest that
targeting the structure and folding of the GPCR using polypeptides derived from
transmembrane domains may be a more effective strategy than inhibiting ligand
binding (Tarasova et al., 1999).
1.8. Viral GPCRs
Many of the herpesviruses encode homologues of cellular GPCRs that have probably
been acquired from the host cell genome, and conserved because they confer a
selective advantage. Various hypotheses exist as to the function of viral GPCRs but
it is generally accepted that they play a role in virus persistence. Since the
gammaherpesvirus GPCRs bear greatest resemblance to a mammalian chemokine
receptor, it is possible that they have an immunomodulatory role and contribute to
immune-evasion. Alternatively, their capacity to transduce signals and transform
cells indicates a role in cell growth and proliferation, presumably to increase the
number of infected cells. A third possibility is that they may function as homing
receptors, trafficking infected cells to different lymphoid compartments. However,
as cellular GPCRs participate in such a wide range of biological processes, it is
perhaps unlikely that viral GPCRs share a single function. Table 1.8.1 lists examples
of viral GPCRs and their homology with CXCR2 and the MHV-68 GPCR.
1.8.1. The KSHV GPCR
KSHV encodes a functional G-protein coupled receptor with homology to the
mammalian IL-8 receptor, CXCR2 (Cesarman et al., 1996b; Guo et al., 1997).
Competitive binding studies have shown that unlike CXCR2, the viral receptor binds
a wide range of both CC and CXC chemokines. The KSHV GPCR exhibits agonist-
independent signalling activity, as measured by the accumulation of the second
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Table 1.8.1. Similarity between Viral GPCRs and Mammalian CXCR2




HVS ORF74 30% 23%
KSHV ORF74 27% 25%
RRV ORF74 29% 27%
EHV-2 ORF74 21% 22%
EHV-2 E1 34% 23%




CMV US28 34% 28%
CMV UL33 26% 23%
MCMV M33 23% 21%
RCMV R33 26% 19%
HHV-6 U12 19% 19%
HHV-7 U12 19% 23%
The percentage amino acid (aa) identity between each known herpesvirus GPCR
homologues and the MHV-68 GPCR was calculated using the gcg10 "GAP" alignment
programme. The identity between each viral receptor and CXCR2, the closest
homologue of the MHV-68 GPCR, is also shown.
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messenger, inositol phosphate (Arvanitakis et al., 1997). This has also been
demonstrated by deletion of the N-terminus, which abrogates chemokine binding but
does not affect basal signalling activity (Ho et al., 1999). However, signalling
activity is up-regulated by the angiogenic chemokines IL-8 and growth-related
protein a (GRO-a) and inhibited by angiostatic chemokines - interferon inducible
protein (IP-10), platelet factor 4 (PF-4), monokine induced by IFNy (MIG) and
interferon-inducible T cell a attractant (I-TAC, GerasRaaka et al., 1998;
Gershengom et al., 1998). The GPCR signals via the phosphoinositide-protein
kinase C pathway but also activates two other protein kinase pathways (Arvanitakis
et al., 1997; Bais et al., 1998).
The KSHV GPCR has been shown to have a transforming activity when expressed in
NIH3T3 cells and transformed cells expressing the GPCR are also tumorigenic in
nude mice. The GPCR triggers an "angiogenic switch" resulting in secretion of large
amounts of vascular endothelial growth factor (VEGF, Bais et al., 1998). As KS is a
vascular tumour, stimulation of angiogenesis by induction of VEGF and other
angiogenic chemokines is likely to contribute to oncogenesis. In situ hybridisation
experiments have detected expression of the GPCR in only a minority of spindle
cells within KS lesions and in uninduced BCBL-1 cells, coincident with other lytic
cycle genes (Kirshner et al., 1999).
1.8.2. EBV and Cellular GPCRs
The Epstein Barr virus does not encode a GPCR homologue. However, it does
induce expression of three GPCRs: EBI1, a homologue ofCXCR2 (40% amino acid
identity); EBI2, which shares limited amino acid identity (24%) with the thrombin
receptor and BLR1 (Kaiser et al., 1993; Birkenbach et al., 1993; Burgstahler et al.,
1995; Dobner et al., 1992). EBI1, now designated CCR7, is expressed exclusively in
lymphoid tissues and activates B and T cells (Yoshida et al., 1997). It is strongly up
regulated in EBV-infected cells and is transactivated by EBNA-2. BLR1 is
expressed in lymphocytes and is the first GPCR shown to be involved in B-cell
trafficking. In transgenic mice lacking BLR1, lymphocytes fail to migrate into
splenic follicles and since activated B cells do not traffic from the T-cell rich zone
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into B-cell follicles, there are no functional germinal centres (Forster et al., 1996).
The advantage of BLR1 to EBV, a B-cell tropic virus, would presumably involve
targeting of infected B cells to germinal centres for expansion. Interestingly, EBI1 is
also induced by HHV-6 and HHV-7 (Hasegawa et al., 1994).
1.8.3. The HVS GPCR
Like KSHV and MHV-68, the HVS ORF74 encodes a GPCR also known as ECRF3
(Nicholas et al., 1992). The HVS GPCR selectively binds and responds to CXC
chemokines, as measured by calcium fluxes in Xenopus laevis oocytes reconstituted
with ECRF3 cRNA (Ahuja & Murphy, 1993). Unlike the KSHV GPCR, the
signalling activity does not appear to be ligand-independent.
1.8.4. The CMV GPCRs
Four GPCR homologues have been identified in the HCMV genome: US27, US28,
UL33 and UL78 (Chee et al., 1990; Gompels et al., 1995). US28 mediates vascular
smooth muscle cell migration in response to CC chemokines, as evidenced by
abrogation of this function in recombinant HCMV lacking US28 (Streblow et al.,
1999; Vieira et al., 1998). It is likely that US28 plays a role in the pathology of
vascular conditions associated with HCMV such as atherosclerosis and organ
transplant vascular sclerosis (Melnick et al., 1996; Peterson et al., 1980; Zhou et al.,
1996). Human immunodeficiency virus (HTV-1 and HIV-2) utilises as many as ten
different GPCRs as co-receptors for entry into cells, of which one is US28 (Pleskoff
etal., 1997).
An unusual feature of UL33 is its presence in the virus envelope, suggesting that it
might be inserted directly into the host cell membrane upon virus entry (Margulies et
al., 1996; Welch et al., 1991). Ablation of the mouse CMV (MCMV) UL33
homologue results in a lower mortality rate in immunocompromised rats and failure
of the virus to replicate in the salivary glands (DavisPoynter et al., 1997). A similar
observation has been made of the UL33 gene in rat CMV (Beisser et al., 1998).
GPCR homologues are also present in the other human betaherpesviruses, HHV6 and
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HHV-7 (Gompels et al., 1995; Nicholas, 1996). HHV-6 UL12 encodes afunctional
receptor that binds CC chemokines (Isegawa et al., 1998).
1.8.6. Other GPCR Homologues
The swinepox and capripox viruses both encode GPCR homologues, the function of
which has not been determined (Cao et al., 1995; Massung et al., 1993). Other
gammaherpesvirus GPCRs include the AHV-1 GPCR, rhesus rhadinovirus (RRV)
ORF74 and equine herpesvirus 2 (EHV-2) El and E6 (Alexander et al., 2000; Ensser
et al., 1997; Telford et al., 1995). Again, little is known of the gene function
although an in vitro transforming activity has been demonstrated for the RRV GPCR
(Estep & Wong, 2000).
1.9. Viruses and Transformation
The study of DNA tumour viruses has provided a wealth of information regarding
cellular transformation. Many tumour viruses and carcinogens will rapidly and
reproducibly alter fibroblasts in vitro so that certain aspects of their morphology and
growth characteristics come to resemble tumour cells. After being altered in this
way, a cell is said to be transformed. Since the oncogenic properties of viruses,
carcinogens and individual genes are conventionally tested on fibroblasts,
transformation is defined by a set of differences in the growth properties of
fibroblastic cells in culture. Transformed cells may exhibit any of the following
characteristic changes, although a cell that possesses any one of these alterations
does not inevitably possess all of the others (Tooze, 1973).
1.9.1. Fibroblastic Cells in Culture
Following explantation of human foetal cells, the type of cell that predominates in
the primary culture is fibroblastic. Cultured "fibroblasts" have the same morphology
as tissue fibroblasts but are less differentiated, retaining the capacity to form
mesodermal cells such as fat, connective tissue and muscle if supplied with
appropriate stimulatory factors. A primary human fibroblast culture will undergo
approximately 50 rounds of cell division before they cease growth and die (Hayflick
& Morehead, 1961). A lineage of cells originating from an initial explant has a finite
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lifespan and is known as a cell strain. Unlike human cells, embryonic rodent cells
readily give rise to cell lines, which are immortal. After about 30 divisions, a
primary rodent cell strain will undergo "crisis", during which most of the cells die.
At this time, a rare cell variant may emerge that continues to divide and takes over
the culture. The emergent immortal cell line usually has an abnormal number of
chromosomes and other changes in growth properties associated with transformation.
However, there is a clear distinction between immortalisation and transformation.
Todaro and Green discovered that if a primary culture ofmouse fibroblastic cells was
maintained at low density throughout the crisis period, the post-crisis cell line
retained normal growth controls and was not tumorigenic in vivo (Todaro, 1963).
This cell line, named 3T3 because it was derived from 3x105 cells transferred every 3
days, has an infinite capacity to divide but ceases division once the cells have formed
a confluent monolayer. It was found that the degree of saturation density under
which the cell lines were maintained was directly proportional to their
tumorigenicity. Thus 3T12 was highly tumorigenic, requiring fewer cells and a
shorter period of time to generate a tumour than 3T6 (Aaronson & Todaro, 1968).
This demonstrated for the first time, the importance of cell-cell contact in the control
of cell division. Despite retaining most of the features of untransformed fibroblasts,
3T3 cells are nevertheless aneuploid, immortal and are more readily agglutinated by
lectins such as concavalin A (Stoker, 1967).
1.9.2. Properties of Transformed Cells
The growth of primary fibroblast cells is regulated by contact from neighbouring
cells and it has been shown that cell contact plays a role in inhibiting cell division
(Dulbecco, 1970). Primary fibroblast cells and the cells of most fibroblastic cell
lines also require attachment to a solid surface in order to divide, a phenomenon
termed anchorage dependence ofmultiplication (Stoker et al., 1968). In transformed
cells, these growth control signals are de-regulated resulting in loss of contact
inhibition and anchorage-independent growth.
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Most mammalian cells in tissue culture require to be supplemented with serum in
order to divide (Jainchill, 1970). Serum contains essential growth factors such as
epidermal growth factor, insulin, insulinlike growth factor and transferrin, which are
required by most cells in tissue culture (Gospodarowicz & Moran, 1976). The
addition of lfesh serum to a quiescent culture reinitiates growth and generates a
number of cells proportional to the level of serum added, thus revealing that cell
growth is controlled by factors other than cell-cell contact (Holley & Kiernan, 1968).
Transformed cells, however, have a reduced serum requirement, presumably because
overriding normal growth control mechanisms reduces the need for growth factors.
In some cases, transformed cells produce both growth factors and their cognate
receptors thus providing autocrine stimulation. Transformed cells are said to have
lost the capacity for growth arrest and will even continue dividing to the point at
which the whole culture dies because nutrients in the medium have been exhausted.
Many of the changes in growth properties of transformed cells are related to
alterations in cell surface molecules. Modification of the links between cytoskeletal
elements and proteins in the plasma membrane are thought to cause the increased
mobility of the latter. This would account for the greater ease of agglutination by
antibodies or lectins in transformed cells than in normal cells (Burger & Martin,
1972). Actin microfilaments that normally extend the length of normal cells tend to
be either diffusely distributed or concentrated at the cell surface of transformed cells
(Weber, 1974). In addition to altering the mobility of plasma membrane proteins,
changes in the cytoskeleton also directly affect cellular morphology, resulting in a
more rounded appearance. Transformed cells also exhibit a higher glycolytic activity
due to the cell surface expression of a rapid high-affinity glucose transporter that is
ordinarily expressed on brain cells and erythrocytes (Hatanaka, 1974). The amount
of fibronectin on the surface of transformed cells is also greatly reduced, which is
presumably a major factor in facilitating anchorage independent growth.
Transformed cells often secrete plasminogen activator, an enzyme that converts
plasminogen to the protease, plasmin. The secretion of proteases by transformed
cells has been implicated in their capacity to form tumours as protease digestion of
the basal lamina may promote tumour cell invasion of surrounding tissues.
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Another feature of transformed cells is genetic instability. Most cell lines are
aneuploid, for example 3T3 cells have on average 70 chromosomes per cell but their
chromosomal complement continually expands and contracts in culture. Tumour
cells are generally heteroploid but may also exhibit chromosomal translocations e.g.
Burkitt's lymphoma cells. Of course, all the changes associated with immortalisation
and transformation described above have a genetic basis. A change in the expression
of one or two genes, proto-oncogenes or tumour suppressors, is sufficient to
transform a cell. The "two-hit hypothesis" of oncogenesis was proposed by
Knudson, who showed that both alleles of the Rb gene must be inactivated in order to
produce retinoblastoma (Knudson, 1971). Transfection of primary rat embryo cells
with the ras oncogene induces morphological changes associated with transformation
but does not result in immortalisation (Land et al., 1986). However, co-transfection
with ras and myc produces fully transformed, immortal, tumorigenic cell lines, thus
indicating that there are two broad classes of oncogene: cytoplasmic rav-like
oncogenes and nuclear myolike oncogenes. Although this model of co-operativity
has been complicated by experiments showing single-step transformation with
certain oncogenes, it suggests that immortal cell lines such as 3T3 provide a good
substrate for assessing transformation since they already possess an active myc-Y\ke
oncogene. Many types of proto-oncogene have been described including growth
factors and their receptors, intracellular signalling molecules, transcription factors
and cell-cycle control genes. In general, oncogenes are mutated or aberrantly
expressed forms of cellular genes. Oncogenic viral genes are often homologues of
cellular genes but some viruses encode transforming genes that have no cellular
counterparts. Examples of herpesvirus oncogenes are given in the following
sections.
1.9.3. Viral Oncogenes
The role of viral oncogenes is somewhat puzzling as tumour development has been
described as a biological "dead-end" for the virus, killing the host and with it any
chance of transmission to a new host (Moore & Chang, 1998). Promoting cell
division facilitates viral replication and transmission to daughter cells but is an
inefficient method of generating progeny. It seems more likely that viral oncogenes
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have a more complex function, perhaps subverting tumour-suppressor pathways in
order to overcome host defences against infection and induce lytic cycle replication.
It is also worth remembering that tumours associated with viruses usually occur in
organisms other than the natural host. For example herpesvirus saimiri and
adenoviruses are only oncogenic in non-natural host species (Rangan et al., 1977;
Wold et al., 1994). Herpesviruses in general are tumorigenic only in abnormal
circumstances such as immunosuppression of the host e.g. AIDS-KS or the
expression of a complementing oncogene e.g. Burkitt's lymphoma. Viruses have
accrued a range of strategies to escape cell cycle control and these include the
acquirement of cellular gene homologues involved in cell growth control as well as a
number of unique genes with oncogenic properties.
1.9.4. Cyclin D Homologues
HVS, KSHV and MHV-68 all encode cyclin homologues (Cesarman et al., 1996b;
Nicholas et al., 1992; Virgin et al., 1997). Cyclins activate cellular kinases (cyclin-
dependent kinases, cdks), which in turn phosphorylate cell cycle checkpoint
molecules and thereby facilitate progression of cells through the cell cycle.
Activation of cdk6 results in phosphorylation of the retinoblastoma protein (RBI),
causing it to dissociate from the replication factor, E2F. The KSHV v-cyclin
activates cdk6, a kinase normally stimulated by type D cyclins that drive the cell
through the Gi checkpoint. The KSHV v-cyclin is more promiscuous than cellular
type D cyclins, not only promoting phosphorylation of RBI but also histone HI.
(Chang et al., 1996; Godden-Kent et al., 1997). The MHV-68 v-cyclin also
promotes cell cycle progression and transgenic mice that express the gene in T cells
develop lymphomas (van Dyk et al., 2000). In addition, recombinant MHV-68
lacking the v-cyclin gene does not reactivate efficiently from latency (Hoge et al.,
2000). Therefore, viral cyclins are likely to play an important role overriding cell
growth control mechanisms to facilitate virus replication and persistence.
1.9.5. Anti-Apoptotic Gene Homologues
In a normal cell, the main defence against de-regulated growth and uncontrolled
division is induction of apoptosis, a strategy of self-destruction for the greater benefit
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of the whole organism. Apoptosis is also a typical response to virus infection,
thereby limiting production of virus progeny. Viruses have evolved a variety of
mechanisms to inhibit apoptosis, one of which appears to be encoding a homologue
of the cell-rescue factor, Bcl-2. The bcl-2 gene was first discovered at the junction of
a chromosomal translocation in B cell lymphomas. Overexpression of bcl-2 permits
survival of B cells that would normally undergo programmed cell death, thus
resulting in lymphoma. Functional Bcl-2 homologues are encoded by HVS, KSHV,
EBV and MHV-68 (Hendersonetal., 1993; Navaetal., 1997; Smdetal., 1997; Roy
et al., 2000; Wang et al., 1999). Therefore, conservation of a functional Bcl-2
homologue in gammaherpesviruses suggests that overcoming apoptosis is an
important part of their pathobiology.
The KSHV vIRF has a transforming activity in vitro and effectively inhibits IFN
signalling (Gao et al., 1997; Zimring et al., 1998). This appears to be a common
characteristic among viruses: adenovirus El A protein and the EBV EBNA-2 protein
both down regulate the IFN response (Kanda et al., 1992; Reich et al., 1988). As
mentioned previously, IFN is an important part of the antiviral immune response.
For instance, IFN up-regulates MHC molecules to enhance immune detection and
shuts off nucleic acid synthesis in uninfected cells. In addition, the IFN response
initiates cell cycle arrest and apoptosis in infected cells. Therefore, inhibiting IFN
signalling is another mechanism viruses have evolved for suppressing apoptosis that
also has an oncogenic consequence.
KSHV also encodes a homologue of the cellular FLICE-inhibitory protein (FLIP), a
molecule that blocks cell death induced by the tumour necrosis (TNF) family of
receptors. A likely function of the KSHV v-FLIP is to protect virus-infected cells
from apoptosis and therefore contribute to persistence (Thome et al., 1997).
Although no direct transforming activity of v-FLIP has been demonstrated in vitro,
there is evidence that overriding apoptotic signals mediated by the TNF family of
receptors (i.e. CD95) is a contributory factor in the development of hepatomas and
melanomas (Hahne et al., 1996; Strand et al., 1996).
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1.9.6. Gammaherpesvirus-specific Oncogenes
A feature of the HVS, EBV, KSHV and RRV genomes is the presence of oncogenic
genes at the left-hand end. These are all transmembrane signalling proteins and
include HVS saimiri transforming protein (STP) and tyrosine kinase interacting
protein (Tip); EBV LMP-1; KSHV K1 and K15; RRV Rl.
HVS STP is essential for the transforming activity of the virus and variations in STP
differentiate the three HVS strains. Strain C is the most highly oncogenic and the
association of STP-C with the cellular oncogene, ras, is vital to its transforming
activity (Jung & Desrosiers, 1995). STP-C also interacts with the tumour necrosis
associated factor (TRAF) family of signalling molecules, which activate the cellular
transcription factor, NFkB. Interestingly, STP-A does not interact with Ras and
although it associates with TRAFs, it fails to activate NFkB (Lee et al., 1999). HVS
Tip, which is unique to strain C, associates with the T-cell tyrosine kinase, Lck,
thereby inhibiting signalling via the T cell receptor. Mutations in Tip that abrogate
interaction with Lck increase the transforming activity of strain C (C488), which
suggests that Tip may have a role in regulating the transforming potential of HVS
(Duboiseeta/., 1998b).
The EBV LMP-1 protein is an integral membrane phosphoprotein with a cytoplasmic
amino terminus, six transmembrane domains and a long cytoplasmic carboxy
terminus. Multimerisation of LMP-1 mimics the activated ligand-induced
conformation of the B cell receptor, CD40. This generates a constitutive activation
signal that contributes to B cell transformation. The carboxy terminus of LMP-1 has
been shown to interact with members of the TRAF signalling proteins and also the
TNF-receptor death domain (TRADD) (Eliopoulos et al., 1999; Mosialos et al.,
1995). This results in activation of the transcription factor, NFkB, and the JNK
signalling pathway (Huen et al., 1995), which induces expression of a variety of
proteins including epidermal growth factor (EGFR, Miller et al., 1995b) and Bcl-2.
The TRAF-binding domain has been shown to be essential for transformation (Wang
etal., 1988).
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KSHV K1 and RRV R1 are positional homologues of HVS STP and EBV LMP-1.
K1 and R1 both have transforming activity in rodent fibroblasts and can functionally
substitute HVS STP in T cell transformation (Damania et al., 1999; Lee et al., 1998).
K1 is a constitutively active receptor that interacts with cellular tyrosine kinases such
as Vav, p85 and Syk to activate the transcription factor, NFAT, leading to cell
growth (Lagunoff et al., 1999).
1.9.7. SV40 Tumour Antigens
Although not a herpesvirus, the transforming activity of the SV40 early region is
mentioned here with relevance to the transformation assays described in chapter
three. The SV40 early region encodes three tumour antigens (TAg): large T, middle
T and small T, all arising from differential splicing of the early region transcript.
Although large TAg is sufficient to cause immortalisation and transformation of
primary rodent cells, small TAg enhances large TAg-induced transformation (Bikel
et al., 1987). The mechanism of large TAg transformation appears to be functional
inactivation of Rb by preventing binding of the replication factor, E2F (Sullivan et
al., 2000).
Therefore, viruses have evolved various ways of circumventing the host antiviral
responses, including apoptosis, immune activation and cell cycle arrest. Either by
encoding viral homologues of cellular signalling molecules or by inducing
expression of host proteins, gammaherpesviruses are capable of modulating host cell
growth and proliferation to facilitate virus replication and persistence.
AIMS
The aim of this project was to characterise the MFTV-68 GPCR and investigate its
role in the pathogenesis of the virus. Several approaches were taken including
analysis of the transcription pattern of the GPCR gene and the sub-cellular
localisation of the GPCR protein. The potential transforming activity of the gene
was examined and lastly, attempts were made to define the contribution of the gene
to MHV-68 pathogenesis by constructing a recombinant virus lacking the GPCR.
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2.1. General Solutions
Unless otherwise stated, all chemicals were obtained from Sigma or BDH Merck.














lOmM Tris-HCl [pH 7.9]
ImM EDTA [pH 8.0]
0.04M Tris-acetate
ImM EDTA [pH 8.0]
0.045M Tris-borate
ImM EDTA [pH 8.0]
1Og/L bactotryptone
5g/L bacto yeast extract
lOg/L NaCl
LB + 15g/L bacto-agar
LB + lOmM glucose, lOmM MgSC>4, 20mM MgCI2
50mM glucose





2M acetic acid [pH 4.8]
3M NaCl
0.2M NaH2P04.H20















dH20: Distilled water was used throughout for making up
solutions and for rinsing glassware etc. Milli-Q water
(Millipore) was used in all enzymatic reactions and in
preparation of nucleic acid and protein.
2.2. DNA Extraction and Manipulation
Molecular cloning was carried out essentially as described by (Sambrook et al.,
1989).
2.2.1. Plasmid Vectors
The following plasmid vectors were used: pKS(-) (Stratagene), pGEX-2T
(Amersham Pharmacia), pBABE/puro (Morgenstern & Land, 1990) and
pVR1255/uc~ (Hartikka et al., 1996). Appendix 2 contains diagrammatic information
on these plasmids.
2.2.2. Polymerase Chain Reaction
The polymerase chain reaction (PCR) was typically performed in a volume of 1 OOpl
containing a final concentration of 0.25mM 2'-deoxyadenosine-5'-triphosphate
(dATP), 2'-deoxyguanosine-5'-triphosphate (dGTP), 2'-deoxycytidine-5'-
triphosphate (dCTP), 2'-deoxythymidine-5'-triphosphate (TTP, Ultrapure dNTP set,
Amersham Pharmacia), reaction buffer (lOmM Tris-HCl, 1.5mM MgCl2, 50mM KC1
[pH 8.3], Life Technologies) 0.2pmole/pl each primer, 100-500ng DNA template
and 1U Taq DNA polymerase (Life Technologies). PCR was carried out in thin-
walled 0.5ml Eppendorf tubes on an Omnigene thermal cycler (both Hybaid) under
the following conditions: reactions were heated to 94°C for 5mins, then held at the
annealing temperature while the enzyme was added ("hot-start"), thus limiting non¬
specific amplification. The block was programmed to repeat 25-40 cycles of 30s
denaturation at 94°C, lmin annealing at specific temperatures, 1.5-3min extension at
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72°C ending with 5mins at 72°C. DNA was also amplified using PfuTurbo™ DNA
polymerase (Stratagene). Reactions were performed in a volume of IOOjlxI containing
cloned Pfu DNA polymerase reaction buffer (20mM Tris-HCl [pH 8.8], 2mM
MgS04, lOmM KC1, lOmM (NH4)2S04, 0.1% Triton® X-100, O.lmg/ml nuclease-
free BSA, Stratagene) 0.25mM each dATP, dCTP, dGTP, TTP, 0.3pmole/pl each
primer, 100-500ng DNA template and 2.5U Pfu Turbo'" DNA polymerase. The
cycling parameters were similar to those used for PCR with Taq DNA polymerase
except that no "hot-start" was required. Oligonucleotide sequences and annealing
temperatures are listed in Appendix 1. All primers were obtained from MWG-
Biotech with the exception of primer pair 1 (Cruachem). PCR products were
analysed by agarose gel electrophoresis.
2.2.3. Agarose Gel Electrophoresis
DNA (typically '/io reaction or <lpg) was mixed with lp.1 gel loading buffer (15%
ficoll type 400 (w/v), 0.25% bromophenol blue (w/v), 0.25% xylene cyanol (w/v),
0.25% orange G (w/v) in dH20). Sample volumes were equalised with dH20 and
loaded onto agarose gels containing 0.8-2% agarose (SeaKem®, Flowgen) and
0.5pg/ml (w/v) ethidium bromide in TAE buffer. Electrophoresis was carried out in
a horizontal tank (BIO-RAD) containing TAE or TBE buffer at 60-70V. The size of
DNA bands was estimated by comparison with DNA molecular weight markers (lkb
DNA ladder, Life Technologies). DNA bands were visualised using a short wave
UV transilluminator (UVP inc.).
2.2.4. Isolation of DNA Fragments from Agarose Gels
DNA bands were excised from agarose gels using a scalpel blade. Dialysis tubing
was prepared by boiling for several minutes in ImM EDTA. The tubing was washed
thoroughly in dH20 and closed at one end with a clip. The agarose gel slice was
inserted into the tubing with 0.5-1.0ml TAE. All air bubbles were removed and the
tubing was sealed at the other end. The dialysis tubing was placed in a mini-gel tank
and electrophoresed at 60V for one hour. The current was briefly reversed (30s) to
remove any DNA attached to the inside of the tube. Elution of DNA was verified
using a short wave UV transilluminator. The DNA was transferred to a clean
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Eppendorf tube and a phenol-chloroform extraction was performed. The DNA was
recovered by ethanol precipitation.
2.2.5. Purification of PCR Products
Amplified DNA was purified using the Wizard® PCR Product Purification kit
(Promega) according to the manufacturer's instructions. Briefly, DNA was
resuspended in lOOpl direct purification buffer (50mM KC1, lOmM Tris-HCl [pH
8.8], 1.5mM MgCh, 0.1% Triton® X-100) then incubated with 1ml purification resin
for lmin. During this time, the slurry was mixed three times using a vortex. The
mixture was applied to a mini-column using a 5ml syringe. The column was washed
with 2ml 80% propan-2-ol and dried by centrifugation (10,000g, 2mins). The DNA
was eluted with 50pl MilliQ dfEO at 70°C.
2.2.6. Phenol-Chloroform Extraction
DNA was purified by a phenol-chloroform extraction procedure. A mixture of
phenol [pH 7.9], equilibrated with TE, chloroform and iso-amyl alcohol in a ratio of
25:24:1 (v/v) was added to an equal volume ofDNA in a 1.5ml Eppendorf tube. The
contents of the tube were thoroughly mixed using a vortex for 30s then centrifuged
(9000g) for 2mins. The upper aqueous phase containing the DNA was transferred to
a clean tube and the procedure was repeated until the interface between the aqueous
and non-aqueous solutions became clear. A single chloroform extraction was
performed to ensure removal of phenol from the DNA. The DNA was recovered by
ethanol precipitation.
2.2.7. Ethanol Precipitation
DNA was precipitated in 2.5vols ethanol (96% Analar) and 0.5vol 7.5M ammonium
acetate or 0.1 vol 3M sodium acetate at -20°C for one hour. The precipitated DNA
was centrifuged (9000g, lOmins), washed in 70% ethanol and resuspended in an
appropriate volume ofTE or MilliQ dH20.
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2.2.8. Quantification of DNA
DNA concentration was assessed using a fluorometer (DyNAQUANT™ 200, Hoefer
Amersham Pharmacia). Briefly, DNA was diluted 1:1000 in a solution containing
Hoechst dye (bisbenzimide). Binding of the dye to the minor groove ofDNA results
in a shift in the emission spectrum that can be measured using a filtered
photodetector. The DNA concentration is calculated by comparing the signal to that
obtained with a DNA standard of known concentration.
2.2.9. Digestion of DNA with Restriction Enzymes
DNA restriction enzymes were obtained from Life Technologies and used with the
supplied buffers according to the manufacturer's instructions. DNA restrictions were
typically carried out for three hours at 37°C in a volume of lOOpl containing 10 units
of each enzyme per l-10pg ofDNA.
2.2.10. Blunt-Ending of DNA Fragments
DNA overhanging ends generated by restriction enzymes were filled in to facilitate
ligation with blunt-ended vector DNA. DNA fragments with 3'-overhanging ends
(100-500ng) were incubated in a volume of lOOpl containing a final concentration of
0.25mM dATP, dGTP, dCTP, TTP, T4 DNA polymerase buffer (33mM tris-acetate
[pH 7.9], 65mM sodium acetate, lOmM magnesium acetate, 5mM dithiothreitol,
lOOpg/ml bovine serum albumin) and 1U T4 DNA polymerase (Life Technologies).
The mixture was incubated at 37°C for 20mins.
2.2.11. De-phosphorylation of Linearised DNA
In order to prevent re-circularisation during ligation reactions, the 5'-phosphate
group on each end of linearised vector DNA was removed using calf intestinal
phosphatase (CIP, Roche). Following restriction digest, the DNA was incubated
with 10U CIP for 20mins at 37°C. The DNA was extracted with phenol-chloroform,
ethanol-precipitated and quantified prior to ligation.
55
CHAPTER TWO MATI -RIALS & METHODS
2.2.12. Ligation of DNA Fragments
Ligation was carried out overnight at 4°C in a final volume of 20pl containing
approximately 250-500ng of the DNA fragment to be inserted and 50-100ng of
linearised vector DNA in a 5:1 ratio, ligation buffer (50mM Tris-HCl [pH 7.6],
lOmM MgCb, ImM ATP, ImM dithiothreitol, 5% (w/v) polyethylene glycol-8000)
and 1U T4 DNA ligase (both Life Technologies).
2.2.13. Transformation of Competent Bacteria
Escherichia coli bacteria (Epicurean coli XL 1-Blue sub-cloning-grade competent
cells, Stratagene) were transformed according to Hanahan, 1983. Competent cells
(50pl) were thawed on ice and incubated for lOmins with 0.8pl 1.44M (3-
mercaptoethanol in a 15ml polypropylene Falcon tube. Ligation mix (2pl)
containing 30-60ng DNA was added and the mixture incubated on ice for a further
30mins. The bacteria were placed at 42°C for 45s and then chilled on ice for a
further 2mins. SOC medium (900pl) was added and shaken for one hour at 37°C.
Bacteria (25pi or lOOpl) were spread onto LB agar plates containing an appropriate
antibiotic (lOOpg/ml ampicillin or 30pg/ml kanamycin A, both Sigma). The
remaining volume was centrifuged (9000g, lmin) and the pellet resuspended in
lOOpl before spreading onto a separate LB agar plate. Plates were incubated
overnight at 37°C.
2.2.14. Small-Scale Preparation of Plasmid DNA
A number of single bacterial colonies (12-24) were grown overnight at 37°C with
shaking in 10ml L-Broth containing lOOpg/ml ampicillin or 30pg/ml kanamycin A.
Bacteria were pelleted by centrifugation (1500g, 5mins) and resuspended in 200pl
glucose solution containing 70pg/ml lysozyme (Sigma) and incubated at RT for
5mins. Bacteria were disrupted by the addition of 400pl denaturation solution,
inverted several times to mix and incubated on ice for 5mins. Ice-cold neutralisation
solution (300pl) was added to the tubes, which were mixed by inversion and placed
on ice for 5mins. The mixture was centrifuged (1 l,000g, 5mins) and the supernatant
transferred to a new Eppendorf containing 500pl ice-cold propan-2-ol. The
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precipitated DNA was centrifuged (ll,000g, 5mins) and resuspended in 200pl TE.
Insoluble material was precipitated by the addition of 0.5vol 7.5M NH4AC.
Following centrifugation, the supernatant containing the DNA was transferred to a
new Eppendorf containing 2vols ice-cold ethanol and incubated at -20°C for one
hour. The DNA was centrifuged (1 l,000g, lOmins), and the pellet washed with 70%
ethanol, air-dried and resuspended in 50pl TE.
2.2.15. Small-Scale Preparation of Plasmid DNA for Sequencing
Plasmid DNA required for the purpose of sequencing was prepared using the
QIAprep® Spin Miniprep Kit (QIAGEN), according to the manufacturer's
instructions. A single colony was used to inoculate 5ml of LB (supplemented with
an appropriate antibiotic) and grown overnight at 37°C with shaking. Bacteria were
pelleted by centrifugation (1500g, 5mins) and resuspended in 250pl of buffer PI.
The cells were lysed by the addition of250pl of buffer P2 and then neutralised by the
addition of 350pl of buffer N3. The cell debris was pelleted by centrifugation
(lOOOOg, lOmins) and the supernatant decanted onto the spin column. The column
was centrifuged (10000g, lmin) and the flow-through was discarded. The column
was washed by the addition of 750pl of Buffer PE and centrifuged as above. The
flow-through was again discarded and the column centrifuged for an additional lmin
to remove residual wash buffer. The DNA was eluted from the column by the
addition of 50pl of buffer EB.
2.2.16. Large-Scale Preparation of Plasmid DNA on CsCl Gradients
Large-scale plasmid purification was carried out on CsCl gradients. Bacterial
cultures (400ml) were grown overnight in LB containing appropriate antibiotic.
Bacteria were centrifuged in 250ml centrifuge bottles (5000g, 5mins, 4°C) and the
pellet resuspended in 20ml glucose solution containing 70p.g/ml lysozyme.
Following lOmins incubation at RT, the bacteria were disrupted by the addition of
40ml denaturation solution and chilled on ice for 5mins. A volume (20ml) of ice-
cold neutralisation solution was added and the lysate incubated on ice for a further
15mins. The lysate was centrifuged (12,000g, 30min, 4°C) and the supernatant
filtered through gauze into a clean bottle. DNA was precipitated in 0.6vol propan-2-
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ol and pelleted by centrifugation as above after 30mins. The pellet was air-dried
before being resuspended in 6ml TE and transferred to a 30ml corex tube. A volume
(3ml) of 7.5M ammonium acetate was added and the mixture incubated on ice for
30mins. Following centrifugation (12,000g, lOmins, 4°C) the supernatant was
transferred to a clean tube containing 2.5vols ethanol and incubated at -20°C for one
hour. The DNA precipitate was pelleted by centrifugation (12,000g, lOmins, 4°C)
and resuspended in 30ml 1:1 CsCETE (w/v) containing 140pg/ml ethidium bromide.
The solution was transferred to plastic quick-seal centrifuge tubes (Beckman) and
centrifuged for 16 hours at 200,000g using a Beckman Vti50 rotor. Two bands
representing closed circular plasmid DNA were visualised using a UV light source.
The lower band containing supercoiled plasmid DNA was removed by piercing the
side of the tube with a hypodermic syringe. The whole band was taken off in a
volume of less than 3ml. Ethidium bromide was extracted by repeated mixing with
an equal volume of 1-butanol saturated with 1:1 CsCETE (w/v) until the upper phase
became clear. The DNA was precipitated in 2.5vols ethanol at -20°C for one hour,
pelleted by centrifugation (12,000g, lOmins) and washed in 70% ethanol. The DNA
was resuspended in 10ml TE and dialysed against TE to remove the CsCl. The
dialysed DNA was re-precipitated in ethanol and resuspended in 1ml MilliQ dFEO.
2.2.17. Large-Scale Plasmid Preparation on Anion Exchange Columns
Large-scale plasmid purification was also performed using the CONCERT™ High
Purity Plasmid Purification System according to the manufacturer's instructions (Life
Technologies). The column was equilibrated with 30ml Equilibration Buffer
(600mM NaCl, lOOmM sodium acetate [pH 5.0], 0.15% Triton® X-100 [v/v]) and
drained by gravity flow. An overnight culture (500ml) was centrifuged (5000g,
5mins) and the pellet resuspended in 10ml Cell Suspension Buffer (50mM Tris-HCl
[pH 8.0], lOmM EDTA) containing O.lmg/ml RNaseA. Bacteria were disrupted by
the addition of 10ml Cell Lysis Solution (200mM NaOH, 1% SDS [w/v]) and
incubated for 5mins at RT. The mixture was incubated for a further 5mins following
addition of 10ml Neutralisation Buffer (3.1M potassium acetate [pH 5.5]). The
mixture was then centrifuged (15,000g, lOmins) and the supernatant loaded onto the
column. Once the solution in the column had drained by gravity flow, 60ml Wash
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Buffer (800mM NaCl, lOOmM sodium acetate [pH 5.0]) was applied to the column.
The DNA was eluted by adding 15ml Elution Buffer (1.25M NaCl, lOOmM Tris-HCl
[pH 8.5]) and precipitated by the addition of 10.5ml isopropanol to the eluate. The
mixture was centrifuged (15,000g, 30mins, 4°C) and the DNA pellet washed with
5ml 70% ethanol. Once dried, the pellet was resuspended in 500pl TE.
2.2.18. Preparation of DNA from Eukaryotic Cells
Small-scale preparation of DNA from cells was carried out using the QIAmp®DNA
Mini Kit (QIAGEN) according to the manufacturer's instructions. Briefly, cells
(Ixl05-lxl07) were harvested and counted as described below (2.4.2). The cell
pellet was resuspended in 200pl PBS and transferred to a 1.5ml Eppendorf tube
containing 20pl proteinase K. The cells were mixed thoroughly with 200pl buffer
AL and incubated at 56°C for lOmins. The lysate was mixed with 200pl 96%
ethanol and applied to the spin column. The column was centrifuged (6000g, lmin)
and the flow-through discarded. The column was washed first with 500pl buffer
AW1 then 500pl buffer AW2. The DNA was eluted in 200pl buffer AE.
2.2.19. Large-Scale Preparation of Recombinant Virus DNA
BHK-21 cells (8xl06) were infected with recombinant virus and grown in T175
flasks for five days or until 100% cytopathic effect was observed. The cells were
scraped into 10ml of sterile PBS, pelleted (450g, 5mins) and resuspended in 10ml
extraction buffer (0.1M EDTA, 0.5% SDS, 0.2M Tris-HCl [pH 8.0]) in
polypropylene Falcon tubes. The cellular lysate was incubated with 20pg/ml RNase
A at 37°C for 1 hour. Proteinase K (100 pg/ml) was added to the lysate and
incubated at 56°C overnight. The DNA was subjected to three rounds of phenol-
chloroform extraction followed by one chloroform extraction. The final supernatant
was precipitated in 2vols 96% ethanol and O.lvol 3M sodium acetate at RT. The
DNA was washed in 70% ethanol and resuspended in 200-400pl TE. For Southern
analysis, the DNA was quantified and three aliquots were each digested with a single
restriction enzyme overnight. The DNA underwent phenol-chloroform extraction
and re-precipitation prior to electrophoresis.
59
CHAPTlik TW O MATL-:RIALS & Ml I HOPS
2.2.20. Southern Analysis of DNA
DNA was electrophoresed on a 0.8%-1% agarose gel. The DNA was denatured by
soaking the gel in denaturation buffer (0.5M NaOH, 1M NaCl) for 40mins. The gel
was then immersed in neutralisation buffer (0.5M Tris-HCl [pH 7.5], 1.5M NaCl) for
40mins. The gel was rinsed in dH^O and equilibrated in transfer buffer (lOxSSC)
before assembly of the blotting rig. A piece of 3MM fdter paper (Whatman) was
pre-wetted with lOxSSC and used to cover the gel platform of an electrophoresis
tank so that the ends were submerged in thelOxSSC filling the wells of the tank. The
gel was placed on top of the filter paper. A piece of membrane (0.22pM nylon
membrane Magnagraph, MSI) was cut to exactly the same size as the gel, re-
hydrated in dt^O, and equilibrated in lOxSSC. The membrane was placed directly
on top of the gel, ensuring that air bubbles were eliminated. The gel was surrounded
with saran wrap to prevent the transfer buffer by-passing the gel into the stack of
paper towels. Three pieces of 3MM filter paper, also cut to the same size, were
equilibrated in lOxSSC and placed on top of the membrane. Dry paper towels
formed the final layer and facilitated capillary transfer ofDNA to the membrane. A
weight was placed on top of the paper towels and the DNA transferred overnight.
The following morning, the blot was carefully dismantled and the positions of the
wells of the gel were marked on the membrane. The DNA was fixed to the
membrane by UV cross-linking (Stratalinker 1800, Stratagene). The section of the
blot corresponding to the DNA markers was carefully removed for staining using a
scalpel blade. The membrane was either transferred to pre-hybridisation solution or
stored at -20°C.
2.2.21. Staining of DNA Molecular Weight Markers
The membrane strip bearing the DNA markers was soaked in 1M acetic acid
(lOmins, RT). The markers were then transferred to staining solution (0.4M acetic
acid, 0.4M sodium acetate, 0.2% methylene blue) and incubated for lOmins. The
staining solution was poured off and the membrane washed in dH^O. The distance
each DNA band had migrated from the well was measured and plotted against the
logio of its molecular weight. A line was drawn through the points and the graph
used to estimate the molecular weight ofDNA bands detected by hybridisation.
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2.2.22. Radiolabelling ofDNA
DNA probes for hybridisation were labelled using the Random Primed DNA
Labelling kit according to the manufacturer's instructions (Roche). Briefly, 25ng
DNA was denatured by heating to 95°C for lOmins, cooled on ice and added to a
solution containing 0.025mM dATP, TTP, dGTP, hexanucleotide primer, 50pCi
[a32P]dCTP (Amersham Pharmacia) and 2U Klenow polymerase (large fragment of
DNA polymerase I). DNA was labelled for 40mins at 37°C and unincorporated
nucleotides were removed by chromatography on a Nick® Sephadex G-50 column
(Amersham Pharmacia). Labelled DNA was incubated with O.lvol 1M NaOH for
5mins at 37°C immediately prior to hybridisation.
2.2.23. Hybridisation of Southern Blots with DNA Probes
The blot was pre-hybridised in 25ml hybridisation solution (6xSSC, 5% milk) for at
least 2 hours at 68°C. The solution was poured off and replaced with 25ml fresh
hybridisation solution containing the denatured DNA probe. The blot was incubated
with the probe at 68°C overnight. The blot was washed for 15mins twice in each of
the following solutions: lxSSC, 0.1% SDS at RT; lxSSC, 1% SDS at 37°C;
O.lxSSC, 1% SDS at 60°C. The blot was then wrapped in saran wrap and exposed to
autoradiographic film (X-OMAT, Kodak) at -70°C. Films were developed using an
X-OMAT automatic X-ray film processor.
2.2.24. Automated Sequencing ofDNA
TM
DNA sequencing reactions were performed using a SequiTherm EXCEL II DNA
Sequencing kit (cycle sequencing protocol) on a 4000L automated sequencing
machine (MWG-Biotech) by Ian Bennet (Dept. of Veterinary Pathology, University
ofEdinburgh).
2.2.25. Sequence Analysis ofDNA
Storage of sequence, mapping of restriction sites and comparison to other database
sequences was made using the University of Wisconsin Genetics Computer Group
Sequence Analysis Software Package v. 10 (Devereux et al., 1984).
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2.3. RNA Extraction and Manipulation
In all procedures involving RNA, precautions were taken to prevent degradation by
RNase enzymes. Glassware and other equipment was routinely rinsed with 5M
NaOH followed by copious rinsing with sterile dH20. All solutions were made up
with chemicals reserved solely for RNA use. Barrier tips and sterile plastic-ware
were used throughout. RNA samples and Northern blots were stored at -70°C.
2.3.1. Cytoplasmic RNA Extraction
Cells were washed twice in sterile PBS. Adherent cells were removed from the
monolayer by scraping and centrifuged (450g, 5mins). The pellet was resuspended
in 1ml ice-cold Tris-saline (25mM tris [pH 7.4], 130mM NaCl, 5mM KC1) and
transferred to a 1.5ml Eppendorf tube. The addition of lOOpl Igepal buffer (1%
Igepal (Sigma)/ 0.5% sodium deoxycholate/ 0.01% dextran sulphate in Tris-saline)
resulted in lysis of plasma membranes but not nuclear membranes. The lysate was
centrifuged (2000g, lmin) and the nuclear pellet discarded. The supernatant was
transferred to a new tube containing 500pl (25:24:1) phenol:chloroform:iso-amyl
alcohol (v/v), 25pl 20% SDS and 15pl 5M NaCl. After vigorous mixing using a
vortex, the tube was centrifuged (1 l,000g) and the upper aqueous phase removed to a
clean tube. The RNA underwent three phenol-chloroform extractions, a single
chloroform extraction and was recovered by ethanol precipitation. The RNA was
centrifuged (ll,000g, 20mins, 4°C), washed in 80% ethanol, air-dried and
resuspended in 50pl sterile dH20 (Sigma). RNA was quantified using a Cecil
spectrophotometer. The concentration was calculated using the following equation
where an A26o of 1.0 is equivalent to 40mg/ml ofRNA:
RNA concentration = Absorption at 260nm (A26o) x 40 x dilution factor
The purity of the nucleic acid sample, with respect to protein contamination, was
assessed using the ratio A26o/A2go, where a value greater than 1.8 indicates that the
sample is free from protein contamination. The RNA was also analysed by gel
electrophoresis on a 1% agarose gel containing TBE.
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2.3.2. Purification of Polyadenylated RNA from Total RNA
Total RNA was enriched to 50% polyadenylated RNA using a kit (mRNA
Purification kit, Amersham Pharmacia). RNA was diluted in 1ml elution buffer
(lOmM Tris-HCl [pH 7.4], ImM EDTA), denatured at 65°C for 5mins and placed on
ice. A volume (200pl) of sample buffer (lOmM Tris-HCl [pH 7.4], ImM EDTA, 3M
NaCl) was added to the RNA and the mixture applied to the column. The column
was centrifuged (350g, 2mins, Beckman TJ-6). The column was washed and
centrifuged twice with 250pl high salt buffer (lOmM Tris-HCl [pH 7.4], ImM
EDTA, 0.5M NaCl), three times with 250pl low salt buffer (lOmM Tris-HCl [pH
7.4], ImM EDTA, 0.1M NaCl) and eluted in 1ml elution buffer pre-warmed to 65°C.
The mRNA was precipitated in 2.5vols ethanol containing lOOpl sample buffer and
lOpl glycogen. The precipitate was recovered by centrifuging for lOmins at 4°C
(12,000g), washed in 80% ethanol, air-dried and resuspended in lOpl MilliQ dH20.
2.3.3. Purification of Total RNA
Total RNA was also isolated from eukaryotic cells using the RNeasy® Mini Kit,
QIAGEN. Briefly, cells (lxlO7) were harvested, pelleted by centrifugation (450g,
5mins) and lysed by the addition of 600pl buffer RLT. The lysate was homogenised
by passing through a 20-G needle fitted to a syringe. Ethanol (70%, 600pl) was
added and the sample was applied to the mini spin column. Following brief
centrifugation, the column was washed once with 700pl buffer RW1 and twice with
500pl buffer RPE. The RNA was eluted in 30-50pl RNase-free dH20.
2.3.4. Direct Purification of Polyadenylated RNA from Cells
Polyadenylated RNA was also purified directly from cells using the QuikPrep™
Micro mRNA Purification kit (Amersham Pharmacia). Cells (lxlO7) were harvested,
counted and transferred to a 1.5ml Eppendorf. The cells were pelleted and
resuspended in 400pl extraction buffer containing guanidium thiocyanate and N-
lauroyl sarcosine and thoroughly homogenised using a vortex. The sample was
diluted in 800pl elution buffer (lOmM Tris-HCl [pH 7.5], ImM EDTA) and
centrifuged (ll,000g, lmin) to produce a cleared cellular homogenate. Oligo(dT)-
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cellulose (1ml of 25mg/ml solution) was centrifuged simultaneously and the buffer
discarded. The cleared homogenate was added to the oligo(dT)-cellulose and gently
mixed by inversion for 3mins to allow binding of the polyadenylated RNA. The
sample was centrifuged (ll,000g, lOsecs) and the pellet was washed with 1ml high-
salt buffer (lOmM Tris-HCl [pH 7.5], ImM EDTA, 0.5M NaCl). Five washes were
performed with the high-salt buffer followed by two washes with low-salt buffer
(lOmM Tris-HCl [pH 7.5], ImM EDTA, 0.1M NaCl). The pelleted oligo(dT)-
cellulose was resuspended in 300pl low-salt buffer and applied to a spin column.
The column was centrifuged (ll,000g, 5secs) and washed three times with 500pl
low-salt buffer. The polyadenylated RNA was eluted with 200pl elution buffer pre-
warmed to 65°C. The elution step was repeated a second time resulting in a final
volume of 400pl. The RNA was ethanol precipitated in lOpl glycogen solution (5-
lOmg/ml glycogen), 40pl 2.5M potassium acetate [pH 5.0] and 2.5vols 96% ethanol
at -70°C for one hour. The RNA was centrifuged, washed and quantified as
described above.
2.3.5. Northern Analysis
RNA was electrophoresed on a 1.2% agarose gel containing lx MOPS buffer and
2.2M formaldehyde. RNA samples were diluted in 0.5x MOPS containing 17.5%
formaldehyde and 50% formamide in a volume of 20pl. Typically, l-3pg of
polyadenylated RNA or 5-10pg total RNA was loaded per well. RNA molecular
weight markers (5pg, 0.24-9.5kb RNA ladder, Life Technologies) were prepared in
the same way. RNA was denatured at 65°C for 15mins, cooled on ice and mixed
with 2pl loading buffer (50% glycerol, ImM EDTA [pH 8.0], 0.25% bromophenol
blue) immediately prior to loading. The gel was electrophoresed overnight in
lxMOPS and the buffer re-circulated using a pump. The gel was rinsed in dH20
before being transferred to the blotting rig. The Northern blot was assembled
identically to the Southern blot (2.2.20) with the exception of the transfer buffer,
which was lOxSSPE. As with the Southern blot, transfer took place overnight after
which the blot was carefully removed, the positions of the wells marked and the
RNA fixed by UV cross-linking. The lane corresponding to the RNA molecular
weight markers was removed and stained in the same way as the DNA markers.
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2.3.6. Radiolabelling of RNA
In vitro transcription of RNA was carried out using a kit (Riboprobe In Vitro
Transcription Systems, Promega) according to the manufacturer's instructions. The
plasmid DNA template (0.2-1.0pg) was linearised with an appropriate restriction
enzyme as described above. Following digestion, the DNA was extracted with
phenol-chloroform and precipitated in 96% ethanol. The pellet was resuspended in
lpl MilliQ dH20. The components of the transcription reaction were added in the
following order in a final volume of 20pl: 5x transcription optimised buffer, lOOmM
DTT, 20U recombinant RNasin ribonuclease inhibitor, 2.5mM each rATP, rGTP,
rCTP, lOOpM rUTP, template DNA, 50pCi [a-32P]rUTP (Amersham Pharmacia),
20U T7 RNA polymerase. The transcription mixture was incubated at 37°C for one
hour. The DNA template was removed by digestion with RNAse-free DNAsel
(lU/pg DNA) at 37°C for 15 minutes. The radiolabelled transcripts were isolated via
phenol-chloroform extraction and ethanol precipitation. The final pellet was
resuspended in 50pl TE and immediately added to the hybridisation mix.
2.3.7. Hybridisation of Northern Blots with DNA Probes
Northern blots were pre-hybridised for at least 2 hours at 45°C in a mixture
containing 50% formamide, 5xSSPE, 5xDenhardt's, 0.5% SDS, lOOpg/ml sheared
single-stranded salmon sperm DNA. Hybridisation took place overnight at 45°C in a
similar mixture containing also 10% dextran sulphate and 200pg/ml salmon sperm
DNA. High stringency washes were carried out as follows: 2xl5mins in 5xSSPE/
0.5% SDS at RT; 2xl5mins in lxSSPE/ 0.5% SDS at 37°C; 3xl5mins in O.lxSSPE/
1% SDS at 65°C. The blot was exposed to autoradiographic film (X-OMAT, Kodak)
at -70°C or to a phosphorous-coated screen (Molecular Dynamics). The film was
developed using an X-OMAT automatic developer (Kodak). The phosphorous-
coated screens were visualised using a phosphorimager (Molecular Dynamics).
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2.3.8. Hybridisation ofNorthern Blots with Riboprobes
The hybridisation conditions for RNA probes are similar to those described for DNA
probes (2.3.7) except that the pre-hybridisation, hybridisation and washing solutions
all contained 1% SDS.
2.3.9. Stripping ofNorthern Blots
DNA probes were removed from Northern blots by incubating in recently boiled
dH20 containing 0.1% SDS for 15mins. The blot was then washed in 6xSSC for
15mins at RT before being exposed to autoradiographic film to verify complete
removal of the labelled probe.
2.3.10. Reverse Transcription PCR
RNA (2pg total RNA or 0.5-lpg polyadenylated RNA) was added to the following
reaction mixture containing a final concentration of lx first strand synthesis buffer
(Life Technologies), ImM each dATP, dCTP, dGTP, and TTP, lpmole primer, 2mM
DTT and 10U RNAse-free DNAsel (Roche) in a final volume of 25pl. The mixture
was incubated at 37°C for 30mins to ensure complete digestion of any contaminating
DNA. Heating to 80°C for 5mins inactivated the DNasel. The reaction mixture was
cooled on ice before addition of 200U reverse transcriptase (Superscript II RNaseH"
Reverse Transcriptase). The cDNA synthesis reaction was carried out at 42°C for
one hour. The enzyme was heat-inactivated at 95°C for 5mins and the tubes cooled
on ice. Typically, 2pl of the reaction was used as a template in subsequent PCR
reactions.
2.3.11. Rapid Amplification of cDNA Ends (RACE)
The polyadenylation site of the GPCR transcript was identified by 3'RACE. Total
RNA was harvested from CI27 cells infected with MHV-68 at 24h post-infection.
Reverse transcription was carried out as described above using an oligo(dT) primer.
The cDNA was amplified with a primer corresponding to the 5' region ofGPCR and
the oligo(dT) primer.
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Attempts were made to identify the unknown 5'-end of the GPCR transcript using a
5'RACE kit (5'-Full RACE Core Set, Takara Shuzo) according to the manufacturer's
instructions. The target RNA was the same as for 3'RACE. Synthesis of cDNA was
carried out with a primer complementary to the 5' end of the GPCR coding region
thus transcribing the unknown upstream region of the GPCR transcript. The target
RNA was degraded by treating with RNAseH for one hour at 30°C and the cDNA
recovered by ethanol precipitation. The cDNA was ligated with T4 RNA ligase
overnight at 16°C, resulting in circularisation or concatomerisation of the cDNA.
Primers were designed to the 5'-end known coding region of the GPCR. Nested
PCR was carried out resulting in amplification of the unknown region lying between
two copies of the known region.
2.4. Culture of Cells and Virus
2.4.1. Cell Lines
All cells lines were cultured in sterile plastic-ware (Nunc) and incubated at 37°C in




BHK-21 Hamster kidney fibroblast cells (Stoker, 1961)
C127 RIII mouse mammary carcinoma cells (Lowy, 1978)
NIH 3T3 Mouse fibroblast cells (Bojan et al., 1983)
293 Human embryonic kidney epithelial cells (Graham et al., 1977)
NSO Non-immunoglobulin secreting mouse myeloma cells (Kholer, 1976)
Sll Mouse B lymphoma cells carrying latent MHV-68 (Usherwood et al., 1996c)
U937 Human Caucasian histiocytic lymphoma exhibiting
monocytic characteristics
(Sundstrom & Nilsson, 1976)
Table 2.4.1. Description of cell lines
Baby Hamster Kidney (BHK-21) cells were cultured in Glasgow modified Eagle
medium (GMEM, Life Technologies) supplemented with 10% (v/v) tryptose
phosphate broth (Life Technologies) and 10% (v/v) new born calf serum (NBCS,
Life Technologies), 70pg/ml penicillin (Merck BDH), lOpg/ml streptomycin
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(Sigma) and 2mM L-glutamine (Merck BDH). Murine 3T3 cells were maintained in
Dulbecco's Modified Eagles medium containing glutamax (DMEM, Life
Technologies) and supplemented with 10% non-heat-treated NBCS, 70pg/ml
penicillin and lOpg/ml streptomycin. The 293 cell line, was also maintained in
DMEM supplemented with 10% FCS, 70pg/ml penicillin, lOpg/ml streptomycin and
2mM L-glutamine. The B cell lines (NSO and SI 1) and the U937 line were cultured
in RPMI 1640 (Life Technologies) containing 10% foetal calf serum (FCS,
Globepharm), 70pg/ml penicillin, lOpg/ml streptomycin, 50pM P-mercaptoethanol
(Sigma) and 2mM L-glutamine.
2.4.2. Harvesting and Counting of Cells
Adherent cells were maintained in sub-confluent growth and passaged by removing
them from the monolayer with trypsin. The medium was poured off and the
monolayer washed in 0.02% versene. The monolayer was then incubated with
0.25% trypsin (Life Technologies) until the cells could be removed from the surface
of the flask by gentle tapping. The trypsin was then diluted in an equal volume of
medium and cells were centrifuged (450g, 5mins). Non-adherent cells were also
centrifuged for 5mins at 450g. The cell pellet was resuspended in appropriate
growth medium and a small aliquot (50pl) was mixed with 50pl 0.1% trypan blue
(w/v). The number of un-stained viable cells was counted using a haemocytometer.
2.4.3. Electroporation of Cells
Sub-confluent (60-80%) cells were washed and removed from the monolayer. Cells
(2xl06) were resuspended in lml medium and transferred to a chilled electroporation
cuvette (EquiBio) containing 20pg of the DNA to be transfected. Cells were
electroporated using a double-pulse setting (HV=600v, 25pF, 99Q; LV=260V,
1500pF, 329Q; 0.1s inter-pulse delay) on an Easyject electroporator (EquiBio).
Cells were immediately transferred to a universal tube containing fresh medium then
divided between two wells of a 6-well plate and incubated at 37°C. The efficiency of
transfection was estimated using a control plasmid expressing GFP. Transiently
transfected cells were generally harvested 24 hours post-infection.
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2.4.4. Lipofection of Cells
Cells (60-80% confluent) were transfected using the DOTAP Liposomal
Transfection Reagent (Roche). The DNA was diluted in Hepes buffer to a final
concentration of 0.1pg/pl in a volume of 50pl. DOTAP (6pg per lpg of DNA) was
also diluted in Hepes buffer to a final volume of lOOpl. The DNA was added to the
DOTAP solution, gently mixed and incubated at room temperature for 10-15mins.
The DOTAP/DNA mixture was added to fresh culture medium at a concentration not
exceeding 30pg/ml DOTAP and applied gently to the cells using a pipette. Cells
were incubated for 24 hours at 37°C.
2.4.5. Generation of Stably Transfected Cell Lines
Murine NIH 3T3 cells were transfected with the expression vector pBABE/pwro
encoding GPCR, EBV LMP-1 or empty plasmid. Post-transfection, 3T3 cells were
incubated at 37°C for 3 days before being exposed to the selection agent (3pg/ml
puromycin, Sigma). The concentration of puromycin required to select only cells
carrying the puromycin resistance gene was previously determined. Foci of resistant
cells were identified and isolated using plastic rings coated in silicone. The focus of
cells within the ring was removed with lOOpl trypsin and immediately transferred to
a 10mm well of a 24-well plate containing 1ml DMEM. Cells were propagated in
1.5 pg/ml puromycin.
2.4.6. Focus Formation Assay
Murine NIH 3T3 cells that were transiently or stably transfected with expression
constructs encoding GPCR, EBV LMP1 or SV40 early region, were grown to
confluence in 6 well-plates. The medium was replaced on alternate days for 3-4
weeks until cellular foci were observed under the light microscope.
2.4.7. Growth in Soft Agar
Soft agar assays were performed as described by Baichwal & Sugden, 1988. A 3.5%
stock solution of low gelling temperature agarose (SeaPlaque®, Flowgen) was
prepared in sterile PBS. The stock solution was diluted 1:7 in medium equilibrated
to 37°C. Six-well plates were layered with 2ml of the resulting 0.5% agarose and
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placed at 4°C to set. Cells (lxl04) were resuspended in 1.8ml medium warmed to
37°C. Cells were then mixed with 0.2ml 3.5% agarose and layered on top of the
0.5% agarose. The agarose was gelled at 4°C for several minutes before being
incubated at 37°C. The cells were supplemented with 2-3 drops of medium (DMEM
+ glutamax, Life Technologies) containing 10% FCS, 70pg/ml penicillin and
10pg/ml streptomycin, on alternate days for 3 weeks. Cellular foci (diameter
>50pM) were counted with the aid of a calibrated graticule and a light microscope.
2.4.8. Tumorigenicity Assay
The tumorigenicity of stably transfected cell lines expressing the GPCR was tested in
nude mice (Bantin and Kingman). Six groups of four six-week old mice each
received a subcutaneous injection in the left flank of lxl06 cells in a volume of
lOOpl. The mice were monitored for the formation of tumours at the site of
injection. The experiment was repeated using lxlO7 cells. Each mouse received the
same cell line as in the previous experiment but injected in the right flank.
2.4.9. Preparation of Virus Stocks
Stocks ofMHV-68 were generated in BHK-21 cells. Cells were grown in T175cm2
flasks (~lxl07 cells/flask) and harvested and counted as described. Cells were
resuspended in medium (lxl07/ml) and infected with MHV-68 at a multiplicity of
infection (MOI) of 0.01. The cells were incubated for one hour at 37°C with shaking
and seeded (2xl06 cells/flask) in T175cm2 flasks. The infected cells were incubated
at 37°C for 5-7 days until gross cytopathic effect was observed. The cells were
dislodged from the monolayer by scraping or gentle tapping of the flask and
centrifuged (2000g, 20mins, 4°C). The pellet was resuspended in a small volume of
sterile PBS (5-10ml) and homogenised with 20-30 strokes of a chilled Wheaton-
Dounce homogeniser. The homogenate was transferred to a glass universal tube and
sonicated in a water-bath for 15mins at 4°C. Following centrifugation (2000g,
20mins, 4°C), the supernatant was transferred to a clean universal tube and kept on
ice. The pellet was resuspended in 1ml sterile PBS, re-homogenised and centrifuged
(2000g, 20mins, 4°C). The supernatants were pooled, aliquoted and stored at -70°C.
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2.4.10. Titration ofMHV-68
Titres of virus stocks were determined using a plaque assay as described by Sunil-
Chandra et al., 1992a. Duplicate serial dilutions of the virus sample were prepared
(10"1 to 10"8) in 1.8ml medium. BHK-21 cells (5xl05) were added to each virus
dilution and incubated for one hour at 37°C with shaking. The infected cells were
transferred to 60mm culture plates and incubated at 37°C for four days. Uninfected
BHK-21 cells were also seeded in duplicate plates at the same density as a negative
control. Cells were fixed in 4% buffered formaldehyde (v/v) (Surgipath) and stained
with 0.1% toluidine blue. Virus plaques were counted using a light microscope
(Leitz ortholux) thus allowing calculation of virus titre in plaque forming units
(pfu/ml).
2.4.11. Infective Centre Assay
The titre of virus in latently infected splenocytes or B cell lines was determined using
the infective centre assay. For splenocytes, the spleen was removed from the mouse
and transferred to a petri dish containing a few mis of medium. The splenocytes
were teased from their outer coating using a scalpel blade and transferred to a pre-
rinsed sterile universal tube. Following centrifugation (450g, 5mins), the supernatant
was decanted and the cell pellet resuspended in the remaining few drops of medium.
The erythrocytes were lysed by addition of 1ml sterile dFEO for 15s. The osmotic
balance was immediately restored by the addition of 9ml PBS and once the cellular
debris had settled, the cell suspension was carefully removed. The cells were
centrifuged as before, resuspended in 5ml RPMI and counted. Duplicate serial
dilutions (lO '-lO"3) of the cells were prepared and added to 60mm plates containing
5xl05 freshly harvested BFIK-21 cells in RPMI. The cells were incubated for five
days at 37°C, fixed in 4% formal saline and stained in 0.1% toluidine blue. Virus
plaques were counted using a light microscope. An aliquot of splenocytes was
freeze-thawed to disrupt the cells and used for a plaque assay to determine the titre of
free virus in the sample.
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2.4.12. Generation of MHV-68 and MHV-76 Recombinants
Recombinant viruses were generated by co-transfection of BHK-21 cells with virus
DNA and a homologous recombination cassette. The DNA sequences extending 2kb
upstream and downstream of the GPCR coding region were amplified and inserted
into the pKS(-) vector. The GFP gene, under control of the CMV promoter, was
inserted between the two flanking sequences. The cassette was excised from pKS(-)
prior to transfection. BHK-21 cells were transfected (see 2.4.3) with 10pg virus
DNA and 10pg of the DNA cassette. Recombination of the cassette with virus DNA
resulted in the generation of virus that expressed the GFP gene. Following
transfection, the cells were transferred to 6-well plates and incubated at 37°C
overnight. The following morning, the cells were washed twice with 2ml medium
and overlaid with medium containing 1% agarose (Seaplaque®, Flowgen). The
plates were incubated at 37°C and examined daily for the presence of GFP+ virus
plaques using a UV microscope (Nikon Diaphot 200).
2.4.13. Plaque Purification of Recombinant Virus
A plaque purification method was used to separate recombinant virus expressing
GFP from wild-type virus. The positions of isolated GFP+ plaques were marked on
the underside of the plate. A 1ml Pasteur pipette was used to remove an agarose plug
containing virus-infected cells. The agarose plug was transferred to a 1.5ml
Eppendorf tube containing 500pl medium. Virus particles were released from cells
by sonication at 4°C for 60s followed by three rounds of freeze-thawing at -70°C.
The lysate was centrifuged for 2mins (11,000^) to remove cellular and agarose
debris. A volume of the supernatant (100-250pl) was used to re-infect cells and the
procedure was repeated until no wild-type plaques were observed. Subsequent
plaque purification and liming dilution assays were carried out using CI27 cells
because the virus plaques formed on this cell line were more discreet than those
formed on BHK-21 cell monolayers.
2.4.14. Limiting Dilution Assay
Virus samples obtained from picking plaques were serially diluted (1:5, 1:10, 1:20,
1:50, 1:100, 1:250, 1:500, 1:1000, 1:5000) to estimate the virus titre. C127 cells (1-
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2xl04) were grown in 5mm 96-well plates. Each dilution of virus was added to 10
wells containing a CI27 monolayer and the number of recombinant and wild-type
plaques formed was scored in each well. CI27 cells were then infected with virus at
a concentration of 0.4pfu/well giving rise to single plaques in 40% of wells. The
single isolated plaques were harvested and the virus DNA analysed by Southern
blotting.
2.4.15. Infection of Mice with Recombinant Virus
Transgenic mice lacking the a/J3 interferon receptor (Dutia et al., 1999) were
infected with a mixed population of wild type and recombinant MHV-76. Four mice
9 T
were infected intranasally with either 1x10" or 1x10 pfu virus in a volume of 40pl
sterile PBS.
2.4.16. Ligand Binding Assay
Cells (293, NIH3T3 or U937) were harvested, counted and washed in Hank's
Balanced Salt Solution (HBSS). Cells (1x10s) were incubated in 200pl HBSS
containing ImM PMSF and either 0.02pmole 2000Ci/mM human recombinant
[125I]IF-8 plus 20pmoles unlabelled IF-8, or [125I]IF-8 alone (both Amersham
Pharmacia). The samples were rotated at 4°C for two hours. The cells were
centrifuged (450g, 2mins) and washed three times with 1ml HBSS. The final cell
pellet was solubilised in 200pl 0.4M NaOH and a lOOpl sample was mixed with
scintillation fluid (Optiphase Hisafe, Wallac). The radioactive emission of each
sample was measured in counts/min using a liquid scintillation counter (1450
Microbeta Plus, Wallac).
2.5. Immunological Methods
2.5.1. Production of a Fusion Protein
A 93bp fragment corresponding to the predicted N-terminal region of the GPCR was
amplified by PCR. The product was inserted into the bacterial expression vector,
pGEX-2T (Amersham Pharmacia) in frame with the Schistosoma japonicum
glutathione-S-transferase gene (GST). Figation and transformation were carried out
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as described (2.12 and 2.13). Positive clones were tested for expression of the fusion
protein. Bacterial colonies were picked and grown overnight in 10ml LB containing
lOOpg/ml ampicillin then diluted 1:10 in fresh LB. Isopropyl-[3-D-
thiogalactopyranoside (IPTG) was added at a concentration of 0.5mM during
exponential growth phase (O.D.595 = 0.6). The bacteria were grown for a further
three hours.
2.5.2. Purification of a Fusion Protein
Bacterial cultures were centrifuged (2000g, 5mins) and the pellet resuspended in
300pl PBS containing 1% (v/v) triton, ImM PMSF and 1% (v/v) aprotinin. The
bacteria were lysed by sonication and the insoluble material was pelleted by
centrifugation (1 l,000g, 5mins). An aliquot of the insoluble fraction was retained for
analysis and the soluble fraction was incubated for 5mins at RT with 50pl 50%
glutathione sepharose beads (Amersham Pharmacia) that had been equilibrated with
PBS. The beads were washed once in 1ml PBS + 1% Triton® and centrifuged at low
speed (250g, 2mins). This was repeated twice using PBS alone. A volume of elution
buffer (150pl) was added and the beads pelleted by centrifugation as before. Elution
buffers were comprised of increasing concentrations of glutathione (5-15mM), NaCl
(0.1M-3.0M) or urea (3.0M-5.0M). Both the eluate and glutathione-sepharose
fraction were analysed by SDS-PAGE.
2.5.3. Generation ofAntibody in Rabbits
Two NZW rabbits were immunised with fusion protein. Each rabbit received two
intra-muscular injections in a volume of lOOpl containing 25pl bed volume of the
fusion protein-sepharose complex resuspended in 25pl PSB and mixed with 50pl
adjuvant (TiterMax® Gold, Sigma). A blood sample (5-10ml) was taken from each
animal prior to immunisation and three weeks post-immunisation. Both rabbits
received three booster injections at three-week intervals. Blood samples were taken
three weeks after each injection and the serum assessed for reactivity with the GPCR
by western blotting and immunoprecipitation.
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2.5.4. Preparation of Serum
Blood samples were allowed to clot overnight at 4°C. The clot was detached from
the sides of the universal tube using a Pasteur pipette prior to centrifugation (450g,
5mins). The serum supernatant was carefully removed and stored at 4°C.
2.5.5. Preparation of Peptides
Two peptides were synthesised corresponding to predicted hydrophilic regions of the
GPCR (MWG Biotech) for the purpose of raising anti-GPCR antibody in sheep.





GPCR1 was conjugated via its amino terminus to bovine serum albumin (BSA) using
the heterobifunctional reagent, m-maleimidobenzoyl-N-hydroxysuccinimide ester
(MBS, Kitagawa & Aikawa, 1976). BSA was dissolved in PBS at a concentration of
lOmg/ml. A 25mg/ml solution of MBS was prepared in dimethylformamide and
0.1 vol was added drop-wise to the BSA. The reaction was stirred for 30mins at RT.
The activated BSA was separated from free MBS by gel filtration. A Sephadex® G-
25M column (PD-10, Amersham Pharmacia) was equilibrated with 20ml PBS
according to the manufacturer's instructions. Non-specific binding of the activated
carrier was blocked by the addition of 2.5ml lOmg/ml BSA. The activated BSA
(2.5ml) was eluted from the column in a volume of 3.5ml. The GPCR1 peptide
(0.9mg) was resuspended in PBS and added to the activated BSA (0.35mg) in a ratio
of 1 mole peptide to 50 amino acids BSA resulting in a 12-fold molar excess of
peptide. The coupling reaction was carried out in a final volume of 90pl in a 0.5ml
Eppendorf. The tube was rotated at RT for three hours. Conjugated peptide was
stored at -70°C.
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2.5.6. Generation of Antibody using Peptides
Two Finn sheep (8F042 and 8F045) were immunised with plasmid DNA encoding
the GPCR. One sheep was also vaccinated with DNA encoding granulocyte
macrophage colony stimulating factor (GMCSF). A volume of 250pl was injected
into each leg muscle at the hip and shoulder. Sheep 8F045 was immunised with 4x
25pg of the pVR1255+GPCRHA3 construct in MilliQ dH20. Sheep 8F042 received
4x 25pg of the pVR1255+GPCRHA3 construct and 4x 25pg of pEGFP-Nl+GMCSF
construct (Craig Watkins, University of Edinburgh) in MilliQ dH20. A secondary
DNA vaccination was administered after an interval of four weeks. Both sheep
received a tertiary vaccination with 4x 12.5pg GPCR1 (conjugated to BSA carrier)
and 4x 12.5pg GPCR2 resuspended in PBS 1:1 adjuvant (TiterMax® gold) in a
volume of 4x 250pl. A blood sample was taken from each sheep 2 weeks after the
peptide injection.
2.5.7. SDS-Polyacrylamide Gel Electrophoresis
Proteins were analysed by discontinuous polyacrylamide gel electrophoresis
according to the method of Laemmli, 1970. Samples were diluted 1:1 in gel loading
buffer (lOOmM Tris-HCl [pH 6.8], 200mM dithiothreitol, 4% SDS, 0.2%
bromophenol blue, 20% glycerol) and denatured at 100°C for 5mins prior to loading.
Electrophoresis was carried out on 15% resolving gel (15% v/v)
acrylamide/methylene bisacrylamide (Protogel, National Diagnostics), 0.375M Tris-
HCl [pH 8.8], 0.1% SDS. Stacking gel was 5% acrylamide, 0.125M Tris-HCl [pH
6.8], 0.1% SDS. Gels were set by addition of 2% ammonium persulphate and 0.08%
N, N, N', N'-tetraethylmethylenediamine (TEMED, Sigma). SDS-PAGE running
buffer was comprised of Tris-glycine (39mM glycine, 48mM Tris) and 0.5% SDS.
Protein molecular weight was estimated by comparison with pre-stained broad-range
standards (BIO-RAD). Gels were stained in Coomassie blue (0.25% Coomassie
brilliant blue, 10% glacial acetic acid, 45% methanol) and de-stained in 20%
methanol + 5% glacial acetic acid.
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2.5.8. Western Analysis
Proteins were transferred to PVDF membrane (Immobilon-P, Millipore) in transfer
buffer (lx Tris-glycine, 20% methanol). Non-specific binding to the membrane was
blocked by incubation with blotto (5% Marvel milk in TBS) for 30mins at RT. The
membrane was incubated with the primary antibody in 10-20ml blotto for 1-2 hours
at a temperature and concentration recommended by the manufacturer. The
membrane was washed three times in TBS + 0.2% Tween then incubated with the
secondary antibody for 30mins. The blot was washed extensively in TBS + 0.2%
TM
Tween and TBS alone then developed in NBT/BCIP (Sigma FAST 5'Bromo-4-
chloro-3-indolyl phosphate/ Nitro blue tetrazolium tablets).
2.5.9. Radiolabelling of Cells and Immunoprecipitation
BHK-21 cells were grown to 80% confluence in 6-well plates. The monolayer was
infected with 5pfu/cell MHV-68 in a volume of 500pl for one hour at 37°C. The
medium containing the virus was replaced with 2ml fresh medium. At 12 hours post¬
infection, the medium was removed and the monolayer washed in serum-free,
methionine-free medium (Life technologies). The cells were incubated for four
hours at 37°C in 3ml of the serum-free, methionine-free medium containing lmCi
35S-methionine. The medium was removed and the monolayer washed once with
PBS. The cells were lysed by addition of 1ml RIPA buffer (20mM Tris [pFI 7.2],
0.15M NaCl, 1% Triton® X-100, 1% sodium deoxycholate, 0.1% SDS), transferred
to an Eppendorf tube. PMSF (ImM) and 5% aprotinin were added to the lysate and
stored at -70°C.
The lysate was pre-cleared by incubating with 50% (v/v) sepharose 4B in RIPA
buffer with rotation for four hours at 4°C. A volume of the test serum (20pl) was
added to the lysate and incubated overnight at 4°C with rotation. As a positive
control, an aliquot of lysate was incubated with 2.5)ul polyclonal antibody to MHV-
68. The pre-immune serum was used as a negative control. The lysate samples were
incubated with 40pl 50% (v/v) protein A sepharose in RIPA buffer for four hours at
4°C with rotation. The protein A sepharose was centrifuged (450g, 5mins) and the
pellet washed five times with RIPA buffer. The final pellet was resuspended in 40pl
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SDS-PAGE sample buffer and boiled for 5mins. The sample was centrifuged (450g,
5mins) to remove the protein A sepharose before being loaded on an SDS-PAGE gel.
Following electrophoresis, the gel was fixed in 10% glacial acetic acid and 30%
methanol before being impregnated with EN3HANCE™ (Dupont) for one hour at RT.
The gel was then immersed in dH20 for 30mins to precipitate the protein. The gel
was dried and exposed to autoradiographic film.
2.5.10. Immunofluorescence
Cells (2xl05) were washed in PBS, removed from the monolayer, centrifuged and
resuspended in lOOpl PBS. Cells were applied to glass microscope slides
(Surgipath) using a Cytospin (Shandon). The slides were air-dried and fixed in
acetone for 3mins at -20°C. Fixed cells were incubated with lOOpl PBS containing
5% BSA (Sigma) at 37°C for 30mins to block non-specific binding. Cells were
washed in PBS + 0.05% Tween for 5mins followed by PBS alone for 5mins before
incubation with the primary antibody. The primary antibody was diluted in lOOpl
PBS at a concentration recommended by the manufacturer and incubated for 1 hour
at RT or 37°C. Cells were washed three times in PBS + 0.05% Tween then
incubated for 30mins with the secondary antibody. The cells were washed three
times in PBS + 0.05% Tween and once in PBS alone. At this stage, cell nuclei were
sometimes counterstained with propidium iodide. Cells were incubated with PBS
containing lng/ml propidium iodide and lOng/ml DNase-free RNaseA for 30mins at
37°C in darkness. Cells were mounted in Citifluor (UKC) and examined using a UV
microscope (Nikon Diaphot 200 or Leica TCSNT confocal microscope).
2.5.11. Prediction of Protein Structure
Structural motifs were predicted from protein sequence using the following
programmes that can be found at the listed web sites. The position of transmembrane
helices and the orientation of the MHV-68 GPCR in the membrane was predicted
using "TMpred" (Hofman, 1993) that is found at http://www.ch.embnet.org/
so ftware/TM PREDeform .html. The presence of common motifs was determined
using "Scan Prosite" that is found at http://wwwexpasy.cbr.nrc.ca/tools/
scnpsitl .html. The alignment of multiple proteins was performed using the Blosum
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scoring matrix with the "ClustalW" programme (Thompson et al., 1994) that is
found at http://www.ch.embnet.org/software/ClustalW.html. The prediction of
phosphorylation sites was made using the programme "NetPhos" (Blom et al., 1999)
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3.1. Sequence Analysis of the GPCR
Preliminary analysis of the MHV-68 DNA sequence revealed homology between
MHV-68 ORF74 and the mammalian IL-8 receptor, CXCR2 (Virgin et al., 1997). A
database search was performed using the programme, "BLAST", which confirmed
that the ORF74 gene product shared greatest identity with mammalian CXCR2
(28%) and the KSHV GPCR (25%) at the amino acid level. To demonstrate the level
of amino acid identity between the MHV-68 GPCR and other gammaherpesvirus and
mammalian GPCRs, the sequences were aligned using the programme, "Clustal W"
(Thompson et al., 1994). As shown in figure 3.1.1, the limited number of identical
and similar amino acids (highlighted black and grey respectively) demonstrates that
the similarity between the MHV-68 GPCR and the other gammaherpesvirus
receptors is not high.
Since this level of amino acid identity was significant but low, it was necessary to
investigate the relevance of the similarity by analysing the MHV-68 ORF74
sequence for conserved motifs that are characteristic of GPCRs using a variety of
bioinformatics programmes that are available online (see section 2.5.11). As shown
in figure 3.1.2A, analysis of potential transmembrane helices using the "TMpred"
programme (Hofman, 1993) revealed the presence of seven 20-25 amino acid
transmembrane regions, a feature of all GPCRs (highlighted yellow). This
programme also showed that the orientation of the protein is consistent with other
GPCRs: an extracellular hydrophilic amino terminal domain and an intracellular
carboxy terminal domain (underlined). There are also predicted to be three
intracellular (underlined) and three extracellular loops.
Most GPCRs possess a highly conserved aspartic acid-arginine-tyrosine (DRY) motif
at the base of the third transmembrane domain and the start of the second
intracellular loop that is required for coupling of G proteins (Dohlman et al., 1991;
Probst et al., 1992). As shown in figure 3.1.2B, the MHV-68 ORF74 sequence
contains a predicted histidine-arginine-cysteine (HRC) motif in this position
(highlighted blue). The Y —> C substitution occurs rarely in other GPCRs such as the
V-formyl-L-leucyl-L-phenylalanine (fMLP) receptor and is therefore conservative
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Figure 3.1.1. Alignment of Mammalian and Viral GPCRs













































Sequence alignment of four gammaherpesvirus GPCRs (AHV-1 GPCR, HVS GPCR,
KSHV GPCR, MHV-68 GPCR) with the mammalian IL-8 receptor (CXCR2) and the
cellular chemokine receptor, CCR7, (EBI-1) which is induced by EBV. The sequences
were aligned using the Blosum scoring matrix with the "Clustal W" programme, which
can be found at http://www.ch.embnet.orq/software/ClustalW.html. Residues that are
identical in two or more sequences are highlighted in black, while synonymous
residues are highlighted in grey.
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Figure 3.1.2. Conserved Structural Motifs of the MHV-68 GPCR
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Diagrammatic representation of the structural motifs predicted to be present in the
MHV-68 ORF74 gene product. Panel A shows the amino acid sequence with predicted
motifs as follows: transmembrane helices (highlighted yellow); N-linked glycosylation
sites (boxed); intracellular domains (underlined); conserved residues (asterisk below);
targets for phosphorylation (highlighted grey). B. Comparison of the sequence at the
start of the 2nd intracellular loop in the mammalian CXCR2 and fMLP receptor, the
KSHV GPCR and the MHV-68 GPCR. The sequences were aligned using the "Clustal
W" programme. Residues that are identical in two or more sequences are highlighted
black. The sequence surrounding the conserved arginine is boxed.
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(Boulay et al., 1990). However, the D —» H change is a non-conservative mutation
that has been observed in other gammaherpesvirus GPCRs and is associated with
constitutive GPCR signalling (Ahuja & Murphy, 1993; Arvanitakis et al., 1997;
Burger et al., 1999). The MHV-68 ORF74 gene product also contains two predicted
N-linked glycosylation sites in the N-terminal domain (boxed) and cysteine and
tryptophan residues (asterisked) that are all conserved in GPCRs. In addition, the
third intracellular loop is highly cationic, which is a feature of mammalian
chemokine receptors. Using the "NetPhos" programme (Blom et al., 1999), two
serine residues in the carboxy terminal domain (highlighted grey) were predicted to
be potential targets for phosphorylation. When taken together, these predicted
features indicated that the MHV-68 ORF74 gene product was most likely a
functional receptor that had diverged from an ancestral mammalian chemoattractant
receptor. The ORF74 product was therefore named MHV-68 GPCR.
3.2. Transcription Pattern of the GPCR
3.2.1. Cloning of the MHV-68 GPCR
The aim of this project was to characterise the MHV-68 GPCR and examine its role
in the pathogenesis of the virus. This was achieved, firstly, by establishing the
transcriptional pattern of the gene and the sub-cellular localisation of the protein. A
second approach was to investigate the potential transforming activity of the GPCR.
Finally, attempts were made to generate a recombinant virus lacking the GPCR that
would yield insight into the function of this gene in vivo.
It was essential to all these experimental strategies to amplify the GPCR DNA
sequence. This allowed insertion of the gene into plasmid vectors and provided a
DNA probe for hybridisation reactions. The coding region of the GPCR was
amplified from MHV-68 genomic DNA using a standard PCR method (2.2.2). The
primers (pair 1, appendix 1) included sites for the restriction enzymes, Bamlil and
EcoBA at their 5' end which facilitated insertion of the 1030bp PCR product into the
cloning vector, pKS (-) (appendix 2), using molecular cloning techniques. The PCR
product is shown in figure 3.2.1.
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The GPCR coding region was amplified from MHV-68 genomic DNA (100ng) using Taq
polymerase. The PCR negative control (-VE) contained no DNA. The 1030bp PCR
product was electrophoresed through a 0.8% agarose gel.
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3.2.2. Northern Analysis
To understand the role of the GPCR in the virus life cycle, it was necessary to
determine when the gene was transcribed. The temporal expression pattern of the
GPCR during lytic infection was investigated by Northern blotting. BHK-21 cells
(8xl07) were infected with MHV-68 at a multiplicity of infection of 5 pfu/cell.
Total RNA was harvested from the cells at 0, 4, 8, 12, and 24 hours post-infection.
Chemical inhibitors were used to establish the kinetic class of gene expression:
immediate early, early or late. Early and late gene expression requires de novo
protein translation and thus can be suppressed using cycloheximide, a drug that
inactivates the host cell ribosomes. Therefore, to isolate the RNA specific for the
immediate early stage of infection, one flask of cells was treated with cycloheximide
(lOOpg/ml) for 30mins prior to adsorption of the virus and harvested at 8 hours post¬
infection.
Late gene expression follows replication of the virus genome therefore drugs that
inhibit virus replication prevent expression of late genes. Phosphonoacetic acid
(PAA) inhibits DNA polymerase. Acyclovir (ACV) is a nucleoside analogue that is
phosphorylated by the virus thymidine kinase but not by the cellular thymidine
kinase. The pro-drug is activated only in infected cells and incorporated into the
replicating DNA. The absence of a hydroxyl group prevents binding of the
subsequent base resulting in premature chain termination. Therefore, early RNA was
harvested (2.3.1) at 24 hours post-infection from cells that had been incubated with
either PAA (lOOpg/ml) or ACV (100pm) for 2 hours prior to adsorption of the virus
and throughout infection. Late RNA was obtained from un-treated infected cells at
24 hours post-infection.
Total RNA was enriched for polyadenylated RNA using a kit (Amersham Pharmacia,
2.3.2) and analysed by Northern blotting (2.3.5). The blot was hybridised (2.3.7)
with a [a32P]dCTP-labelled DNA probe corresponding to the GPCR coding region
(2.2.22). Specific GPCR transcripts were detectable at 12 hours and 24 hours post¬
infection (Figure 3.2.2A). As a control for even loading and integrity of the RNA,
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Figure 3.2.2. Northern Analysis of GPCR Transcription
0 4 8 8C 12 24 PAA ACV
8.7kb
Northern blot of mRNA (10j_ig/lane) harvested from BHK-21 cells infected with MHV-68
at 0, 4, 8, 12, and 24 hours post-infection. The Northern blot was hybridised with 32P-
labelled DNA probes corresponding to A. GPCR (3wk exposure), B. gp150 (24h exp)




the blot was stripped and re-hybridised with a DNA probe corresponding to the
ubiquitous cellular gene, P-actin (Figure 3.2.2B). Lytic infection of the BHK-21
cells was confirmed by hybridisation of the blot with an MHV-68 structural gene,
gpl50 (figure 3.2.2C). Transcription of the GPCR was barely detectable using the
Northern blotting technique. Blots of gels loaded with 5-10pg of total RNA or l-3pg
of polyadenylated RNA per lane did not produce a hybridisation signal. Expression
of the GPCR was only detected when lOpg of polyadenylated RNA was loaded in
each lane of the gel. Following hybridisation, the blot was exposed to a
phosphorous-coated screen for 24 hours. Analysis of the screen using a
phosphorimager revealed a faint signal. However, an exposure time of three weeks
was required to detect a visible signal on autoradiographic film. Therefore, like the
KSHV GPCR, the MHV-68 GPCR was expressed at very low abundance.
Transcription of the GPCR was not blocked by PAA, which indicates that the GPCR
is an early gene. Expression appeared to be down regulated in the presence of PAA
but this could have resulted from the toxicity of PAA to the BHK-21 cells.
Transcription of the classic late gene, gpl50, was completely abolished in the
presence of PAA. ACV did not inhibit transcription of the GPCR, which again
indicates that the GPCR is an early gene. However, there was low-level expression
of gpl50 in the presence of ACV, which suggested a certain degree of leakage
through this block. Since the GPCR transcripts were not detectable at early time-
points during lytic infection, it was not possible to determine whether their
expression was inhibited by cycloheximide. At 8 hours post-infection, it is likely
that the GPCR transcripts were expressed at a level beyond the sensitivity limits of
this assay.
The size of each band was calculated using a graph generated from RNA molecular
weight standards that were electrophoresed alongside the RNA samples. The logio of
molecular weight was plotted against the distance migrated on the gel, thus allowing
the size of the transcripts to be determined. The GPCR-specific probe detected
several low abundance transcripts at 12 and 24 hours post-infection. There were two
major transcripts of 3.4kb and 4.4kb in length and two lower abundance messages of
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6.6kb and 8.7kb. Since the size of the GPCR coding region is only l.Okb, it was
possible that they represented polycistronic transcripts. The low abundance of the
GPCR transcripts prevented their analysis by conventional methods such as SI
nuclease mapping. Therefore the identity of other potential genes encoded on these
transcripts was further investigated using RT-PCR as described below.
3.2.3. Co-Transcription of the GPCR with v-Bci-2
Previous Northern analysis suggested that the polycistronic transcripts detected by
the GPCR probe might also encode the MHV-68 homologue of Bcl-2, Ml 1 (data not
photographically reproducible). Ml 1 lies approximately 2kb upstream of the GPCR
and is transcribed in the same direction (Virgin et al., 1997). It is also expressed at
early and late times during lytic infection (Roy et al., 2000). When taken together,
these pieces of information suggested that Mil might be co-transcribed with the
GPCR.
BHK-21 cells were infected with MHV-68 (5 pfu/cell) and RNA was harvested at 24
hours post-infection. This time-point was chosen on the basis of the Northern
analysis, which showed that the GPCR transcripts were most prevalent at 24 hours
post-infection. The RNA was reverse transcribed (2.3.10) using random hexamer
primers (primer 15, appendix 1) and amplified with a sense primer corresponding to
Ml 1 and an anti-sense primer corresponding to the GPCR (pair 5, appendix 1). The
result was a 2.7kb product shown in figure 3.2.3. No product was seen when the
same reaction was performed in the absence of reverse transcriptase, which
confirmed that the DNase treatment had been effective and the 2.7kb band was not
derived from contaminating DNA. The PCR product was inserted into the pKS(-)
cloning vector and sequenced, revealing that the 2694bp cDNA sequence was
identical to the MHV-68 genomic sequence. This would suggest that the transcript
was not spliced. However, since the reverse transcription reaction was performed
using random hexamer primers as opposed to gene-specific primers, it is not possible
to conclude that this transcript originated from the v-Bcl-2 and GPCR coding strand
and does not represent a transcript arising from the opposite strand.
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Figure 3.2.3. Co-transcription of the GPCR and v-Bcl-2
2694bp
RT-PCR was performed on cells infected with MHV-68. Using an upper primer
specific for v-Bcl-2 and a lower primer corresponding to the GPCR, a 2.7kb PCR
product was amplified using Pfu polymerase. The PCR products (10jal) were
electrophoresed through a 0.8% agarose TAE gel. A negative control that contained
no reverse transcriptase (-RT) showed that the product was not amplified from
contaminating genomic DNA.
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3.2.4. Expression of the GPCR in vivo
Expression of the GPCR had previously been detected in the peritoneal cells of mice
that were persistently infected with MHV-68, thus suggesting a role for the GPCR in
latent infection (Virgin et al., 1999). However, the route of infection utilised in this
study was that of intraperitoneal injection, which does not produce an acute infection
in the lung. Since it has been demonstrated that the lung is a major site of
persistence (Stewart et al., 1998), it seemed logical to confirm this finding in mice
that had been infected via the more natural intranasal route. This experiment was
performed in conjunction with Dr Douglas Roy and Dr James Stewart (Laboratory
for Clinical and Molecular Virology, University ofEdinburgh).
Six BALB/c mice were infected intranasally with MHV-68 and viral gene expression
in the lung and spleen was analysed using RT-PCR. Tissues were harvested from
three mice at 14 days post-infection (p.i.) when the acute infection is resolving in the
lung, persistence is being established and latently infected cells are present. The
remaining tissues were harvested at 10 months p.i., by which point the virus has
established a stable latent infection in the host (Sunil-Chandra et al., 1992a; Sunil-
Chandra et al., 1992b).
The RNA was reverse transcribed using random hexamer primers (2.3.10) and
amplified with primers corresponding to the coding region of the GPCR (pair 1,
appendix 1). The cDNA samples were also amplified with primers specific for v-
Bcl-2 (pair 6, appendix 1), as co-expression of v-Bcl-2 and the GPCR had previously
been demonstrated in vitro. In addition, the expression of ORF50 and ORF57 was
investigated (primers described by Virgin et al., 1999). These genes encode
transcriptional transactivators that are only transcribed during the virus lytic cycle
(Liu et al., 2000; Mackett et al., 1997; Wu et al., 2000). The sensitivity of the PCR
reactions was checked by limiting dilution of cloned fragment templates and found to
be equivalent and equal to one copy in all cases. No product was seen when the
same reaction was performed in the absence of reverse transcriptase, which
confirmed that the positive signals did not originate from contaminating DNA. As a
control for the integrity of the RNA and efficiency of the cDNA synthesis reaction,
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In vivo transcription of the GPCR and v-Bcl-2. Total RNA was extracted from the
spleens and lungs of BALB/c mice at 2 weeks and 10 months post infection with MHV-
68. RT-PCR was then performed using sets of primers corresponding to viral genes
and the cellular gene, p-actin, as indicated at the left. To control for the presence of
carry-over genomic DNA, parallel RT-PCR reactions were carried out without reverse
transcriptase. The PCR products were electrophoresed through a 1% TAE gel and
analysed by Southern blotting. The individual mice used are indicated at the foot of
the diagram.
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all cDNA samples were amplified with primers specific for the cellular gene, (3-actin
(pair 19, appendix 1). The PCR products were analysed by Southern blotting using
[a32P]dCTP-labelled DNA probes corresponding to each gene product (2.2.20). As
shown in figure 3.2.4, transcripts corresponding to the region of the genome
encoding ORF50 and ORF57 were detected in both the lung and the spleen at 14
days p.i. in all three mice. However, at 10 months p.i., expression was un-detectable,
indicating that productive viral gene expression was still occurring at 2 weeks p.i. but
had been completely resolved by 10 months p.i. Expression of transcripts
corresponding to the region of the genome encoding the GPCR and v-Bcl-2 were
expressed at 14 days p.i. in both the lung and the spleen of all three mice tested,
consistent with prior Northern analysis showing transcription of these genes during
lytic infection. These transcripts were still detectable at 10 months p.i. in all three
lung samples and one spleen sample.
Unfortunately, this experiment does not conclusively prove that the GPCR and v-
Bcl-2 are co-expressed during virus latency. Since the reverse transcription was
carried out with random hexamers rather than gene-specific primers and the PCR
products were detected with double-stranded DNA probes, there is a strong
possibility that the transcripts may have arisen from genes on the opposite strand of
the virus genome. Although the coding regions of the GPCR and v-Bcl-2 do not
overlap with the adjacent genes, ORF73 and ORF75, it is likely that due to the
complex nature of transcription in this region, their transcripts may well overlap.
Nevertheless, it is quite possible that these transcripts do correspond to the GPCR, v-
Bcl-2, ORF50 and ORF57. This being the case, the expression of the GPCR and v-
Bcl-2 in the absence of lytic cycle genes such as ORF50 and ORF57 indicates that
these transcripts might have originated from latently infected cells. However, further
experiments would be required to confirm this finding.
3.2.5. 3'RACE
Having determined that the GPCR and v-Bcl-2 were encoded on the same bicistronic
transcript, a 3'RACE technique (2.3.11) was used to investigate the sequence
downstream of the GPCR gene and identify the polyadenylation signal. Total RNA
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3'RACE was performed on RNA isolated from cells 24 hours post-infection with MHV-
68. Reverse transcription was carried out using an oligo(dT) primer. The cDNA was
amplified with Taq polymerase using the same oligo(dT) primer and a primer
complementary to the GPCR coding region. The PCR products (10fo.l) were
electrophoresed through a 0.8% agarose TAE gel. An RT-PCR negative control (-RT)
that contained no reverse transcriptase confirmed that the PCR products did not
originate from contaminant genomic DNA.
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was harvested from BHK-21 cells infected with MEIV-68 (5pfu/cell) at 24 hours
post-infection. RT-PCR was carried out using an oligo(dT) primer (16, appendix 1),
which resulted in selective transcription of polyadenylated RNA. The cDNA was
amplified using the same oligo(dT) primer and a primer corresponding to the GPCR
coding region (primers IS and 16, appendix 1). The products of the PCR reaction
are shown in figure 3.2.5. The 1.6kb band corresponds to a potential polyadenylation
site approximately 600bp downstream of the end of the GPCR coding region at
106622. Southern analysis of the 3'RACE products revealed that all the bands were
specific for the GPCR. However, there were no intervening potential
polyadenylation sites downstream of the GPCR translation start-site. This suggested
that at the low annealing temperature required for this PCR reaction, the oligo(dT)
primer hybridised non-specifically with several of the AT-rich regions present in the
GPCR coding region.
3.2.6. 5'RACE
An attempt was made to identify the GPCR transcriptional start-site using a 5'RACE
method (2.3.11). A diagrammatic representation of this technique is given in figure
3.2.6A. The target RNA was total RNA harvested from BHK-21 cells infected with
MHV-68 at 24 hours post-infection. The RNA was reverse transcribed using a
primer (14, appendix 1) that corresponds to the known GPCR coding region. The
resulting cDNA extended into the unknown upstream region of the transcript. Once
the RNA was degraded using RNaseH, the cDNA underwent a ligation reaction. The
presence of the phosphate group on the 5'end of the RT primer facilitated
circularisation or concatomerisation of the cDNA molecules. The unknown region,
now flanked by regions of known DNA sequence, was amplified using the first
round A1 and SI primers (pair 12, appendix 1). A nested PCR reaction was carried
out using the A2 and S2 primers (pair 13, appendix 1). The products of the second
round PCR are shown in figure 3.2.6B. The major 247bp band was extracted from
the gel and cloned into the vector, pKS (-). Sequencing of the DNA fragment




Figure 3.2.6A Diagram of 5'RACE
RESULTS
UNKNOWN REGION KNOWN REGION
UNKNOWN REGION UNKNOWN REGION
4eh
The start site of the bicistronic transcript was investigated using 5'RACE. As shown,
this method involves using RT-PCR to extend into the unknown upstream sequence
of the transcript. By circularisation or concatomerisation of the cDNA, the unknown
sequence is placed between two regions of known sequence thus allowing the 5'
region to be amplified.
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5'RACE was carried out using RNA isolated from cells infected with MHV-68. The
cDNA was ligated and amplified using Taq polymerase. The products of the second
round PCR reaction (10pl/lane) were electrophoresed through a 0.8% agarose TAE gel.
The DNA template was the product of the first round PCR used neat (lane 1), 1:10
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This diagram summarises the Northern, RT-PCR and 3'RACE data. Together they
suggest that the GPCR and v-Bcl-2 are transcribed bicistronically on a transcript
represented by the 3.4kb band on the Northern blot.
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3.2.7. Summary of the GPCR Transcription Pattern
Northern analysis revealed that the GPCR was expressed at early and late time-points
during MHV-68 lytic infection in vitro on rare polycistronic transcripts. The
evidence suggested that the GPCR was co-transcribed with the MHV-68 homologue
of Bcl-2. Taken together, the RT-PCR and 3'RACE data suggest that the 3.4kb band
detected by Northern blotting represents a bicistronic transcript encoding v-Bcl-2 and
the GPCR. The results are summarised in figure 3.2.7.
3.3. Expression of the GPCR Protein
3.3.1. Production of a GPCR Fusion Protein
As a first step in the investigation of the GPCR protein, it was decided to raise an
antibody. In order to produce an antibody to the GPCR, it was necessary to generate
a source of antigen that could be used to raise an immune response in vivo. The
GPCR was therefore expressed as a GST fusion protein using the pGEX bacterial
expression system (Amersham Pharmacia). A 93bp region of the GPCR
corresponding to the predicted extracellular NH-terminus was amplified using Taq
polymerase and primer pair 2 (appendix 1). The DNA fragment was cloned into the
pGEX-2T vector, in frame with the Schistosoma japonicum glutathione-S-transferase
gene under the control of the tac promoter (pGEX-GPCRNter, figure 3.3.1A). It
was reasoned that the hydrophobic transmembrane domains of the protein were less
likely to be immunogenic and were therefore not included in the fusion protein.
Four pGEX-GPCRNter clones were tested for their ability to express the fusion
protein in XL-1 blue bacteria (2.5.1). Expression of the fusion protein was induced
by addition of IPTG during exponential growth phase of the culture. Half of each
bacterial culture was induced with IPTG while the other half was retained as an un-
induced negative control. The cultures were incubated at 37°C for three hours before
being pelleted and resuspended in SDS-PAGE sample buffer. The crude bacterial
lysates were electrophoresed on an SDS-PAGE gel (2.5.7) as shown in figure 3.3.IB.
All four bacterial clones that were induced with IPTG produced a band of
approximately 29kDa that was not present in the un-induced negative controls.
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Figure 3.3.1A The pGEX-2T Bacterial Expression Construct
6amHI EcoRI
A 93bp DNA region that was predicted to correspond to the extracellular N-terminus
of the GPCR was amplified (pair 2, appendix 1) and cloned into the pGEX-2T
expression vector in frame with the S.japonicum glutathione-S-transferase gene to
produce a GST gene fusion. This vector expressed the fusion protein from the
inducible prokaryotic tac promoter, which is activated upon addition of IPTG. The
vector also encodes the lac repressor gene (/aclq) and an ampicillin resistance gene
for selection in bacteria.
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Figure 3.3.1 B Expression of the Fusion Protein
Four separate GEX-GPCRNter clones were tested for expression of the fusion protein.
Crude lysates were electrophoresed on a 15% SDS-PAGE gel. Lanes 1, 3, 5 and 7
contain clones 1-4 that were induced with IPTG, while lanes 2, 4, 6 and 8 contain the
un-induced negative controls.
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Western analysis using an anti-GST antibody. Lane 1: crude lysate of bacteria
carrying the empty pGEX-2T vector and induced with IPTG to express GST. Lane 2:
crude lysate of bacterial clone no.1, induced to express the fusion protein. Lane 3:
fusion protein that was purified using GS beads. The blot was incubated with a rabbit
anti-GST antibody, washed and incubated with swine anti-rabbit-AP antibody. A
colorimetric reaction was produced by addition of NBT/BCIP.
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Since the size of the fusion protein was predicted to be 3kDa larger than GST
(26kDa), it was probable that this band represented the GST-GPCRNter fusion
protein. The expression level of the fusion protein appeared to be equivalent in each
clone.
To confirm that this band represented the fusion protein, a Western blot was
generated that was incubated with an anti-GST antibody. The IPTG-induced crude
bacterial lysate corresponding to clone no.l was electrophoresed on an SDS-PAGE
gel. A crude lysate of bacteria expressing GST from an empty pGEX-2T vector was
electrophoresed on the same gel. The protein was transferred to a Western blot as
described in section 2.5.8 and incubated with a rabbit anti-GST antibody (Stewart,
unpublished). This was followed with a secondary swine anti-rabbit antibody
conjugated to alkaline phosphatase. Finally, the blot was incubated with NBT/BCIP
to produce a colorimetric reaction (figure 3.3.1C). The anti-GST antibody reacted
strongly with the pGEX-2T negative control to produce a band of
approximately26kDa that corresponds to GST. The antibody also bound to a band in
the region of 29kDa that was likely to be the GST-GPCRNter fusion protein.
An identical Western blot was produced that was incubated with a rabbit polyclonal
anti-MHV-68 antibody (Sunil-Chandra et al., 1992a). The same secondary antibody
was used and the blot was incubated with NBT/BCIP as before. The anti-MHV-68
antibody, however, did not recognise the GPCR region of the fusion protein (data not
shown).
3.3.2. Purification of the Fusion Protein
The fusion protein was isolated using an affinity purification system that involved
glutathione-sepharose (GS) beads (2.5.2). To test whether the fusion protein was
soluble in aqueous solution and bound to the GS beads, clone no. 1 was cultured and
induced with IPTG. The bacteria were lysed by sonication and the soluble fraction
was incubated with the GS beads. The beads were washed, resuspended in SDS-
PAGE sample buffer and loaded onto an SDS-PAGE gel. The protein was
transferred to a nylon membrane by Western blotting and incubated with anti-GST
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antibody as described above (figure 3.3.1C). The anti-GST antibody recognised the
purified fusion protein thus showing that it was present in the soluble fraction and
bound to the GS beads.
The next step in the purification process was to elute the fusion protein from the GS
beads using a glutathione solution to compete with the glutathione sepharose for the
GST binding site. To test this, bound GS beads were mixed with 5mM glutathione
as recommended by the manufacturer (Amersham Pharmacia). The beads were
pelleted by centrifugation and the supernatant removed. Both fractions were mixed
with SDS-PAGE sample buffer and electrophoresed on an SDS-PAGE gel. No
protein was visible in the eluate: the fusion protein remained attached to the GS
beads. This experiment was repeated using clone no.2 and the same result was
obtained. The concentration of glutathione was increased from 5mM to lOmM and
15mM but this did not effect elution (figure 3.3.2).
It was surmised that since the protein could be visualised on an SDS-PAGE gel, it
must be removed from the beads by boiling in SDS-PAGE sample buffer. However,
it was with reluctance that the stringency of the elution was increased as raising the
temperature or salt concentration might denature the protein and therefore abrogate
any chance of the antibody recognising the native GPCR protein. It was also deemed
inappropriate to use SDS or other detergents that could not be removed by dialysis
and would therefore render the antigen unsuitable for application in vivo.
Nevertheless, attempts were made to elute the fusion protein using a range of
concentrations of glutathione (5-100mM), sodium chloride (0.1-3.0M) or urea (3.0-
5.0M). The protein-bound GS beads were also heated to 100°C in a solution of
15mM glutathione but no protein was ever visualised in the eluate. It was observed
that some fusion protein was still present in the insoluble fraction after sonication of
the bacteria. This suggested that the fusion protein was only partially soluble which
might prevent elution into an aqueous solution. Therefore, it was decided to use the
fusion protein as an antigen while still bound to the GS beads.
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Figure 3.3.2. Failure to Elute the Fusion Protein
Testing elution of the fusion protein from GS beads. Aliquots of GS beads bound to
the GST-GPCRNter fusion protein were mixed with elution buffer. The beads were
pelleted and resuspended in SDS-PAGE sample buffer while the eluate was mixed 1:1
(v/v) with sample buffer. The eluted beads and eluates were electrophoresed through
a 12% SDS-PAGE gel. Lane 1: un-eluted beads. Lane 2: beads treated with 10mM
glutathione and corresponding eluate (lane 3). Lane 4: beads with 15mM glutathione
and eluate (lane 5). Lane 6: beads with 15mM glutathione + 1M NaCI and eluate (lane
7). Lane 8: beads eluted with 15mM glutathione + 3M NaCI (lane 9).
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3.3.3. Analysis of Antisera
The fusion protein was purified on a large scale and two rabbits were immunised
with a mixture containing the bound GS beads and adjuvant (2.5.3). After three
weeks the sera were tested against cells infected with MHV-68 (24 hours p.i.) by
Western blotting. When compared with the pre-immunisation sera samples, the
antisera displayed no specific reactivity with the virus-infected cell sample (not
shown). The rabbits received three booster injections at 3-week intervals and the
antisera was tested by Western blotting between each injection. Although the
antisera generated by both rabbits recognised the GST-GPCRNter fusion protein,
they failed to recognise the native GPCR protein in MHV-68 infected cells or in a
stable 3T3 clone expressing the GPCR (GPCR1, section 3.4.3). The potentially low
level of GPCR protein expression in the infected and stably transfected cells may
have been beyond the sensitivity limit of the Western analysis. Therefore, the more
sensitive radio-immunoprecipitation assay was used.
BHK-21 cells were infected with MHV-68 and radiolabeled with 35S-methionine at
12 hours p.i. when, according to Northern analysis, the GPCR was expressed (2.5.9).
Un-infected cells were also radiolabeled as a negative control. The cells were lysed
and the lysates incubated with antisera and pre-immune sera from each rabbit in
addition to a positive control anti-MHV-68 antibody. In order to isolate the antigen-
antibody complexes, the lysates were incubated with protein A sepharose, which
binds to the Fc receptors of immunoglobulin molecules. The protein A sepharose
beads were washed, pelleted and electrophoresed on an SDS-PAGE gel. The gel was
dried and exposed to autoradiographic film (figure 3.3.3). The samples incubated
with the positive control anti-MHV-68 antibody confirmed that the BHK-21 cells
had efficiently incorporated the radiolabeled methionine. The difference between
the infected and un-infected samples (lanes 9 and 10) showed that there was also
efficient labelling of MHV-68 proteins. However, in neither of the rabbit samples
was there any specific difference between the antisera and the pre-immune sera that
was also specific to the MHV-68 infected cells. This indicated either the GPCRNter
portion of the fusion protein was not sufficiently immunogenic or that any antibody
specific for the fusion protein failed to recognise the native GPCR protein.
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Figure 3.3.3. Radio-lmmunoprecipitation Assay to Test Antisera
Rabbit 1 Rabbit 2
I 1 | 1 Anti-MHV-68
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BHK-21 cells were infected with MHV-68 and radiolabelled with [35S]-methionine and
incubated for 4 hours (37°C). The cells were lysed in RIPA buffer and the lysates pre-
cleared by incubating with sepharose. Lysates were incubated with rabbit test sera or
anti-MHV-68 antibody and precipitated by mixing with protein A sepharose. The
sepharose beads were washed, resuspended in SDS-PAGE sample buffer and
electrophoresed through a 12% SDS-PAGE gel. P: Pre-immune sera, S: Test sera, I:
Infected, M: Mock Infected.
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Figure 3.3.4A Location of Peptides in the GPCR Amino Acid Sequence
GPCR1
1 MLVLRDLDLE DLQAFLENSS LSYDDYYDNA TWIPDLASPC TVSLKYGVLF
51 ALALFMFVLS VLGNLTVVCV FCAYRAACKG ADVLMLVFCF VCMLASLAHV
101 LEISHLLYTM PGSMLLCVLF TLYVSTLDFC IVFILMIISI HRCLLVMTPN
151 RLFLNSKCFG ACLAWFAVIL AIGAAAVETV FVKPLDLSQI ITHGAFICAM
201 ELGGTTRVSV RLAQQFLGIW IPVLIIIVCF IMVVCRVRRM RMGKKYRIYV
251 SFICTTILFL IFCVPGKIVA LVDEVVRLGW VQETCEIRTV LATLGTASMI
301 LESLFCALVT LITSLFGSIF KKRMGESVRR AVCRLSS
Two peptides were designed that corresponded to the GPCR amino acid sequence.
The peptide sequences were selected on the basis that they represented hydrophilic,
extracellular regions of the protein, which were more likely to be immunogenic. The
hydrophilic and extracellular domains of the GPCR protein were predicted using a
sequence analysis programme, "TMpred" (Hofman, 1993). GPCR2 encoded the
residues highlighted in grey within the dotted line, thus joining two hydrophilic
regions with a small hydrophobic region.
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3.3.4. Generation of Antibody using Peptides
The inability of the rabbit sera to recognise the GPCR protein prompted a new
immunisation strategy involving the use of peptides as antigen. Two peptides were
synthesised that corresponded to hydrophilic, extracellular regions of the GPCR
amino acid sequence (figure 3.3.4A) and GPCR1 was coupled to bovine serum
albumin as described in section 2.5.6. However, prior to immunisation with the
peptides, two sheep were vaccinated with DNA encoding the GPCR. Each sheep
received four intra-muscular injections of25pg pVR1255-GPCRHA3 (figure 3.3.5A)
in a volume of 250pl. One sheep was also immunised with DNA encoding the
cytokine, GMCSF (4x 25pg pEGFP-GMCSF), in an attempt to enhance the immune
response to the GPCR. The sheep received a booster injection of DNA after three
weeks. Nine weeks after the initial DNA vaccination, the sheep were injected
intramuscularly with 25pg peptide (12.5pg GPCR1 + 12.5pg GPCR2) in a volume of
250pl at four sites. The antisera were tested against 293 cells that were transiently
transfected with pVR1255-GPCRHA3 by Western analysis but no specific bands
were apparent (figure 3.3.4B).
3.3.5. Epitope-Tagging of the GPCR
In the absence of an antibody to the GPCR, the sub-cellular localisation of the
protein was investigated using an "epitope-tagging" strategy. A version of the GPCR
was produced that encoded an epitope derived from the influenza virus
haemagglutinin protein at the carboxy terminus. It was anticipated that expression of
this gene in transfected cells could then be detected using an anti-haemagglutinin
antibody. The GPCR coding region was amplified using an antisense primer
incorporating a 27bp DNA sequence that corresponds to an epitope of the influenza
virus haemagglutinin protein (pair 3, appendix 1). The sequence of nine amino acids
was inserted immediately upstream of the GPCR STOP codon so that it would be
translated in-frame with the receptor.
The PCR product was inserted into the mammalian expression vector pBABEIpuro
(appendix 2) under the control of a retroviral LTR, to give pBabe-GPCRHA (figure
3.3.5A). The construct was transfected into NIH3T3 cells via electroporation (2.4.3)
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Figure 3.3.4B Western Analysis of Sheep Antisera
Western analysis to test the reactivity of sheep antisera to the GPCR protein. 293
cells were transiently transfected with pVR1255-GPCRHA3 and harvested at 24 hours
post-transfection. Cells were resuspended in SDS-PAGE sample buffer and
electrophoresed through a 12% SDS-PAGE gel. A blot of the gel was incubated with
the sheep antiserum (1:1000) followed by biotinylated donkey anti-sheep antibody and
streptavidin-AP. A colorimetric reaction was produced by addition of NBT/BCIP.
Lanes 1, 3 and 5: 293 cells expressing the GPCR. Lanes 2, 4 and 6: negative control
mock-transfected cells. Blots 1 and 2 were incubated with anti-serum from the sheep
immunised with GPCR-derived peptides. As a negative control, blot 3 was incubated
with serum taken from a non-immunised sheep.
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and stable transfectants were selected by treating with 3fig/ml puromycin as
described in section 2.4.5.
Both transient and stably transfected cells were stained using a standard
immunofluorescence technique described in section 2.5.10. No positive control for
the anti-haemagglutinin antibody was available at this time. Un-transfected 3T3
cells were used as a negative control. The slides were incubated with rat anti-
haemagglutinin antibody (1:1000, Roche) for 1 hour at room temperature then
washed before adding the secondary antibody: FITC-labelled goat anti-rat
polyclonal antibody (1:250, Pharmingen). No specific FITC staining was detected in
cells transfected with the GPCR therefore a "bridging" method was employed to
increase the sensitivity of the assay. Following incubation with the primary
antibody, the cells were washed and incubated with a secondary biotinylated anti-rat
antibody (Dako). The cells were then exposed to streptavidin conjugated with
alkaline phosphatase (streptavidin-AP, Roche) and a colorimetric reaction was
produced by addition of NBT/BCIP. Again, no specific staining was detected using
a light microscope. It was concluded that either the level of GPCR protein
expression was below the limits of detection or that a single haemagglutinin epitope
provided insufficient binding sites for the antibody.
To improve the detectable level of GPCR expression, a new expression construct was
generated containing three haemagglutinin epitopes. The GPCR was amplified using
primers (pair 4, appendix 1) that incorporated three identical consecutive
haemagglutinin epitopes at the 3' end of the GPCR. The DNA was inserted into the
mammalian expression vector, pVR^SS'"^ (appendix 2), under the control of the
CMV promoter (pVR1255-GPCRHA3, figure 3.3.5A). This vector, which was
designed for the high-level expression of inserted genes, was obtained under license
from Vical Inc. (Hartikka et al., 1996).
Prior anecdotal evidence had indicated that the transfection efficiency of 293 cells
was superior to that of 3T3 cells. The triple-tagged GPCR construct was transfected
into 293 cells via electroporation and the cells were harvested at 24 hours post-
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Figure 3.3.5A. To generate pBabe-GPCR, the GPCR was amplified using a primer that
incorporated a 27bp sequence encoding a single epitope derived from the influenza
virus haemaggiutinin protein (HA) onto the 3' end of the gene. This HA-tagged GPCR
was inserted into the multiple cloning site of the pBabe/puro retroviral expression
vector under the control of the Moloney murine leukaemia virus long terminal repeats
(LTR). This vector encodes an ampicillin resistance gene (Amp ) for selection in
bacteria and a puromycin resistance gene (PuroR) for selection in mammalian cells. A
polyadenylation site (PolyA) is present within the downstream LTR. A non-functional
MuLV gag gene is included as a packaging signal for the production of recombinant
virus in a complementary helper cell line. However, in these experiments, the
pBabe/pi/ro vector was used solely as an expression plasmid.
For construction of pVR1255-GPCRHA3, the GPCR was amplified using a primer
that incorporated three consecutive HA epitopes at the 3' end of the gene. The triple
HA-tagged GPCR was inserted by blunt-end cloning into the EcoRV site of the
pVR1255luc' expression vector. This vector contains the CMV IE enhancer/promoter
upstream of the CMV intron A, cloning sites and a rabbit p-globin polyadenylation site.
There is also a kanamycin resistance gene for selection in bacteria but no selective
marker for use in mammalian cells.
A triple HA-tagged Jk contained in the pSG5 expression vector (pSG5-Jic) was
used as a positive control for haemaggiutinin expression. pSG5 expresses inserted
genes from the SV40 early promoter and includes intron II of the rabbit p-globin gene,
a polyadenylation signal and ampicillin resistance gene.
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transfection. The cells were fixed and stained with the rat anti-haemagglutinin and
FITC-labelled anti-rat antibodies as before. Mock-transfected 293 cells were used as
a negative control. As a positive control for the anti-haemagglutinin antibody, cells
were transfected with a triple HA-tagged version of the cellular signalling protein,
Jk, inserted into the pSG5 (Stratagene) expression vector obtained from Dr Clare
Sample (Zhao et al., 1996).
A small percentage of cells transfected with pVR1255-GPCRHA3 construct showed
specific FITC staining. The experiment was repeated and the cell nuclei were
counterstained red with propidium iodide. As shown in figure 3.3.5B, the anti-
haemagglutinin antibody detected patches of GPCRHA3 quite separate from the
intra-nuclear propidium iodide staining. This staining pattern was consistent with
expression of the GPCR at the plasma membrane. Transfection of 293 cells with the
pSG5-JK construct resulted in characteristic nuclear staining with the anti-
haemagglutinin antibody whereas the negative control mock-transfected cells failed
to show positive staining.
The low percentage of cells exhibiting immunofluorescence did not reflect the
efficiency of transfection. A positive control plasmid expressing GFP in a parallel
transfection demonstrated a transfection efficiency of 50-60%. This implies that the
level of GPCR expression in the majority of cells is below detectable limits in this
assay. As discussed below, this protein appears to be toxic to bacteria and
mammalian cells. This suggests that cells that have not taken up the plasmid and
cells expressing only very low levels of the protein may have a selective advantage
following transfection. Therefore in this context, the original pBabe-GPCRHA
construct may have been almost impossible to detect. Expression of the GPCRHA
gene was driven by a retroviral LTR, which is a weaker promoter than the CMV
immediate early promoter used to drive expression of the GPCR in pVR1255-
GPCRHA3. In addition, pBabe-GPCRHA encoded only one binding site for the
anti-haemagglutinin antibody compared with three sites in pVR1255-GPCRHA3.
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Figure 3.3.5B Expression of the GPCR in 293 Ceiis













Composite confocal image of 293 cells transiently transfected with pVR1255-
GPCRHA3 (A). The cells were harvested at 24 hours post-transfection, fixed and
stained with an anti-haemagglutinin antibody (rat anti-haemagglutinin antibody, clone
3F10, Roche) followed by a FITC-labelled goat anti-rat antibody. The cell nuclei were
counterstained red using propidium iodide. Panels D, E and F show three of the
single slice images of which the composite image in panel A is composed. Panel B
shows the characteristic nuclear staining of the HA-tagged positive control, pSG5-Jk.
Mock transfected negative control cells are shown in panel C.
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3.3.6. Toxicity of the GPCR
The insertion of the GPCR into expression vectors and subsequent expression of the
protein in mammalian cells has revealed the toxicity of this gene in both bacteria and
eukaryotic cells. Cloning of the GPCR into the pBabe/puro vector was a prolonged
process and the bacterial clone obtained did not grow rapidly in culture. In addition,
the gene was subject to rearrangement in this vector. When a bacterial glycerol stock
of the pBabe-GPCR clone was streaked onto an LB-agar plate containing ampicillin,
large rapidly growing colonies were produced alongside the characteristically small
colonies. A mixture of colonies was cultured and DNA was extracted and digested
with appropriate restriction enzymes to excise the GPCR insert. As shown in figure
3.3.6, only 50% of the clones (nos.3, 4, 6, 9, 10 and 11) were fully digested even
with addition of excess enzyme and an extended incubation period. This suggested
that a rearrangement of the DNA had occurred resulting in loss of the restriction
sites. Therefore, prior to large-scale preparation of pBabe-GPCR, the clone was
streaked on an LB-agar plate and the DNA in individual colonies tested by restriction
digest. The pBabe-GPCR clone used subsequently in transformation experiments
(section 3.5) was sub-cloned into the pKS (-) vector and sequenced to ensure that it
was free of mutations (2.2.24). Transfection of mammalian cells (3T3 and 293 cells)
with expression vectors encoding the GPCR (pBabe-GPCR and pVR1255-
GPCRHA3) resulted in fewer viable cells at 24 hours post-electroporation compared
with control vectors (i.e. empty pBdbdpuro). The number of cells expressing the
GPCR (<1%), as detected by immunofluorescence, was also well below the
transfection efficiency of a positive control vector expressing GFP (50-60%). This
suggests that expression of the GPCR is toxic to mammalian cells when expressed at
high levels.
3.3.7. Binding of IL-8 to the GPCR
The closest homologue of the MHV-68 GPCR is the mammalian chemokine
receptor, CXCR2. CXCR2 binds the CXC chemokines IL-8, GROa and NAP-2
with high affinity. The KSHV and HVS GPCR homologues have both demonstrated
chemokine-binding activity in vitro (Ahuja & Murphy, 1993; Arvanitakis et al.,
1997). The HVS GPCR exhibits a similar cytokine profile to CXCR2 while the
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Figure 3.3.6. Toxicity of the GPCR in Bacteria
A bacterial glycerol stock of the pBabe-GPCR (see figure 3.3.5A) clone was streaked
on an LB agar plate containing ampicillin. Twelve colonies were picked and grown.
DNA was extracted (2.2.14) and digested with restriction enzymes (BamHI and EcoRI)



















KSHV GPCR appears to be a more promiscuous receptor with the capacity to bind
both CXC and CC chemokines. Nevertheless, both receptors bind IL-8 with high
affinity, which made it reasonable to speculate that the MHV-68 GPCR might also
bind IL-8.
The potential interaction between the MHV-68 GPCR and IL-8 was investigated
using a competitive ligand-binding assay (2.4.16). Stably transfected 3T3 cells
expressing the GPCR (GPCR1, section 3.4.3) were incubated with radiolabeled
human recombinant [125I]IL-8. Un-transfected 3T3 cells were used as a negative
control and all samples were tested in triplicate. The lymphoma cell line, U937, was
used as a positive control. U937 cells, which possess monocyte-like characteristics,
have been shown to bind IL-8 and are often used as a positive control in this type of
assay (Milne et al., 2000). All cells were extensively washed to remove unbound
ligand then solubilised with sodium hydroxide. Radioactive emission was estimated
using a liquid scintillation counter. To control for non-specific binding, a parallel
assay was performed in which cells were incubated with [125I]IL-8 in the presence of
a thousand fold excess of unlabelled IL-8. Competitive inhibition of radiolabelled
cytokine with the "cold" unlabelled cytokine is indicative of specific binding.
The GPCR1 cells consistently failed to show specific binding to [125I]IL-8 (figure
3.3.7). This suggested that either the MHV-68 GPCR does not interact with IL-8 or
that there was insufficient expression of the GPCR to demonstrate binding. The
assay was also performed using 293 cells that were transiently transfected with the
pVR1255-GPCRHA3 expression construct. However, there was no significant
difference between cells transfected with GPCRHA3 DNA and mock-transfected
negative controls. Incubation of U937 cells with [125I]IL-8 produced a strong
radioactive signal that was reduced in the presence of unlabelled IL-8, thus
confirming that the parameters of the assay were appropriate for detection of
chemokine binding. As discussed in the preceding sections, expression of the GPCR
in mammalian cells appears to be toxic. It is likely that expression of the GPCR was
at barely detectable levels in both the transiently and stably transfected cells.
Therefore, it is not clear using this assay whether the GPCR binds mammalian IL-8.
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Competitive binding of [125i]IL-8 to cells expressing the GPCR. Cells were incubated
with radiolabeled IL-8 alone or in the presence of excess unlabelled IL-8. The
radioactive emission generated by the bound [125l]IL-8 was measured using a liquid
scintillation counter (Wallac) in counts/min. The results are expressed as the mean of
the three determinations ± standard deviation from the mean. A two-sample students'
T-test revealed a significant difference between the competitive and non-competitive
positive control U937 samples with a confidence level of 95% where a value of P =
0.05 is significant (P = 0.019). There was no significant difference between cells
expressing the GPCR and negative controls.
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3.4. Transforming Activity of the GPCR
3.4.1. Generation of Stable Cell Clones
The description of a transforming activity associated with the KSHV GPCR raised
the possibility that the MHV-68 GPCR might also have the capacity to transform
cells (Arvanitakis et al., 1997; Bais et al., 1998). However, despite the predicted
structural similarity of these proteins, the level of sequence identity between the
KSHV and MHV-68 receptors is not high (25% amino acid identity). It was
therefore necessary to assess whether these viral GPCRs shared functional similarity.
The potential transforming activity of the GPCR was investigated using tissue culture
techniques, which addressed two different criteria of cellular transformation: loss of
contact inhibition and anchorage independence. Since conventional assays for
transformation have been based on fibroblast cells, transformation has been defined
by a set of differences in the growth of fibroblastic cells in culture (Tooze, 1973).
The growth of normal fibroblast cells is regulated by contact from neighbouring cells
and it has been shown that cell contact plays a role in inhibiting cell division
(Dulbecco, 1970). Primary fibroblast cells and the cells of most fibroblastic cell
lines also require attachment to a solid surface in order to divide, a phenomenon
termed anchorage dependence ofmultiplication (Stoker et al., 1968). In transformed
cells, these growth control signals are de-regulated resulting in loss of contact
inhibition and anchorage-independent growth. The focus formation assay was used
to demonstrate loss of contact inhibition in cells expressing the GPCR and
anchorage-independence was assessed in the soft agar assay.
In order to express the GPCR in cells, it was essential to insert the gene into an
expression vector. Therefore, the GPCR gene was amplified (pair 1, appendix 1) and
inserted into the retroviral expression vector, pBabe/puro (appendix 2) under the
control of the Moloney murine leukaemia virus (MoMuLV) long terminal repeats.
This vector was chosen on the basis that it would express the GPCR at a relatively
physiological level in transfected cells. The transformation construct is shown in
figure 3.4.1. Two positive controls for transformation were used: the EBV latent
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membrane protein (LMP-1) gene and the SV40 virus early genome region, which
includes the large T antigen. LMP-1 is expressed in EBV-transformed
lymphoblastoid cell lines and is essential for EBV-induced B cell transformation
(Kaye et al., 1993). LMP-1 has also been shown to transform rodent fibroblast cells
in vitro (Wang et al., 1985). A region of DNA encoding the LMP-1 gene was
excised as a BamHl fragment from a construct available in the laboratory (pAT153,
(Stewart et al., 1989)) and sub-cloned into the pBabe/puro plasmid.
The SV40 early region encodes the small, middle and large T antigen (TAg). During
productive SV40 infection, large TAg regulates the level of virus gene expression
and stimulates virus replication. The large T antigen has been shown to be necessary
and sufficient for transformation of rodent cells in vitro (Tooze, 1973). The pBR328
construct containing the SV40 early region (pPVU-0) was obtained from Paul
Brickell, Middlesex Hospital Medical School, London (Kalderon et al., 1982). All
three transformation constructs are depicted in figure 3.4.1.
A clone of NIH3T3 cells (Bojan et al., 1983) that had been selected for their lack of
growth in soft agar and formation of foci was obtained from Dr Simon Stacey,
Paterson Institute for Cancer Research, Manchester. Given that cell-cell contact
promotes cellular transformation (Todaro, 1963), cells were passaged when only
80% confluent to minimise the risk of spontaneous transformation. Cells (2xl06)
were transfected with 20pg of each expression construct (pBabe-GPCR, pBabe-
LMP, pPVU-0 or empty pBabe/puro plasmid) as described in section 2.4.3. The
medium was replaced every 2-3 days and foci of puromycin resistant cells were
observed after 7 days. Resistant cellular foci were cloned using a modified method
described by Puck, 1956 (section 2.4.5). 3T3 clones were propagated in medium
containing lpg/ml puromycin to prevent reversion to a puromycin-sensitive
phenotype.
3.4.2. Focus Formation Assay
The puromycin-selected stable 3T3 clones and cells that were transiently transfected
with the pPVU-0 plasmid were assessed for a transformed phenotype using the focus
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Figure 3.4.1. Constructs used in Transformation Assays
The retroviral-based plasmid vector, pBabelpuro, (Morgenstern & Land, 1990)
expresses genes inserted in the MCS under the control of the Moloney murine
leukaemia virus (MoMuLV) long terminal repeats (LTR). It encodes the ampicillin
resistance gene (AmpR) for selection of the plasmid in bacteria and the puromycin
resistance gene (PuroR) that is driven by the SV40 promoter for selection in
mammalian cells. A polyadenylation site is present in the downstream LTR. A
disabled MuLV gag gene is included as a packaging signal for when the vector is used
to generate recombinant virus in a complementary cell line. In these experiments, the
pBabelpuro vector has been used solely as an expression plasmid. The GPCR and
LMP-1 genes were inserted into the plasmid multiple cloning site as shown. The
pPVU-0 construct is comprised of a DNA region encoding the SV40 early region
inserted into the pBR328 plasmid, which resulted in the loss of the Pvull restriction




formation assay (2.4.6). Each clone was maintained as a confluent monolayer in
triplicate wells of a 6-well plate in DMEM containing 10% foetal calf serum. The
medium was replaced on alternate days for 3-4 weeks until cellular foci were
observed using phase-contrast light microscopy (figure 3.4.2). Cells that were stably
transfected with the pBabe-GPCR or pBabe-LMP constructs, or transiently
transfected with pPVU-0, exhibited signs of transformation. The cell monolayers
contained regions of cells that were not contact-inhibited and whose growth had
extended over neighbouring cells (figure 3.4.2B). In places, these areas of loss of
contact-inhibition had developed into cellular foci (figure 3.4.2A). The 3T3 clones
carrying only the empty pBabdpuro vector did not display this transformed
phenotype (figure 3.4.2C).
3.4.3. Generation of Transformed 3T3 Clones
Individual cellular foci produced by four of the puromycin-resistant cell lines in the
focus formation assay were cloned as previously described (2.4.5), to generate stably
transformed cell lines. The expression of the GPCR or LMP-1 in each of these cell
lines (GPCR1, GPCR6, LMP1, LMP4) was confirmed using RT-PCR (figure 3.4.3).
Total RNA was harvested from cells using a kit (RNeasy® Mini Kit, QIAGEN, 2.3.3)
and reverse transcription was carried out as described in section 2.3.10. The cDNA
was amplified with Taq polymerase using primers specific for the GPCR (pair 1,
appendix 1) or the LMP-1 coding region (pair 18, appendix 1). Two stable
puromycin-resistant cell clones carrying only the empty pBabe//?«ro vector tested
negatively for expression of the GPCR by RT-PCR. The 3T3 cells transiently
transfected with pPVU-0 produced a smaller number of foci due to the low efficiency
of transfection. Two cellular foci were cloned and propagated. Punctate nuclear
expression of the large T antigen was detected by immunofluorescence (2.5.10) in
one cell clone (SV402) using an anti-SV40 large T antigen monoclonal antibody
(TCS Biologicals). A small percentage of cells (1-2%) exhibited a low level of
positive staining that was not photographically reproducible.
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Figure 3.4.2. Focus Formation Assay
The transforming activity of the GPCR was investigated using the focus formation
assay. 3T3 cells were transfected with pBabe-GPCR, pBabe-LMP, pBabelpuro or
pPVU-0. Stably transfected 3T3 clones expressing the GPCR or LMP-1 were
generated by puromycin selection. Cells (1x106) were seeded in 30mm 6-well plates in
DMEM containing 10% FCS. The medium was replaced on alternate days and the cells
were maintained in a confluent monolayer for a period of 3-4 weeks. Changes in
cellular morphology were observed using phase-contrast light microscopy. Stable
3T3 clones expressing the GPCR or LMP-1, or transiently transfected with pPVU-0,
exhibited loss of contact inhibition (C = GPCR1) and formation of cellular foci (A =
GPCR1; B = LMP4). 3T3 clones stably transfected with the pBabelpuro vector did not
display any signs of transformation (D). Images A, B, and C are shown at equivalent
magnification with the size bar indicating approximately 100^m.
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The expression of the GPCR or LMP-1 was confirmed in stably transfected,
transformed 3T3 cell clones (GPCR1, GPCR6, LMP1 and LMP4 respectively). Total
RNA was harvested from cells (5x106) and 2pg each sample was reverse transcribed
using Superscript II reverse transcriptase (Life Technologies) as described in section
2.3.10. The GPCR coding region was amplified using specific primers (pair 1,
appendix 1) from the cDNA obtained from the GPCR1 and GPCR6 cell clones. LMP-1
was amplified using primers corresponding to the coding region (pair 18, appendix 1)
from cDNA generated from the LMP1 and LMP4 cell clones. As positive controls, the
GPCR was amplified from MHV-68 DNA (100ng) and LMP-1 was amplified from pBabe-
LMP DNA (100ng). No PCR products were generated using the negative control (-RT)
cDNA samples thus showing that the RT-PCR products were not derived from
contaminating DNA. Two stably transfected negative controls (pBabel and pBabe2)
tested negatively for expression of the GPCR. The PCR products (1/10 reaction
volume) were electrophoresed on a 0.8% agarose TAE gel.
125
3.4.4 Growth in Soft Agar
The anchorage independent growth of the stably transformed 3T3 clones, GPCR1,
GPCR6, LMP1, LMP4 and SV402 was demonstrated by growing the cells in soft
agar (Baichwal & Sugden, 1989). Six-well plates were layered with 2ml 0.5% low
gelling temperature agarose. Cells (lxlO4) were resuspended in 2ml DMEM + 10%
FCS containing 0.35% agarose and layered on top of the supporting layer. Two
stable cell clones carrying the empty pBabdpuro vector (pBabel and pBabe2) and
un-transfected 3T3 cells were used as negative controls. Each cell clone was
cultured in triplicate wells and supplemented with 2-3 drops medium on alternate
days. After a period of 2-3 weeks, cellular foci were visualised using phase contrast
light microscopy (figure 3.4.4A) and counted with the aid of a calibrated graticule.
Since normal 3T3 cells went through one or two rounds of abortive division, only
foci of 50pm or greater in diameter were counted. The results, expressed as a mean
of three determinations ± standard deviation from the mean, are shown in figure
3.4.4B. The 3T3 clones expressing the GPCR (GPCR1 and GPCR6), LMP-1 (LMP1
and LMP4) and the SV40 early region (SV402) all produced significantly more foci
than the negative controls, as measured using the students' two sample t-test (table
3.4.4).
3.4.5 Growth in Low Serum
Transformed cells may also acquire the ability to grow and divide in the absence of
serum or with a lower serum requirement than normal cells. This is known as serum
independent growth. The stable cell clones expressing the GPCR, LMP-1 or SV40
early region were tested for their ability to grow with a reduced serum supplement.
Cells were maintained at a range of serum concentrations (0.1%-5%) but the
appropriate conditions required for growth of the transformed cells and concomitant
death of the negative controls were not found. This may reflect the particular
sensitivity of this assay or simply reveal that serum independent growth was not a
property of the transformed cell clones assayed here.
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Figure 3.4.4A Anchorage Independent Growth
Cell clones (GPCR1, GPCR6, LMP1, LMP4, SV402, pBabel and pBabe2) and un-
transfected 3T3 cells were grown in soft agar according to a method described by
Baichwal & Sugden, 1989. After 3 weeks, cellular foci were visualised in 3T3 clones
expressing the GPCR, LMP-1 or SV40 early region e.g. GPCR1, GPCR6 and LMP4
(above). The negative control cells (3T3, pBabel and pBabe2) did not produce cellular
foci. However, they did proceed through one or two rounds of abortive division e.g.




Figure 3.4.4B Growth of Transformed 3T3 Clones in Soft Agar


























3T3 pBabel PBabe2 GPCR1 GPCR6 SV402
Cell Clone
LMP1 LMP4
The transformed 3T3 clones (GPCR1, GPCR6, SV402, LMP1 and LMP4) and negative
controls (pBabel, pBabe2 and un-transfected 3T3 cells) were grown in soft agar.
Cells (1x104) were grown in triplicate 6-well plates containing DMEM supplemented
with 10% FCS and 0.35% LGT agarose (Seaplaque®, Flowgen). After three weeks, the
number of cellular foci generated by each cell line, with diameter equal to or
exceeding 50|4m, was counted. The small size of the error bars indicates the minimal
amount of variation between the samples.
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3.4.6 Tumorigenicity in Nude Mice
Another classical transformation assay involves injection of transformed cells into
mice to assess their ability to form tumours. In order to prevent rejection, cells are
injected into nude mice, which are athymic and therefore lack B and T lymphocytes
(Pantelouris, 1968). As the KSHV GPCR had been shown to be tumorigenic in nude
mice (Bais et al., 1998), and the MHV-68 GPCR had demonstrated a transforming
activity in vitro, the tumourigenicity of stable GPCR+ cells was investigated. Six
groups of four six-week old BALB/c nu/nu mice were injected subcutaneously in the
left flank with lxl06 cells (GPCR1, GPCR6, LMP4, SV402, pBabe2 and un-
transfected 3T3 cells) in a volume of lOOpl as described in section 2.4.8.
The mice were observed for 3-4 weeks, during which time no tumours developed.
The experiment was repeated by injecting lxl07 cells, of the same cell clone as
previously received, into the right flank of each mouse. After a period of 1 -2 weeks,
the mice injected with 3T3 clones expressing the GPCR, LMP-1 or SV40 early
region showed some evidence of tumour formation. The negative control mice,
which had received either pBabe2 or un-transfected 3T3 cells, did not exhibit any
signs of tumorigenesis. However, the tumorigenesis was transient in nature and all
the mice experienced regression of their tumours within the following week.
3.5. Recombinant Virus
3.5.1. Design of the Recombinant Virus Construct
One approach taken to investigate the potentially pathogenic role of the GPCR in
vivo was to generate a virus lacking this gene. Comparison of a GPCR "knock-out"
virus with the wild type virus would provide insights into its role during infection.
As shown in figure 3.5.1A, a homologous recombination strategy was employed to
replace the GPCR with a marker gene, the Aequorea victoria green fluorescent
protein (GFP). This permitted the selection of recombinant virus plaques expressing
GFP under UV illumination. The goal in these experiments was firstly to generate a
GPCR" recombinant virus and secondly to purify it to the standard at which wild type
virus was not detectable by PCR. Ultimately, the intention was to infect mice with
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Table 3.4.4. Statistically Significant Growth of Transformed Clones








Growth of stably transfected cell clones in soft agar. A two-sample student's T-test
was used to compare the number of colonies produced by the 3T3 clones listed above
with that of ordinary 3T3 cells. A P value of less than 0.05 indicates a statistically
significant difference with a confidence interval of 95%.
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pure recombinant virus and compare it with wild type virus infection by titration of
infectious vims in the lung and reactivation of latent vims in the spleen.
A DNA constmct was designed which would recombine with MHV-68 DNA
resulting in deletion of the GPCR (Figure 3.5. IB). In designing the constmct, it was
necessary to consider whether deletion of the GPCR would lead to dismption of
other open reading frames. The genes adjacent to the GPCR, ORF73 and ORF75, do
not overlap with the GPCR, therefore it appeared feasible to delete the entire GPCR
gene without disrupting adjoining coding regions. There is a distance of
approximately 200bp between the start of the GPCR coding region and the ORF73
coding region, which is transcribed in the opposite direction. Therefore, it is possible
that the GPCR coding region contains promoter or enhancer elements corresponding
to ORF73 or ORF75, which, if deleted could modify their expression. In addition,
replacement of the GPCR with a marker gene could alter the chromosomal structure
thus affecting expression of other genes.
With these caveats in mind, a recombination constmct was produced, comprising two
regions of DNA homologous to the sequences flanking the GPCR bisected with the
marker gene, GFP. The size of homologous flanking regions chosen for the
constmct was based on previous experiments with vaccinia vims. Recombinant
vaccinia viruses were generated using recombination cassettes with flanking regions
of only 500bp. Similarly, it has been possible to produce recombinant HSV-1
vimses using relatively short regions of homology. Preliminary attempts to generate
MHV-68 recombinant vimses suggested that 500bp flanks might be insufficient to
achieve homologous recombination. It was hoped that 2kb flanks would provide the
necessary specificity for site-specific integration. The 2kb regions of DNA
immediately upstream and downstream of the GPCR coding region were amplified
by PCR using MHV-68 DNA as a template (pair 7 for left flank; pair 8 for right
flank, appendix 1). The GFP gene was amplified (pair 17, appendix 1) using the
pEGFP-Cl plasmid as a template (appendix 2). The PCR product included the CMV
immediate early promoter, the GFP coding region and an SV40 polyadenylation site.
The pEGFP-Cl multiple cloning site, which is situated at the 3' end of the GFP
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Figure 3.5.1A The Homologous Recombination Event
HOMOLOGOUS RECOMBINATION
Cyclin D Bcl-2 ORF73 GPCR ORF75
■Vv * '
The recombination cassette contains regions of DNA complementary to the
sequences flanking the GPCR. Binding of cassette DNA to the MHV-68 genome
results in a homologous recombination event that replaces the GPCR with the
marker gene, GFP. The picture shows a GFP+ virus plaque on a BHK-21 monolayer.
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coding region, was excised prior to amplification, which assisted subsequent cloning
of the GFP PCR product. The 2kb homologous flanking regions and the GFP gene
were individually inserted into the pKS (-) plasmid in a three-step cloning strategy as
depicted in figure 3.5.IB. The 5.4kb construct was excised from the plasmid using
the restriction enzymes, Xhol and Pvul, to avoid any recombination events leading to
incorporation of the whole plasmid.
3.5.2. Recombination of DNA in Transfected Cells
To facilitate the recombination event, BHK-21 cells were co-transfected with the
excised recombination cassette and MHV-68 DNA. Firstly, it was necessary to
determine the amount ofMHV-68 DNA required to produce a sufficient number of
isolated infectious virus plaques. Two methods of transfection, electroporation
(2.4.3) and lipofection (2.4.4), were used to compare the efficiency ofDNA delivery.
BHK-21 cells were transfected with various amounts of virus DNA (5, 10, 15, 20,
25, 30pg) and incubated for four days. The cells were fixed and stained and the
number of plaques counted. It was shown that transfection of cells with 10pg of
MHV-68 DNA resulted in an appropriate number of isolated infectious virus
plaques. Electroporation proved to be a slightly more efficient method of
transfection than lipofection and so electroporation was used throughout.
Recombinant virus was generated as described in section 2.4.12. BHK-21 cells
(2xl06) were transfected with 10pg MHV-68 DNA and lOpg of recombination
cassette. The cells were overlaid with agar 24 hours post-transfection. At four days
post-transfection, wild type virus plaques were observed using the light microscope
and plaques containing GFP+ recombinant virus were visible using a UV microscope.
3.5.3. Purification of Recombinant Virus
Recombinant MHV-68 was isolated from wild type virus by plaque purification
(2.4.13). Five GFP+ plaques, that were well isolated from wild type plaques, were
picked using a Pasteur pipette. BHK-21 cells were infected with virus that was
extracted from each agarose plug. Four rounds of plaque purification were
performed until only a few wild type plaques were observed. The recombinant virus
was then purified using a limiting dilution assay (2.4.14). A GFP+ plaque harvested
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Cloning strategy for production of a homologous recombination construct. The 2kb
regions of DNA directly flanking the GPCR coding region were amplified by PCR and
inserted into the cloning vector, pKS(-). The GFP coding region, under the control of
the CMV promoter, was inserted between the left and right flanking regions in the
pKS(-) vector. The primers used to amplify each fragment included unique restriction
sites, not encoded on the fragments, to facilitate directional cloning. In the case of
GFP, correct orientation of the gene was confirmed by restriction analysis. The 5.4kb
recombination cassette was excised from the plasmid prior to transfection.
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from the last round of plaque purification was propagated and titrated on BHK-21
cells to determine the concentration of virus required to produce a single plaque per
well on a 96-well plate. CI27 cells were used in this assay since MHV-68 forms
more discrete plaques on this cell line than on BHK-21 cells. The virus was added to
CI27 cell monolayers in 96-well plates at a predicted concentration of 0.4pfu/well.
Therefore, for every 10 wells infected, four wells should have contained a single
plaque arising from a single plaque-forming unit of virus. A single GFP-expressing
plaque was isolated and the virus was propagated for the extraction ofDNA (2.2.19).
The recombinant virus DNA was analysed by Southern blotting (2.2.20). Both
recombinant and wild type DNA was digested with three different restriction
enzymes {BamUl, Bglll and EcoRI) and electrophoresed on four separate agarose
gels alongside DNA molecular weight markers. The DNA was transferred onto
membranes and the lanes bearing the markers were removed and stained (2.2.21).
Each blot was hybridised with an [a 32P]dCTP-labelled DNA probe encoding either
the right flank, left flank, GFP or the GPCR (Figure 3.5.3A). On each blot, the wild
type banding pattern is also evident in the recombinant digests. This indicates that
the recombinant virus was contaminated with wild type virus despite the apparent
absence of wild type plaques. Hybridisation with the left flank reveals an identical
banding pattern in the recombinant and wild type DNA digests, which suggests that
the left flank has been completely deleted. The closely spaced bands, or "laddering"
effect, produced by hybridisation with either the right flank or GFP probe indicates
proximity to a region of repetitive DNA, such as the terminal repeats. The number of
terminal repeats varies in a heterogeneous population of virus thus producing the
1.2kb graduations in size of the bands (Efstathiou et al., 1990b). The molecular
weight of each band was calculated and the integration site of the cassette was
determined by analysis of the MHV-68 restriction sites.
A restriction map was constructed from this data showing the approximate site of
integration (Figure 3.5.3B.). The evidence suggests that a non-homologous
recombination event occurred which resulted in integration and partial deletion of the
cassette at the extreme left-hand region of the genome, proximal to the terminal
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Figure 3.5.3A Southern Analysis of RCVI DNA
EcoRI Bg/ll BamHl
RCVI WT RCVI WT RCVI WT
Southern blots of MHV-68 A. RIGHT
recombinant (RCVI) and wild
type (WT) DNA. Virus DNA was
digested with one of three
restriction enzymes: EcoRI, Bg/ll
or BamHl. RCVI DNA (5fig/lane)
and WT DNA (3|ag/lane) were
electrophoresed on 1% agarose
TAE gels alongside DNA
molecular weight markers (5^g
1kb DNA ladder). The DNA was
transferred to nylon membranes
by capillary transfer and fixed by
UV cross-linking. Each blot was
probed with a different
[a32P]dCTP-labelled DNA probe
corresponding either to the right
flank (A), GFP (B), the left flank B. GFP
(C) or the GPCR (D). Blots were
exposed to autoradiographic film
for 24 hours. Bands
corresponding to wild type virus
DNA are shown in red and
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repeats. There appears to have been a concomitant deletion of the virus genome
between the repeat region and the integration site of the cassette. The relative sizes
of the bands would indicate that the viral tRNAs and genes, Ml, M2 and M3 have
been deleted. Illegitimate recombination at the left-hand end of the MHV-68
genome has been shown to occur when using other recombinant constructs (Roy et
al, unpublished observations). It is probable that this region of the genome contains
a recombinational hot-spot. This region is a potential candidate for the virus origin
of replication, which would have an effect on the genomic structure in this region.
Active regions of DNA have a more open configuration that may increase the
likelihood of recombination. It is possible that integration of the cassette also
occurred at the correct site in addition to the non-specific site. However, since the
deletion of the GPCR may have a deleterious effect on virus growth, it is possible
that the illegitimate recombinant would have a selective advantage. In this case,
selection for GFP-expressing plaques would be unlikely to yield recovery of the
homologous recombinant.
3.5.4. Generation of a Recombinant virus - RCVII
A potential strategy to circumvent the problem of illegitimate recombination was to
produce a construct with longer flanking sequences. Theoretically a construct
containing flanking sequences in the region of 5kb would provide a greater level of
specificity. The disadvantages of using longer flanks, however, were that the DNA
fragments would be more difficult to amplify by PCR and the number of restriction
sites within the 5kb sequences would preclude directional cloning. Moreover, it was
unclear whether a larger cassette would be any less likely to recombine at the MHV-
68 left-hand end hot-spot. Since the problem appeared to be the presence of the hot-
spot rather the construct, it was desirable to use a target virus that did not contain this
region.
MHV-76 is one of the original viruses isolated concurrently with MHV-68
(Blaskovic et al., 1980). Limited sequence and restriction fragment length
polymorphism (RFLP) analysis has shown that MHV-76 is likely to be a deletion
variant of MHV-68 (Macrae, unpublished observations). MHV-76 appears to be
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identical to MHV-68 except that it lacks four of the unique genes (M1-M4) at the
left-hand end of the genome. Therefore, it seemed reasonable to conjecture that
MHV-76 may also lack the recombination hot-spot. As the MHV-76 genome had
not been fully sequenced, it was necessary to ensure that MHV-76 encoded a GPCR
that was equivalent to the MHV-68 GPCR. The MHV-76 GPCR was amplified
using the same primers designed for the MHV-68 GPCR and inserted into the
cloning vector, pKS (-). The DNA sequence of the MHV-76 GPCR was determined
using an automated sequencing machine (2.2.24) and found to be identical to the
MHV-68 GPCR sequence. On the basis of this finding, it was hypothesised that
deletion of this gene in either virus would yield a similar result.
Recombinant MHV-76 was generated in the same way as described for MHV-68.
Five GFP+ plaques were isolated post-transfection and each was grown at three
dilutions (1:10, 1:100, 1:1000) in 6-well plates containing BHK-21 cells. After four
days, the number of GFP+ plaques was counted and then the cells were fixed and
stained. By subtracting the number of GFP+ plaques from the total number of
plaques, it was possible to estimate the amount of wild type virus in each sample
(Table 3.5.4). Virus sample number 1 had the lowest ratio of wild type virus to
recombinant virus plaques and was therefore selected for further purification by
Southern analysis. A PCR strategy was devised to test whether integration of the
construct had occurred at the correct site (figure 3.5.5). Using a primer just outside
the construct and a primer corresponding to GFP (pair 9, appendix 1), it was possible
to amplify across the region of the insertion. The PCR product was produced only if
the construct containing GFP had integrated correctly. Using the same upper primer
and one corresponding to the GPCR (pair 10, appendix 1) it was possible to amplify
a similarly sized region of wild type virus DNA. This provided a method of testing
whether wild type virus was still present in each sample and also controlled for the
quality of the DNA.
3.5.5. Analysis ofRCVII by PCR
Before carrying out further rounds of purification of the recombinant virus, it was
advantageous to examine whether homologous recombination had occurred.
139
RLSU
Table 3.5.4. Ratio of Recombinant to Wild Type Virus
VIRUS DILUTION GFP+ TOTAL
SAMPLE FACTOR PLAQUES PLAQUES WT > RCVII
10"1 - -
1 10"2 92 - 6X
10~3 11 61
10"1 476 -
2 10"2 60 - 8X
10"3 5 43
10"1 265 -
3 10"2 14 - 22X
10~3 2 45
10"1 63 -
4 10"2 8 - 31X
10"3 1 31
10"1 - -
5 10"2 418 - 6X
10"3 30 174
The number of GFP+ and wild type plaques were compared at
each titration to determine the ratio of recombinant (RCVII) to
wild type (WT) virus. The dashed lines indicate that the CPE
was too great to estimate the number of individual plaques.
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Figure 3.5.5. PCR Analysis of Recombinant Virus
ANALYSIS OF RECOMBINANT VIRUS BY PCR
A w 2.3kb
w




MHV-76 LEFT FLANK GPCR
B Recombinant PCR Wild type PCR
1kb 1 2 3 -VE 1 2 3 +VE
••• 2.9kb2.3kb
A. Homologous recombination of the cassette with MHV-76 DNA was detected by
PCR. Amplification across the insertion produced a band of 2.3kb. A PCR product of
similar size (2.9kb) was produced by amplifying the non-recombined region. This
served as a positive control for the quality of the virus DNA and also detected the
presence of wild type virus. B. Three virus clones expressing GFP were isolated by
plaque purification and assayed for the presence of recombinant virus. Recombinant
virus is only detectable in samples 2 and 3 whereas all three are contaminated with
wild type virus. The negative control PCR contained no DNA while the positive
control template was purified MHV-76 DNA.
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Southern analysis was performed as previously described for RCVI on all five of the
virus samples. The data, which was not photographically reproducible, suggested
that sample no.l contained virus that had undergone homologous recombination.
However, the ratio of wild type virus in the sample made it difficult to confirm this
Ten plaques, generated by sample no. 1 in the next round of plaque purification, were
selected and propagated in 24-well plates. The DNA was extracted using a kit
(QIAmp®DNA Mini Kit, QIAGEN) as described in section 2.2.18. The DNA
(lOpl/reaction) was amplified by PCR using Taq polymerase. All ten samples tested
positively for wild type virus and two samples contained recombinant virus.
Following two subsequent rounds of plaque purification, all samples remained
positive for wild type virus and only two samples were positive for the recombinant
genotype. Plaque purification did not yield pure recombinant virus.
3.5.6. Plaque Purification using a Complementary Cell Clone
The failure to isolate recombinant virus by plaque purification indicated that the
GPCR might be essential to virus replication and that deletion of the gene had
severely debilitated the virus. In this scenario, the recombinant virus might require
the presence of the wild type virus to complement the mutation. It might also be
possible to complement the mutation by propagating the recombinant virus in cells
that expressed the GPCR. Therefore, plaque purification was carried out using stably
transfected 3T3 cells expressing the GPCR (GPCR1, see section 3.4.3). A virus
sample that tested positively for recombinant virus by PCR in the previous round of
plaque purification was grown on GPCR+ cells. In contrast to BHK-21 cells and
CI27 cells, the virus did not infect the 3T3 clone efficiently. Only three plaques
were recovered and tested by PCR: all tested positive for wild type virus and only
two plaques contained recombinant virus (figure 3.5.5B.). Thus the complementary
cell line did not appear to resolve the purification problem.
3.4.7. Growth of RCVII in B cells
Murine gammaherpesvirus, like EBV, establishes latency in B cells. There is
evidence to suggest that passage of EBV+ B cell lines in culture results in the
predominance of a single latent EBV episome, as determined by the lack of variation
142
CHAPTER THREE RESULTS
in the numbers of terminal repeats (Kintner & Sugden, 1981). The resistance of
EBV-infected cell lines to superinfection also indicates that each B cell supports only
one episomal genomic variant (Reisman & Sugden, 1984). On the basis of this
finding, a possible purification strategy appeared to be to infect B cells with the
mixed population of wild type and recombinant virus and clone individual cells
carrying either wild type or recombinant latent virus. The non-secreting-
immunoglobulin B cell line, NSO (Kholer, 1976), was used in this experiment. NSO
cells (5xl05) were infected with recombinant virus isolated from the last round of
plaque purification (virus sample no.3, figure 3.5.5B) in a volume of lOOpl for 1
hour at 37°C. The cells were transferred to a T25cm2 flask and propagated for
several days to ensure that all the cells had become infected. The infected cells were
cloned using a limiting dilution method. Cells (lxlO5) were serially diluted in 96-
well plates containing mixed thymocyte medium to a concentration that would give
rise to a single B cell. No single B cells expressing GFP were observed. Attempts
were made to enrich for B cells expressing GFP by selectively pooling GFP+ cells.
However, the expression of GFP appeared to be unstable, indicating either that the B
cells infected with recombinant virus were not surviving or that GFP was not
expressed during virus latency. Therefore, it was not possible to clone a single B cell
expressing GFP.
Instead, the infected B cells were used in an infective centre assay (2.4.11), which
involves co-cultivation of latently infected cells with BHK-21 cells, resulting in
reactivation of virus from single cells. The infected B cells were incubated with the
anti-herpetic drug, 2'-deoxy-5- ethyl-beta-4'thiouridine (C9), for 7 days to suppress
lytic replication prior to overnight co-cultivation with BHK-21 cells. The following
morning, the medium was removed and the BHK-21 cells were overlaid with agar.
No wild type plaques were observed, only plaques expressing GFP. Thirty plaques
expressing GFP were selected and analysed by PCR. All the virus samples contained
both recombinant and wild type virus.
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3.5.8. Infection of Mice with Recombinant Virus
The final purification strategy involved infection of mice with the contaminated
recombinant virus. There was evidence showing that splenic B cells harvested from
mice infected with a mixed population of virus reactivated homogeneous virus in
infective centre assays (Macrae, unpublished). Virus sample no.3 (figure 3.5.5B)
was propagated (2.4.9) and titrated (2.4.10) to determine the concentration. Four
mice were infected intranasally with virus: two received lxlO2 pfu and two received
lxlO3 pfu (2.4.15.). Transgenic mice lacking the a/(3 interferon receptor were used
in this experiment, as they do not resolve acute MHV infection as rapidly as wild
type mice (Dutia et al., 1999). Since MHV-76 is less virulent than MHV-68 in wild
type mice, it was necessary to ensure that the mice yielded sufficient latently infected
splenocytes by using the more susceptible mice. The spleen of each mouse was
harvested on day 14 post-infection when splenomegaly is at its peak. Infectious
virus was reactivated from the splenocytes in the same way as described above.
Again, no wild type virus plaques were observed and thirty isolated GFP+ virus
plaques were selected. PCR analysis showed that all the plaques contained both wild
type and recombinant virus (figure 3.5.8).
3.5.9. Southern Analysis of RCVII
At this point, the recombinant virus had been purified to the standard that no wild
type plaques were visible under the light microscope. Therefore, it was more likely
that Southern analysis could now be carried out to confirm correct integration of the
recombination cassette. Virus sample no.3 was propagated and DNA was extracted
for Southern analysis as previously described for RCVI. As before, restriction maps
were constructed showing the expected banding pattern for each probe (figure
3.5.9A). The results of the Southern analysis are shown in figure 3.5.9B. As was the
case for RCVI, the recombinant banding pattern also contained bands that
corresponded to the wild type virus thus confirming that this virus sample was a
mixed population. There was also a "laddering" effect detected by probes for the
right flank and GFP, which indicates that this population of viruses contains an
illegitimate recombinant. The appearance of large bands in all restriction digests,
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especially EcoBl, indicates that partial digestion has occurred. However, close
examination of the recombinant virus DNA banding pattern reveals the presence of
faint bands that correspond to the expected size. This verifies the PCR data showing
that the cassette has integrated correctly.
Interestingly, the Southern data also raises the possibility that the recombinant virus
is not contaminated with wild type virus but with an illegitimate recombinant. This
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Restriction maps of the murine gammaherpesvirus genome in the region surrounding
the GPCR. Mapping data was obtained using the gcgv.10 sequence analysis
programme (Devereux etal., 1984). MHV-68 genome co-ordinates are given according
to (Virgin et al., 1997). The predicted band sizes are shown for restriction digests of
wild type and recombinant virus DNA digested with SamHI, Bg/ll or EcoRI and
detected using probes for the right flank, left flank, GFP or the GPCR in Southern
analysis.
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Figure 3.5.9B Southern Analysis of RCVII DNA
Recombinant (RCVII) and wild
type (WT) MHV-76 DNA were
digested with one of three
restriction enzymes: EcoRI, Bg/ll
or SamHI. Digested RCVII DNA
(5|ag/lane) and WT DNA (3|ig/lane)
were electrophoresed alongside
DNA molecular weight markers
(1kb ladder, 5(xg/lane) on four 1%
agarose TAE gels. The DNA was
transferred to nylon membranes
by capillary transfer and fixed to
the blot by UV cross-linking.
Each blot was hybridised with a
different [a32P]dCTP-labelled
DNA probe corresponding either
to the right flank (A), GFP (B), the
left flank (C) or the GPCR (D).
The blots were exposed to
autoradiographic film for 1-2
hours. The size of each band
was calculated by reference to
the molecular weight markers.
Bands corresponding to RCVII
DNA are shown in green while
WT bands are shown in red.
EcoRI Bg/ll BamHI
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G protein-coupled receptors are among the many examples of cellular proteins that
have been acquired by viruses, a phenomenon that has been termed "molecular
piracy". Although there is little sequence conservation between viral homologues,
the presence of GPCRs in so many virus genomes indicates that these receptors
confer a selective advantage. Several approaches have been taken to investigate the
role of the MHV-68 GPCR including transcriptional analysis, expression of the
protein and an examination of the potential oncogenicity of the receptor. In order to
evaluate the individual contribution of this gene to viral pathogenesis, attempts were
made to generate a recombinant virus lacking the GPCR.
4.1. Sequence Analysis of ORF74
Various programmes were used to predict that the MHV-68 ORF74 sequence
contains motifs characteristic of a G protein-coupled receptor. Alignment of viral
GPCRs with mammalian CXCR2 and the EBV-induced protein, CCR7,
demonstrated the variation not only between the viral homologues and the
mammalian chemokine receptors but also between the viral genes themselves. It is
clear, however, that the MHV-68 GPCR bears more similarity to the KSHV and
HVS GPCRs than to the AHV-1 GPCR, which is not a positional homologue.
In terms of the DRY motif, the MHV-68 sequence (HRC) appears to most closely
resemble HVS, which encodes LRC at this position. However, the aspartic acid
residue is considered to be the most critical amino acid in the DRY motif as naturally
occurring and engineered substitutions of this residue engenders constitutive GPCR
signalling (Alewijnse et al., 2000; Burger et al., 1999). It has been hypothesised that
replacing the aspartate with a hydrophobic residue such as valine would draw the
intracytoplasmic loop into the plasma membrane, rendering the GPCR in a
permanently active conformation. Since leucine, like valine is a highly hydrophobic
residue, the D->L change bears similarity to the KSHV D—>V change. This implies
that the HVS GPCR may be constitutively active, yet the induction of calcium
mobilisation in response to chemokines suggests that signalling is actually ligand-
dependent (Ahuja & Murphy, 1993). Histidine is a basic amino acid that is unlikely
to be buried in the plasma membrane but since a hydrophobic residue does not
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appear to automatically confer agonist-independence, the MHV-68 HRC motif is not
a reliable indicator of agonist-dependent or independent signalling activity. The
transforming activity of the MHV-68 GPCR did not appear to be dependent on
chemokine stimulation, although there may have been agonists present in the
medium that could have activated the receptor. Therefore, it would be interesting to
examine the signalling activity of the GPCR in response to a range of potential
chemokine agonists.
4.2. Transcription Pattern of the GPCR
4.2.1. Transcription of the GPCR during Productive Infection
The transcriptional expression pattern of the GPCR during productive infection in
vitro was examined by Northern hybridisation. This revealed the presence of four
GPCR-specific transcripts that were only barely detectable using this technique.
This indicates that the gene is expressed at very low abundance and coincides with
the observations of Virgin et al., 1999, who failed to identify GPCR transcripts in
productively infected fibroblasts. It is also in keeping with analysis of the KSHV
GPCR, which has shown that it is expressed at low levels in KS lesions (Kirshner et
al, 1999).
The kinetic class of the GPCR transcripts was established by treating the cells with
chemical inhibitors. GPCR transcription was resistant to treatment with
phosphonoaeetic acid (PAA) and acyclovir (ACV), which both inhibit herpesvirus
DNA replication. Since expression of the late kinetic class of genes occurs only after
virus replication, this indicates that the GPCR is an immediate early or an early gene.
The sensitivity of GPCR transcription to cycloheximide, which suppresses all but
immediate early gene expression, could not be assessed as GPCR-specific transcripts
were not evident prior to 12 hours post-infection (p.i.). Since MHV-68 early genes
are generally visible by 8 hours p.i. and late genes by 12 hours post-infection
(Stewart et al., 1996; Stewart et al., 1994), this in itself indicates that the GPCR is
unlikely to be an immediate early gene.
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The apparent down regulation of GPCR transcription in the presence of PAA is
possibly a result of the toxic effect of PAA on the BHK cells. An alternative
explanation is that the GPCR is expressed at both early and late time-points and that
PAA is suppressing transcription at late time-points. If this were the case, a similar
down regulation might be expected with ACV treatment although the transcription of
gpl50 in the presence of ACV has demonstrated a degree of leakage through this
block. Previous analysis has indicated that ACV is a less potent inhibitor of MHV-
68 than a related nucleoside analogue, C9 (2'-Deoxy-5-ethyl-beta-4'-thiouridine,
(Barnes et al., 1999).
The designation of the GPCR as an early-leaky-late lytic gene corresponds to the
expression pattern of the KSHV GPCR. The induction of productive KSHV
infection with phorbol esters in latently infected cell lines has revealed that GPCR
transcription is resistant to PAA but peaks later than other classic early genes
(Kirshner et al., 1999; Sun et al., 1999). KSHV GPCR expression is barely
detectable in un-induced KSHV+ PEL cells lines but since these lines undergo a low
level of productive replication, it is likely that the GPCR transcripts arise from cells
in the productive cycle (Cesarman et al., 1996b). This is confirmed by in situ
hybridisation analysis of KS lesion showing co-localisation of GPCR transcripts with
lytic cycle genes (Kirshner et al., 1999).
4.2.2. Latent Expression of the GPCR
Expression of the GPCR could not be detected in Sll cells using Northern analysis.
As discussed in section 1.5, Sll cells are latently infected with MEIV-68 but a low
percentage of cells (1-2%) undergo lytic replication that can be suppressed with
ACV or C9 (Usherwood et al., 1996c). Similarly to the KSHV and EBV latently
infected cell lines, productive replication can be induced by stimulation with phorbol
ester. GPCR-specific transcripts were not evident in Northern hybridisations of S11
cells or Sll cells treated with the phorbol ester, TPA. This may reflect the
sensitivity of the technique and the observation that only a proportion of Sll cells
are reactivated by TPA, whereas in vitro infection of a fibroblast population with a
high multiplicity of infection is likely to result in the infection of every cell.
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However, using Southern analysis, it has been shown that cDNA derived from S11
cells hybridises with genomic DNA corresponding to ORF74 and that this effect can
be abrogated by treating the cells with C9 (Simas et al., 1999). This indicates that in
S11 cells at least, the GPCR is not transcribed during latency. As with EBV, there
are apparent differences between the in vitro model of latent infection and the
latency-associated patterns of gene expression observed in vivo.
Using RT-PCR, transcripts corresponding to the region of the genome encoding the
GPCR were detected in the lungs of mice at 10 months p.i. with MHV-68. Since this
experiment was carried out using random primed cDNA and double-stranded DNA
probes, the signals detected may not be specific for the GPCR or v-Bcl-2.
Transcripts specific for ORF73, a gene transcribed in the opposite direction, may
also encode the GPCR and v-Bcl-2. The KSHV homologue of ORF73 encodes the
LANA protein, which has been shown to be latency-associated. Therefore, it is
possible that the positive signals detected in this experiment actually represent
expression of ORF73. Clarification of this point could be achieved by repetition of
this experiment using gene-specific primers for the reverse transcription reaction and
single-stranded riboprobes to detect the PCR products.
Previous analysis identified both linear and episomal MHV-68 genomes in the lung
at late time-points post-infection, implying the presence of latently and productively
infected cells (Stewart et al., 1998). Transcription of the GPCR in the absence of
classic lytic cycle genes such as the immediate early gene, ORF50, would be
indicative of expression in latently infected cells. GPCR expression has also been
observed in latently infected peritoneal exudate cells (PECs) without concurrent
transcription of lytic genes (Virgin et al., 1999). Latency-associated expression of
the GPCR was detected in the spleen of one mouse (1 of 3) at 10 months p.i. This
corresponds to the study by Virgin et al., in which GPCR transcription was observed
in the spleens of a small proportion of infected mice (2 of 16). Since the virus may
establish latency in a variety of cell types, it is reasonable to speculate that latent
gene expression may be regulated differently in these organs.
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4.2.3. Mapping of the GPCR Transcripts
The size of the GPCR transcripts suggested that they might be polycistronic.
Polycistronic transcripts are not an uncommon feature in gammaherpesviruses; in
fact the KSHV GPCR is transcribed bicistronically with the KSHV homologue of the
integrin-like adhesion molecule, Ox-2 (Talbot et al., 1999). Other examples include
the KSHV v-cyclin and v-FLIP genes (Yu et al., 1999), the rat CMV (RCMV) GPCR
which is encoded on a bicistronic transcript (Beisser et al., 1998) and the HVS
dihydrofolate reductase transcript, which encodes two other unknown ORFs and five
small RNA molecules (Whitaker et al., 1995). Using RT-PCR, a transcript was
identified that appears to encode the MHV-68 v-Bcl-2 and the GPCR. Unlike the
KSHV GPCR-v-Ox-2 transcript, the MHV-68 v-Bcl-2-GPCR transcript does not
appear to be spliced. The co-expression of GPCR and v-Bcl-2 is supported by the in
vivo RT-PCR data, which suggests an identical pattern of transcription of the GPCR
and v-Bcl-2 in the lungs and spleen of every mouse.
Analysis of the 3' end of the GPCR transcript using 3'RACE suggested that it
terminates at the only available consensus polyadenylation signal (AAUAAA)
approximately 600bp downstream of the GPCR translational STOP site. Although
the RT-PCR reaction generated multiple GPCR-specific bands, the smaller products
do not correspond to polyadenylation sites and most likely arose from mis-priming of
the oligo(dT) primer at several potential AT-rich regions within the GPCR coding
region. As a low annealing temperature was essential for this amplification, the
stringency of the reaction could not be increased. Confirmation that this is indeed
the 3' end of the transcript would require cloning and sequencing of the PCR
product. However, when considered alongside the RT-PCR data showing expression
of v-Bcl-2 and GPCR on the same transcript, the evidence suggests that the 3.4kb
band detected by Northern hybridisation may represent a bicistronic transcript
encoding the GPCR and v-Bcl-2. The identity of the other Northern transcripts is
unknown. The appearance of less abundant, higher molecular weight transcripts has
also been observed in Northern analysis of KSHV genes including vMIPI, GPCR, v-
Bcl-2 and the capsid protein, ORF26 (Yu et al., 1999). It is possible that they
represent unspliced variants or readthrough transcription past the polyadenylation
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signal into the 3' untranslated region. However, this could be elucidated by further
Northern hybridisation with probes corresponding to genes in the region of the
GPCR such as v-cyclin, v-Bcl-2 and ORF75. Alternatively, they may represent
transcripts running in the opposite direction. Since the Northern blot was hybridised
with a double-stranded DNA probe, it is possible that some of the transcripts
originate from the complementary DNA strand and are not specific for ORF74.
Many of the genes in the region of ORF74 are transcribed in the opposite direction,
including ORF75, ORF73 and ORF72. This could be resolved by repeating the
Northern hybridisation with an antisense riboprobe specific for the GPCR coding
region, which would only hybridise with message from the sense strand of the
genome.
The investigation of the 5' untranslated region of the transcript using 5'RACE did
not yield conclusive results, as the major PCR product fell short of the GPCR
translation initiation site. This was most likely due to premature termination of the
reverse transcriptase enzyme, which can occur at RNA secondary structures. An
alternative approach to circumvent this problem might be to attempt SI nuclease
mapping, a technique that does not involve reverse transcriptase but is nevertheless
much less sensitive. Although the 5'RACE experiment generated multiple PCR
products, none of them were of sufficient molecular weight to represent the v-Bcl-2-
GPCR transcript. It is, however, possible that one of the minor products could
represent a monocistronic GPCR transcript. If this were the case, the PCR reaction
would favour a shorter cDNA template, which might also explain the absence of the
longer bicistronic transcript. However, this seems unlikely as no monocistronic
GPCR transcript was detected using Northern hybridisation, although it could be
beyond the sensitivity threshold of the Northern analysis. Nevertheless, others have
failed to find a monocistronic transcript encoding the KSHV GPCR (Kirshner et al.,
1999), which may provide an insight into the biology of these genes.
The KSHV GPCR may be translated from an internal ribosome entry site (IRES),
which is an inefficient method of translation (Bieleski & Talbot, 2001). However, as
the KSHV GPCR is a constitutively active signalling molecule (Arvanitakis et al.,
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1997), a low level of expression may be sufficient for its function and higher levels
may be detrimental. Overexpression of the gene in vitro has been found to trigger
cell death, therefore KSHV may employ a translational regulation strategy to
suppress expression of a potentially toxic protein (Kirshner et al., 1999). In the case
of MHV-68, the low abundance of GPCR-derived transcripts suggests that a similar
mechanism may operate. The evidence indicates that the MHV-68 GPCR is a toxic
gene: insertion of the GPCR gene into expression vectors was a difficult process,
positive clones grew slowly and were subject to rearrangement; also, the transfection
efficiency ofGPCR expression constructs into eukaryotic cells was very much lower
than control plasmids and produced fewer viable cells. The toxicity in bacteria may
be caused by low-level readthrough transcription from cryptic promoters (Brown &
Campbell, 1993). Expression of eukaryotic proteins can have a deleterious affect on
prokaryotic cells, often causing problems in protein export machinery (Martin et al.,
1989). Overexpression of the GPCR in mammalian cells may induce apoptosis,
however, it would be necessary to confirm this by carrying out TUNEL staining of
transfected cells. Since the electroporation process itself results in a significant
amount of cell death, it may be more informative to use an inducible expression
system and stain stably transfectcd cells. It is perhaps not coincidental that the
GPCR is co-transcribed in vitro and in vivo with v-Bcl-2. Expression of this anti-
apoptotic gene may be required to overcome the toxicity of the GPCR by suppressing
apoptosis
4.3. Expression of the GPCR Protein
The apparent toxicity of the GPCR protein has presented a problem in several aspects
of this project: raising and testing an antibody against the GPCR, investigating the
subcellular localisation of the receptor and determining whether it binds IL-8. All
these experiments require a certain level of protein expression to facilitate
recognition by an antibody or for the binding of radioactive ligand. There may be
additional reasons for the low levels of expression, however. For instance,
mutagenesis of the histamine H(2) receptor DRY motif resulted in structural
instability of the GPCR. Since the MHV-68 GPCR does not encode a classical DRY
motif, this may have implications for its stability.
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4.3.1. Generation of an Antibody to the GPCR
As discussed in section 1.7, GPCRs are comprised of seven hydrophobic
transmembrane domains connected by hydrophilic loops. Hydrophobic regions are
not exposed on the cell surface and are therefore less likely to generate antisera that
would recognise the native protein. For this reason, only the predicted N-terminal
region of the GPCR, as defined by analysis of the hydropathy plot, was used as an
antigen. In hindsight, this probably avoided a potential toxicity problem and
produced a soluble antigen, which theoretically should have been easier to purify.
The GPCR N-terminus was expressed as a GST-fusion protein using the pGEX
bacterial expression system. Inducing expression in bacteria resulted in a protein of
the expected size that was recognised by an anti-GST antibody. However, an anti-
MHV-68 antibody failed to recognise the fusion protein. Initially this suggested that
the N-terminus might not be immunogenic, however it was reasoned that the GPCR
might not generate a significant immune response during MHV-68 infection.
Northern analysis showed that the GPCR is transcribed at barely detectable levels
during productive infection and although the level of transcription does not
necessarily correlate with the amount of protein translated, it is possible that there
was insufficient GPCR protein to generate an immune response.
An affinity purification strategy was used to isolate the fusion protein, which was
present at relatively low levels in the soluble fraction. However, the fusion protein
bound glutathione-sepharose beads strongly and was resistant to elution with the
recommended buffers. The residual presence of the fusion protein in the insoluble
fraction indicated that the protein was only partially soluble, which may explain why
it was refractory to elution in hydrophilic solutions. Nevertheless, the protein-bead
complex was used as an antigen to raise antisera in rabbits.
The antisera were tested against Western blots of BHK cells that were productively
infected with MHV-68 and a stable 3T3 cell clone that had been shown to express
the GPCR using RT-PCR. Despite repeated immunisations, no differences were
observed between the antisera and the pre-immune sera. This may reflect the low-
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level expression of the GPCR protein in both these samples and the sensitivity of the
Western analysis. However, the failure to detect a specific signal using the more
sensitive radioimmunoprecipitation assay, suggests either the fusion protein was not
immunogenic, or that antibody to the N-terminus did not recognise the native GPCR
protein. Both antisera recognised the fusion protein on a Western blot, which
confirmed that a humoural immune response was successfully raised against the
antigen, but not whether it was specific for the GPCR N-terminus as opposed to
GST. It is quite possible that this region of the GPCR had folded differently in
isolation from the rest of the protein or that it was not fully exposed on the surface of
the fusion protein. Alternatively, antibody against the N-terminus may not
necessarily bind to the native GPCR. The principal caveat in using a bacterial
system to express a eukaryotic protein is the lack of post-translational modification
and the possibility of incorrect folding in the absence of eukaryotic molecular
chaperones. Sequence analysis of the GPCR amino acid sequence predicted the
presence of two glycosylation sites within the N-terminal region. Presumably, lack
of glycosylation would affect the tertiary structure of the protein and hence the
potential epitope.
An alternative strategy was to use DNA vaccination and synthetic peptides to
stimulate an antibody response to the GPCR. The use of naked nucleic acid as a
vaccine has generated much interest in the preceding decade and many reports attest
to its efficacy in stimulating immune responses in vivo (Rothel et al., 1997; Vogel &
Sarver, 1995). The generation of an immune response using synthetic peptides has
also been demonstrated (Nardin et al., 2000), and is of particular value in situations
where native protein antigens cannot be effectively expressed. In this case, sheep
were chosen as the experimental animal since they are inexpensive and being larger
than rabbits, they produce more serum. One sheep was also immunised with plasmid
DNA encoding the cytokine, GMCSF, which is a growth factor for dendritic cells.
Since most DNA vaccination is directed towards the skin, dendritic cells are the
primary antigen-presenting cells involved in generating the immune response. The
use ofGMCSF as an immunological adjuvant is therefore an interesting hypothesis.
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Neither sheep appeared to mount an immune response to the GPCR. As with the
rabbit antisera, no specific recognition was observed using Western blotting and
immunisation with the GMCSF DNA did not make any apparent difference. Again it
must be pointed out that there may have been insufficient GPCR protein expressed in
the transiently transfected cells to elicit a positive signal on the Western blot.
Another potential caveat is that an immune response directed against synthetic
peptides may not necessarily recognise the native protein.
4.3.2. Subcellular Localisation of the GPCR
To overcome the lack of anti-GPCR antibody, the subcellular localisation of the
protein was determined using an "epitope-tagging" strategy. Immunofluorescence
experiments detected expression of the GPCR in transiently transfected cells using
the pVR1255-GPCRHA3 construct but not the pBabe-GPCRHA construct. Aside
from having two extra haemagglutinin epitopes, it is not absolutely clear why
expression was detectable using pVR1255 as opposed to pBabdpuro. It is also
puzzling why an apparently toxic gene is expressed at all under the control of the
powerful CMV promoter. However, others have used this plasmid successfully to
express MHV-68 proteins that could not be expressed in alternative vectors (Atkin,
2000). The pVR1255 vector was systematically modified to optimise protein
expression using a luciferase reporter system (Hartikka et al., 1996). It contains the
CMV immediate early intron A immediately upstream of the insertion site (see
diagram 3.3.5A). This element, which has previously been shown to enhance gene
expression in plasmid vectors (Chapman et al., 1991), encodes binding sites for the
transcription factor, nuclear factor 1, and enhanced luciferase expression by 25%
(Hartikka et al., 1996). Substitution of the bovine growth hormone polyadenylation
signal for a minimal transcriptional terminator derived from the rabbit P globin gene
(Levitt et al., 1989) also doubled the expression of luciferase. Surprisingly, it was
also found that replacing the ampicillin resistance gene with the kanamycin
resistance gene significantly enhanced protein expression in a range of vectors
(Hartikka et al., 1996). Although, it is not clear if this effect is peculiar to the vectors
tested by Hartikka et al or whether it is dependent upon the position of the resistance
gene within the vector, it is noteworthy that the pBabdpuro vector encodes the
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ampicillin resistance gene. By the same token, the pBabdpuro vector contains the
puromycin resistance gene but pVR1255 does not encode any marker for selection in
eukaryotic cells.
Insertion of the GPCR gene into pVR1255 was considerably less time-consuming
than with pBabdpuro. Several attempts were also made to insert the GPCR into the
pEGFP-Nl expression vector (Clontech) to generate a GPCR-GFP fusion but this
was not achieved in the course of this project. The positive pVR1255 clones were
still restricted in growth, yet large-scale plasmid preparations appeared to yield
higher levels of DNA. Nonetheless, the transfection efficiency of 293 cells with
pVR1255-GPCRHA3 was much reduced compared with a positive control plasmid
expressing GFP and there appeared to be fewer viable cells post-transfection, thus
indicating that pVR1255 only partially overcame the toxicity problem. The low
number of cells that stained positively with the anti-haemagglutinin antibody
suggests that there was negative selection of cells expressing high levels of the
GPCR. It is not unusual for transforming transmembrane proteins to be toxic when
overexpressed in eukaryotic cells. In addition to the KSHV GPCR, which has
already been discussed, overexpression of the EBV LMP-1 gene has been shown to
be toxic to mammalian cells (Hammerschmidt et al., 1989).
The anti-haemagglutinin antibody reproducibly detected expression of the GPCR
protein in patches consistent with localisation to the cell surface. The individual
image slices generated using the confocal microscope (see 3.3.5B) indicate that the
FITC signal is not co-incident with the nuclear propidium iodide staining. Although
cell surface expression is likely for a transmembrane signalling protein, it would be
necessary to confirm association with the plasma membrane by co-localisation with a
cell surface marker such as MHC class I. The punctate expression pattern is typical
of transmembrane proteins that are activated by aggregation such as EBV LMP-1
(Liebowitz et al., 1986) and the epidermal growth factor receptor (Schechter et al.,
1979; Schreiber et al., 1983).
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4.3.3. Binding of IL-8 to the GPCR
The potential interaction of the GPCR with the chemokine, IL-8, was investigated
using a radioactive binding assay. Chemokine binding has been demonstrated for
three viral GPCRs so far. Despite sharing greater sequence identity with the CCR1
than CXCR2, the HVS GPCR exhibits a binding profile similar to CXCR2 (Ahuja &
Murphy, 1993). The HCMV US28 protein binds CC chemokines such as RANTES
(Vieira et al., 1998) while the KSHV GPCR is a promiscuous receptor that interacts
with both CC and CXC chemokines (Arvanitakis et al., 1997). Since both
gammaherpesvirus GPCRs bound CXC chemokines and the KSHV GPCR had
highest affinity for IL-8, IL-8 appeared a logical first choice to test the binding
activity of the GPCR.
Multiple attempts were made to detect binding of radiolabeled IL-8 to the GPCR1
3T3 cell clone or transiently transfected 293 cells but no difference was ever
observed between the test samples and the negative controls. It is likely that low
expression of the GPCR was a fundamental problem in this assay. Expression of the
GPCR transcript had been verified in the GPCR1 cells but without an antibody, the
presence of the protein could not be confirmed. There is little doubt that this cell
clone expresses the GPCR protein as it exhibits transformed characteristics, however,
the level of expression required to elicit transformation is likely to be far less than
that required for ligand-binding or immunological analysis. A stable cell line
expressing the pVR1255-GPCRHA3 construct may have provided the necessary
substrate but this could not be generated, as the vector encodes no mammalian
selection marker. It may have been possible to engineer a selectable marker into
pVR1255 but the experiments of Hartikka et al have illustrated that the addition or
replacement ofDNA elements can have a profound effect on protein expression. It is
also uncertain whether a stable cell line could support high-level expression of the
GPCR or if it would simply result in selection of non-expressing cells. An inducible
system allowing transient expression of the GPCR may have partially overcome the




Ultimately, binding of radiolabeled IL-8 to positive control U937 cells demonstrated
that the experiment itself was not flawed. As this is a relatively sensitive assay that
should detect even low levels of bound ligand, an alternative explanation is that the
MHV-68 GPCR does not have a high affinity for IL-8. Although IL-8 binding has
been established for the KSHV and HVS receptors, MHV-68 has evolved to persist
in rodents, which do not synthesise IL-8. It would therefore be interesting to repeat
this experiment with a murine chemokine such as KC.
4.4. Transforming Activity of the GPCR
4.4.1. Focus Formation and Anchorage Independent Growth
The transforming activity of the GPCR was demonstrated using classical
transformation assays. Transient transfection of NIH3T3 cells with transformation
constructs (see diagram 3.4.1) resulted in moderate loss of contact inhibition and
occasional focus formation. Due to the poor transfection efficiency ofNIH3T3 cells,
changes in growth characteristics only became obvious following selection of cells
that had taken up the plasmid. Clones of puromycin resistant cells readily exhibited
loss of contact inhibition and focus formation when maintained in a confluent
monolayer for a period of 3-4 weeks. Transformed focal cell clones also displayed
anchorage independent growth in soft agar, in contrast to cells stably transformed
with the empty vector. Interestingly, independent cell clones carrying the same
plasmid exhibited subtle variations in transformation characteristics, with some
clones appearing to be more transformed than others. For instance, the two GPCR+
cell lines, GPCR1 and GPCR2, both exhibited focus formation yet GPCR1 formed a
greater number of foci than GPCR2. In the anchorage independence assay, GPCR1
and GPCR2 generated a similar number of colonies in soft agar but the morphology
of the colonies differed: the colonies produced by GPCR1 were typically larger and
appeared denser than the GPCR2 colonies. A similar distinction was also observed
between LMP1 and LMP4, with LMP4 forming noticeably more colonies than
LMP1. This may reflect a difference in the number of copies of the plasmid and/or
the site of integration, which could affect the levels of protein expression and hence
the growth properties of the cells. However, Southern analysis of the genomic DNA
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would be required to confirm this. There were also qualitative differences in the
cellular morphology of the transformed clones. Cells transformed with EBV LMP1
appeared smaller and rounder which may be a result of the known effect of this
protein on the cell cytoskeleton (Panayiotides et al., 1996). The number of colonies
formed by the SV402 cells was low compared to the other cell clones. A likely
explanation for this is that the pPVU-0 plasmid does not encode a mammalian
selectable marker, which prevented selection of transfected cells. Although SV402
was propagated from a cellular focus, the small number of cells that stained
positively for large T antigen suggests either that this cell strain was not clonal or
that the plasmid had been selectively lost.
4.4.2. Subjectivity of Transformation Assays
It is not appropriate to compare the transforming activity of the GPCR with LMP and
large TAg in the soft agar assay. As discussed previously (see section 1.9.1),
changes associated with transformation are highly dependent on the method of
selection, therefore evidence of one transformed characteristic does not presume
possession of others (Smith et al., 1971). In this case, the cell clones were selected
on the basis of loss of contact inhibition and focus formation so it does not
necessarily follow that they should display an equal ability to grow in soft agar.
Likewise an ability to grow in low concentrations of serum could not be
demonstrated for any of the transformed cell clones. Despite culturing the cells in a
range of serum concentrations (0.1-5% NBC or FCS), conditions required for the
survival of transformed cells and concomitant death of negative control cells could
not be determined.
It is also fair to say that these cell culture-based assays are relatively subjective and
results may vary in the hands of different experimenters. Not only is there variation
between the strains of 3T3 cells used as the substrate in transformation assays but
they also appear highly sensitive to changes in growth conditions. For instance,
focus formation failed to occur when cells were maintained in 10% newborn calf
serum as opposed to 10% foetal calf serum, presumably because growth factors
present in the foetal calf serum were required for transformation.
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4.4.3. Tumorigenicity in Nude Mice
The observation that transformed cells rarely exhibit a full repertoire of
transformation-associated characteristics may also partially explain the failure of the
transformed cell clones to produce tumours in nude mice. There is also an element
of subjectivity in this experiment as the variation in the strain of nude mouse may
have an effect. However, the inability of 3T3 clones expressing the SV40 large TAg
to develop into tumours was surprising since others have previously demonstrated
the tumorogenicity of this gene in vivo (Tooze, 1973). While Rat-1 cells transformed
with EBV LMP-1 are tumorigenic in nude mice, the failure of transformed NIH3T3
cells to grow in nude mice has been previously described (Wang et al., 1985). Even
so, the transient tumorogenesis observed in the second experiment is perhaps more
suggestive of tumour regression than a failure of the cells to grow at all.
Nude mice carry an autosomal recessive mutation on chromosome 11 that prevents
development of the thymus and also renders them hairless (Byrd, 1993; Nehls et al.,
1994). Being athymic, they are T cell deficient and therefore lack the T cell help
required to mount an antibody response (Pantelouris, 1968). However, there is
evidence that nude mice have elevated levels of natural killer (NK) cells, perhaps to
compensate for the lymphocyte deficiency (Grzelak et al., 1984; Su et al., 1993).
There are a large number of reports describing the down regulation of MHC class I
on transformed cells and tumour cells, presumably as a mechanism of immune
evasion (Elliott et al., 1989; Goodenow et al., 1985; Hammerling et al., 1987;
Tanaka et al., 1985). Since NK cells recognise cells that fail to express MHC class
I, it is possible that the transformed cells injected into the nude mice were highly
susceptible to destruction by NK cells. Therefore it would be interesting, using an
immunohistochemical technique, to compare the level of positive staining for MHC
class I in the transformed cell clones and negative control cells. Variation in the
levels and activity of NK cells between different strains of nude mice may also
account for the lack of reproducibility in these experiments (Romijn, 1985). The
problem of elevated NK cell activity may be overcome by treating nude mice with an
immunosuppressive drug such as pristane, which has a known affect on NK activity
(Freund & Blair, 1982; Kripke & Weiss, 1970).
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Conventional transformation assays were first developed in the 1950s and 1960s to
analyse the biological effects ofDNA tumour viruses. Although still very much used
today, they are gradually being replaced or at least complemented by
immunohistochemical assays that can detect transformation-associated changes in
the cytoskeleton and the presence of tumour antigens.
4.5. Recombinant Virus
4.5.1. Homologous Recombination
Prior to the advent of molecular cloning techniques, which facilitated targeting,
mutant viruses were isolated on the basis of altered plaque phenotype (Ejercito et al.,
1968), drug resistance (Tognon et al., 1988) or host-range properties (Aurelian,
1964). Homologous recombination has been used to successfully target a wide range
of herpesvirus genes, thus allowing gene function to be explored in the context of the
whole virus. In particular, the generation of herpes simplex mutant viruses has
provided a wealth of information concerning the roles of individual genes (Balan et
al., 1994; Forrester et al., 1992). Targeted disruption of betaherpesvirus genes has
also been described, including the MCMV and RCMV GPCRs (Beisser et al., 1998;
DavisPoynter et al., 1997). Homologous recombination in gammaherpesviruses
appears to present a greater challenge than in alphaherpesviruses and
betaherpesviruses, nevertheless, several recombinant viruses with dysfunctional
genes have been described (Borza & Hutt-Fletcher, 1998; Marchini et al., 1992;
Wang & Hutt-Fletcher, 1998). The inability of EBV and KSHV to grow
permissively in tissue culture has hampered the study of these viruses at the
molecular level. Conversely, the relatively efficient replication of MHV-68 in vitro
indicates that it would be a more amenable virus for genetic manipulation and the
subsequent analysis of recombinant viruses in vivo. Recombinant MHV-68 viruses
generated to date include "knock-outs" of the Ml and cyclin D genes (Clambey et
al., 2000; Hoge et al., 2000; Simas et al., 1998; van Dyk et al., 2000).
The homologous recombination strategy relies upon the insertional mutagenesis or
complete replacement of a gene with a selectable marker that can be used to identify
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the recombinant. A number of different selectable markers have been used including
the E.coli guanosine phosphoribosyl transferase (gpt) gene (Greaves et al., 1995), the
hygromycin phosphotransferase gene (Marchini et al., 1992), the HSV-1 thymidine
kinase gene (Post et al., 1981), the neomycin resistance gene (Grassmann &
Fleckenstein, 1989; Wang & Hutt-Fletcher, 1998), the p-galactosidase gene (van
Dyk et al., 2000) and GFP (Vieira et al., 1998). GFP is a powerful non-evasive
marker, which offers the advantage of detecting "tagged" virus in individual infected
cells. However, as is discussed below, GFP may not have provided sufficient
selection criteria for purification of recombinant MHV-68 and that using a construct
with a combination of selectable markers might improve the chance of isolating a
pure homologous recombinant.
4.5.2. RCVI
The MHV-68 GPCR was targeted using a recombination construct encoding
approximately 2kb homologous flanking regions on either side of the GFP gene. The
construct recombined with the MFIV-68 genome resulting in recombinant virus that
was selected on the basis of GFP expression. Successive rounds of plaque
purification and limiting dilution were used to purify the recombinant virus to a
standard where no wild type GFP" plaques were visible. However, Southern analysis
revealed that wild type virus was still present in the sample and that illegitimate
recombination of the construct had occurred. The small graduations or laddering
effect detected with two of the Southern probes suggested that recombination had
taken place adjacently to a region of repetitive DNA. Detailed analysis of the
banding pattern revealed partial deletion and integration of the construct at the left-
hand end of the genome.
This discovery raised several issues. Firstly, non-homologous recombination in this
region of the genome had been observed previously using different recombination
constructs (Roy, unpublished observation), implying the presence of a
recombinational "hot-spot". The subsequent insertion of the construct at the correct
site in MHV-76 (RCVII) shows that the homologous flanking regions in the
recombination construct were of sufficient length to achieve specific integration.
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Taken together, these findings indicate that integration at the left-hand end is not a
completely random event. As has been proposed for HVS, this region of the MHV-
68 genome is a potential site for the virus origin of replication (Bowden et al., 1997;
Grassmann & Fleckenstein, 1989). If so, this region may adopt a more open
conformation, which would make it more accessible for recombination.
The second issue to arise from this experiment was the possibility that the GPCR
might be an essential gene or at least confer a growth advantage on the virus. In the
former scenario, deletion of ORF74 would not generate viable recombinant virus,
whereas in the latter, the virus might be severely debilitated. If the GPCR were an
essential gene, a "knock-out" virus might still be able to replicate in the presence of
wild type virus if the mutation could be complemented in trans. This might explain
the persistence of wild type virus through numerous rounds of purification. In either
case, selection of GFP+ virus using plaque purification and limiting dilution would
favour the selection of illegitimate recombinants that were not growth inhibited.
Thirdly, the time spent attempting to purify this non-homologous recombinant
obviated the need for a PCR-based assay to determine whether homologous
recombination had occurred following the initial transfection.
4.5.3. RCVII
To try and circumvent the problem of illegitimate recombination, targeted deletion of
the GPCR was attempted in a different virus. MHV-76 was isolated concurrently
with MHV-68 (Blaskovic et al., 1980) and limited sequence analysis has only
revealed one major difference between the two viruses: the absence of genes M1-M4
and the tRNAs (Macrae, unpublished), all of which are encoded at the left-hand end
of the MHV-68 genome. It was therefore reasoned that MHV-76 might also lack the
highly recombinogenic region encoded by MHV-68. However, the subsequent
generation of a left-hand end recombinant virus using MHV-76 (RCVII) as a target
virus disputes this. If anything, it strengthens the evidence of similarity between
MHV-76 and MHV-68 and suggests that the hot-spot is likely to be situated within
the terminal repeats rather than in the unique region of the genome.
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The PCR assay designed to identify GPCR-negative virus provided the first
indication that homologous recombination had occurred, and this was later confirmed
by Southern analysis. It was possible using PCR to screen large numbers of viral
isolates and the sensitivity of the technique facilitated detection of potentially rare
recombinant virus. If this assay had been developed previously it may well have
detected the presence of the homologous recombinant in the first generation MHV-
68 recombinant virus. Following the first round of plaque purification, the ratio of
recombinant to wild type virus was estimated, revealing that wild type virus was
predominant. Using the sample with the highest ratio of recombinant to wild type
virus, enrichment of GFP+ virus was achieved by plaque purification. Following
each round of purification, virus isolates were tested for the presence of the
homologous recombinant using PCR. It was observed that the number of positive
samples did not increase with successive rounds of purification, despite the absence
of visible wild type plaques. Preliminary Southern analysis (not shown) indicated
the faint presence of the homologous recombinant but also revealed a high level of
illegitimate recombinant. Unfortunately, the PCR assay failed to distinguish between
wild type MHV-76 and virus that had recombined in the left-hand end. Potentially,
there were four viruses present in the population: wild type, left-hand end
recombinant, homologous recombinant and virus containing insertions at both loci.
4.5.4. Purification Strategies
The inability to purify the homologous recombinant or at least enrich its presence in
the population was puzzling. Plaque purification is an established method for
isolating recombinant viruses. The selection of single, well-isolated plaques that
have arisen from a single plaque-forming unit will, in most cases, eventually yield
pure virus. The persistence of wild type virus or left-hand end recombinant, which
grows essentially like wild type virus in vitro, again raised the possibility that the
homologous recombinant was a replication deficient virus that could not be
propagated without the support ofwild type virus.
To address this, plaque purification was carried out using 3T3 cells expressing the
GPCR (GPCR1) to determine whether recombinant GPCR could complement the
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potentially debilitating mutation and thus facilitate the growth of plaques containing
pure virus. Although previous experiments had suggested that the GPCR1 cells do
not express the GPCR at a high level, it was reasoned that since the GPCR transcripts
are at such low abundance during lytic infection, there should be sufficient
expression to complement the virus. Regrettably, it was found that the virus did not
infect these cells efficiently and that all the plaques tested by PCR were
contaminated with wild type or left-hand end recombinant virus. It may have been
advisable to persevere with this strategy and produce a complementary cell line
capable of generating a large number of plaques to increase the chance of finding a
pure virus clone. However, this problem presented itself at a very late stage in the
project and there was no guarantee that a different GPCR+ cell line would be any
more successful. The other theory was that deletion of the GPCR had had a
deleterious affect on the transcription of other genes in the same locus. Although
care was taken to avoid disruption of the ORF73 and ORF75 coding regions and
promoters, it is still possible that the GPCR coding region contains long-range
elements that regulate their expression. In addition, the insertion of the CMV
promoter immediately upstream ofORF73 could have had potentially adverse effects
on its transcription. ORF73 is a potential homologue of KSHV LANA and EBV
EBNA1 and may therefore have an essential transactivation function. However, it
would be impossible to establish if ORF73 transcription has been affected without
actually purifying the recombinant virus.
An alternative strategy that avoided the necessity for lytic replication was to infect B
cells and reactivate latent virus. It was acknowledged, however, that this strategy
would only be successful if the recombinant virus were at a growth disadvantage
rather than completely replication deficient. As previously discussed, there is some
evidence that B cells support only one episomal variant of EBV and are resistant to
superinfection (Kintner & Sugden, 1981; Reisman & Sugden, 1984), which might
allow reactivation of pure virus from individually cloned B cells. Unfortunately, the
expression of GFP proved to be unstable in the virus-infected NSO cells, indicating
that transcription of the GFP gene may have been suppressed during virus latency.
This is supported by the observation that the addition of phorbol ester (TPA)
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noticeably increased the number of GFP+ cells. Physical isolation of individual B
cells that were transiently expressing GFP was attempted using suction with a
micropipette but without success. The inability to clone a single GFP+ B cell meant
that it would be necessary to screen a very large number of B cells in the population
to find one that was infected with the recombinant. Approximately thirty plaques
generated from reactivated B cells were tested using PCR and all contained the wild
type or left-hand end recombinant virus, which disputes the original hypothesis that a
single episomal variant predominates in latently infected B cells. Despite evidence
that pure virus can be reactivated from the latent B cells of infected mice, a similar
result was obtained following infection of mice with the mixed virus population.
Curiously, the presence of both recombinant and wild type/left-hand end
recombinant virus was evident in all the plaques screened. This may reflect the
persistence of infectious virus in the spleen at this time-point but again casts doubt
on the theory that B cells generally harbour only one latent virus genotype.
4.5.5. Different Approaches to Generating a GPCR" Mutant
In conclusion, the failure to purify a recombinant virus lacking the GPCR using a
variety of strategies strongly indicates that replication of this virus was severely
debilitated if not unviable. With the benefit of hindsight, this goal might have been
approached differently with greater success. Firstly, using GFP as the sole marker of
recombinant virus did not allow differentiation between homologous and non¬
specific recombination of the construct. There was also no facility for negative
selection of wild type virus. It might be possible to distinguish illegitimate
recombinants using a construct encoding a selectable marker such as blue fluorescent
protein outside the homologous flanking regions. However, as shown with RCVI,
non-specific integration was accompanied by partial deletion of the construct, which
would create the potential for false positives using this option. Secondly, removal of
the whole GPCR coding region now seems unnecessary. Although retention of
signalling function has been demonstrated for a GPCR encoding only five
transmembrane regions (Ling et al., 1999), destroying the region involved in G
protein coupling should be sufficient to inactivate the GPCR. Restricting the level of
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disruption might assuage the potential impact on the expression of genes surrounding
the GPCR.
There are of course alternative strategies for the generation of mutant viruses that
avoid the purification of recombinant from wild type virus. One approach would be
to use a cosmid system (Cunningham & Davison, 1993; de Wind et al., 1990; van
Zijl et al., 1988). The advantage of using a cosmid library is that it allows mutation
of the gene of interest and cloning of the modified cosmid within bacteria.
Restriction analysis or limited sequencing could be used to identify clones carrying
the mutation. Providing any overlapping sequences encoding regions of the gene of
interest are excised from other cosmids, the intact mutant virus genome can be
reassembled by recombination of the individual genomic fragments in mammalian
cells. The other attractive feature of this method is that it does not require insertion
of a selectable marker thus allowing the generation ofmore discrete mutations within
the gene of interest. The only drawback is that repetitive sequences such as
herpesvirus terminal and internal repeats tend to be unstable in bacteria (Gray &
Kaerner, 1984; Quinn & McGeoch, 1985; Weller et al., 1985).
The bacterial artificial chromosome (BAC) system has also attracted a great of
interest in terms of generating herpesvirus recombinants. Entire virus genomes have
been inserted into single BACs (Delecluse et al., 1998; Horsburgh et al., 1999;
Messerle et al., 1997), thus allowing mutation of viral genes in bacteria. Production
of an MHV-68 BAC has been reported which may provide a useful way of
generating MHV-68 recombinants (Adler et al., 2000), although the stability of virus
genomes within BACs has been called into question.
4.5.6. Conclusions and Potential Functions of the GPCR
This work represents an initial characterisation of the MHV-68 GPCR.
Transcriptional analysis detected expression of the GPCR at early and late time-
points during lytic infection on multiple rare polycistronic transcripts. Co-expression
of the GPCR with v-Bcl-2 has also been demonstrated in vitro. In vivo, the evidence
suggests that the GPCR and v-Bcl-2 are co-expressed and may be latency-associated.
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Evidence has also been presented that the GPCR protein is expressed on the cell
surface and that its overexpression is toxic to both prokaryotic and eukaryotic cells.
Classical transformation assays have established a transforming activity mediated by
the GPCR, which indicates that it is a viral oncogene with a variety of potential
functions in viral pathogenesis.
An immunomodulatory role has been postulated for the MHV-68 GPCR. As
previously discussed, several poxvirus cytokine receptor homologues appear to down
regulate the inflammatory response by sequestering host cytokines. In addition,
expression of the HCMV US28 GPCR in vitro leads to a decrease in the
concentration ofRANTES in the medium (Vieira et al., 1998). However, attempts to
express the MHV-68 GPCR in vitro and the barely detectable level of transcription
during productive infection, suggest that it would be ineffectual in dampening the
immune response. Instead, the low level of expression and the transforming activity
of the GPCR are more consistent with a signalling function. The competitive
binding assay did not demonstrate an affinity of the MHV-68 GPCR for IL-8,
however, it is possible that this receptor may mediate signalling or
immunomodulatory activities via other cytokines.
The KSHV GPCR is a functional, constitutively active receptor that exhibits
transforming activity and induces the angiogenic growth factor, VEGF (Arvanitakis
et al., 1997; Bais et al., 1998). The transforming activity of the MHV-68 GPCR
suggests that it too is a viral oncogene, which may contribute to lymphomagenesis
directly, or indirectly by activating other genes involved in transformation. The
involvement of the KSHV GPCR in tumorigenesis has been questioned since it is a
tightly regulated lytic gene, not expressed during latency. However, expression of
the KSHV GPCR has been demonstrated in KS lesions in the small proportion of
cells undergoing productive infection. A paracrine mechanism of transformation has
therefore been proposed which would be consistent with the evidence of cytokine-
mediated proliferation in the pathogenesis of KS. The MHV-68 GPCR is also a lytic
gene but possible latency-associated expression has been detected in vivo, which
indicates a role for the GPCR in virus persistence. In particular, the co-expression of
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the GPCR with v-Bcl-2 suggests that these genes may act synergistically to stimulate
cell proliferation or reactivate productive infection without inducing apoptosis. It is
perhaps not accidental that three MHV-68 cellular homologues of genes involved in
cell proliferation and survival are clustered together in the genome. It is possible that
v-cyclin, v-Bcl-2 and v-GPCR are expressed as a growth-promoting cassette with
oncogenic potential.
As previously discussed, there seems no apparent advantage to the virus in
stimulating tumorigenesis, which may result in the demise of the host. In support of
this, herpesviruses very rarely cause tumours in their natural immunocompetent
hosts. However, the sheer number of GPCRs encoded by herpesviruses indicates
that they must confer a selective advantage upon the virus. A proliferative receptor
could be valuable to the virus in several different ways. For instance, the MHV-68
GPCR may provide a proliferation signal during acute infection, which would serve
to increase the numbers of infected cells. A more likely explanation is that the
GPCR functions during chronic infection to promote persistence of the virus. It may
be that the GPCR activates cell division in latently infected cells as a way of
increasing the number of cells harbouring the virus. Alternatively, the GPCR may
initiate productive replication, which would generate a far greater number of infected
cells. This would be consistent with the low level of productive infection detected in
the lungs of persistently infected mice (Stewart et al., 1998). Although there is no
direct evidence for a role in reactivation, induction of productive replication by
phorbol esters is based on their structural similarity to diaglycerol, which activates
protein kinase C. It is interesting that the KSHV GPCR and GPCRs in general have
been shown to transduce signals via this pathway.
Another potential role for the GPCR might involve B cell trafficking. EBV induces a
cellular GPCR, CCR7, which appears to be involved in homing of B cells to specific
subatomic compartments of the spleen. In transgenic mice lacking CCR7, activated
B cells failed to migrate from the T cell rich zone into the B cell rich zones of the
splenic follicles and germinal centres were not formed (Forster et al., 1996). The
MHV-68 GPCR could possibly function to increase the number of infected B cells
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by targeting them to germinal centres of the spleen for expansion. Evidence for a
role in cellular tropism is provided by recombinant RCMV lacking the GPCR, R33.
This virus spreads successfully to the salivary glands of infected rats but once there,
fails to replicate, indicating a cell-type specific function (Beisser et al., 1998).
In conclusion, the MHV-68 is a viral oncogene, which may contribute to the
pathogenesis of MHV-68 by several different routes. While the evidence favours a
proliferative signalling function that promotes MHV-68 persistence, it is not
incompatible with other growth-promoting or trafficking roles in acute infection.
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Appendix 1
SENSE(S) ANTISENSE(A) PRIMER PAIR ANNEALING TEMPERATURE AMPLIFIED REGION
.BamHl
IS 5 '-dGCGCGGATCCGCCACGATGCTTGTCCTGCG-3' MHV-68 105057-106070
EcoRI 59°C ORF74
1A 5 '-dGCGCC iAATTCTTAGGAGCTTAGTCTACAAACTG-3' Product size: 1030bp
BamHl
2S 5 '-dGCGCGGATCCGAAGATCTTCAGGCATTCTTAG-3 * MHV-68 105084-105177
EcoRI 53°C ORF74 N-terminus
2A 5'-dGCGCGAATTCTACAGGGGCTCGCCAAATCT-3' Product size: 1013bp
BamHl
3S 5 '-dGCGCGGATCCGCCACGATGCTTGTCCTGCG-3' MHV-68 105057-106067
E'coRI STOP HA Epitope 50°C HA-tagged ORF74











Product size: 1111 bp
BamHl
5S 5 '-dGCGCGGATCCATGAGTCATAAGAAAAGCGGGA-3' MHV-68 103418-106067
E'coRI 59°C Ml l-»ORF74





6A 5 '-dTGTGTCATGCAATCGTTCAA-3' Product size: 219bp
Xhol MHV-68 103171-105064
7S 5'-dGCGCCGATCGCCGAGTTCATAGTGACAG-3' Left flank
EcoRI 57°C Recombinant virus
7A 5 '-dGCGCGAATTCGCTCCTAATCTCTAGATG-3' Product size: 1913bp
EcoRI MHV-68 106063-108018
8S 5 '-dGCGCGAATTCGCTCCTAATCTCTAGATG-3' Right flank
Pvul 47°C Recombinant virus
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Anti-SV40 large T antigen monoclonal antibody
(Clone OG5)
1:1000 - IF TCS
Biologicals
Anti-GST polyclonal antibody 1:500 - Western Stewart,
unpublished
Anti-MHV-68 polyclonal antibody 1:500 - Western (Sunil-
Chandra et
al., 1992a)
Alkaline phosphatase conjugated swine anti-
rabbit polyclonal antibody
1:1000 - Western Dako
Biotin-labelled donkey anti-sheep polyclonal
antibody
1:10,000 - Western Sigma
FITC-labelled goat anti-rat polyclonal antibody 1:250-IF Pharmingen
Biotin-labelled rabbit anti-rat polyclonal antibody 1:10,000 - Western
1:300- IF
Dako
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